0000947871-16-001123.txt : 20160422 0000947871-16-001123.hdr.sgml : 20160422 20160422161825 ACCESSION NUMBER: 0000947871-16-001123 CONFORMED SUBMISSION TYPE: S-4 PUBLIC DOCUMENT COUNT: 11 FILED AS OF DATE: 20160422 DATE AS OF CHANGE: 20160422 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-4 SEC ACT: 1933 Act SEC FILE NUMBER: 333-210873 FILM NUMBER: 161586900 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 S-4 1 ss1454292_s4.htm REGISTRATION STATEMENT
As filed with the Securities and Exchange Commission on April 22, 2016
Registration No. 333-


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM S-4
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
_______________________
CVS Health Corporation
(Exact name of registrant as specified in its charter)
_______________________
Delaware
(State or other jurisdiction of
 incorporation or organization)
5912
(Primary Standard Industrial
Classification Code Number)
05-0494040
(I.R.S. Employer
Identification Number)
_______________________
One CVS Drive
Woonsocket, RI 02895
(401) 765-1500
 
(Address, including zip code, and telephone
number, including area code, of registrant’s
principal executive offices)
David M. Denton
Executive Vice President
and Chief Financial Officer
CVS Health Corporation
One CVS Drive
Woonsocket, RI 02895
(401) 765-1500
(Name, address, including zip code, and telephone number, including
area code, of agent for service)
_______________________
Copies to:
Stephen T. Giove
Shearman & Sterling LLP
599 Lexington Ave
New York, New York 10022
(212) 848-4000
Thomas M. Moriarty
Executive Vice President, Chief Health Strategy Officer
and General Counsel
CVS Health Corporation
One CVS Drive
Woonsocket, RI 02895
(401) 765-1500
_______________________
Approximate date of commencement of proposed sale of the securities to the public:  As soon as practicable after this registration statement becomes effective.
If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box.  o
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
_______________________
Large accelerated filer x
Accelerated filer  o
Non-accelerated filer  o (Do not check if a smaller reporting company)
Smaller reporting company  o
 
If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:
Exchange Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer) o
 
Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) o
 
_______________________
CALCULATION OF REGISTRATION FEE
Title of Each Class of
Securities to be Registered
 
Amount to be Registered
   
Proposed Maximum
Offering Price Per Note(1)
   
Proposed Maximum
Aggregate Offering Price(1)
   
Amount of
Registration Fee
 
4.75% Senior Notes due 2022
  $ 387,285,000       100 %   $ 387,285,000     $ 38,999.60  
5.00% Senior Notes due 2024
  $ 296,255,000       100 %   $ 296,255,000     $ 29,832.88  
(1)           Estimated solely for the purpose of calculating the registration fee under Rule 457(f) of the Securities Act of 1933, as amended.
_______________________
The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.


 
 
 
 
 
The information in this prospectus is not complete and may be changed.  We may not complete this exchange offer until the registration statement filed with the Securities and Exchange Commission is effective.  This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
 
SUBJECT TO COMPLETION, APRIL 22, 2016
PROSPECTUS
 
CVS Health Corporation
 
Offer to Exchange
$387,285,000 Outstanding 4.75% Senior Notes due 2022
for
Registered 4.75% Senior Notes due 2022
and
$296,255,000 Outstanding 5.00% Senior Notes due 2024
for
Registered 5.00% Senior Notes due 2024
_______________________

We are offering to exchange, upon the terms and subject to the conditions set forth in this prospectus and the accompanying letter of transmittal, all of our outstanding 4.75% Senior Notes due 2022 (the “Old 2022 Notes”) for an equivalent principal amount of our registered 4.75% Senior Notes due 2022 (the “New 2022 Notes”), and all of our outstanding 5.00% Senior Notes due 2024 (the “Old 2024 Notes”) for an equivalent principal amount of our registered 5.00% Senior Notes due 2024 (the “New 2024 Notes”).  The Old 2022 Notes and the Old 2024 Notes are collectively referred to as the “Old Notes.”  The New 2022 Notes and the New 2024 Notes are collectively referred to as the “New Notes.”  When we use the term “Notes” in this prospectus, the related discussion applies to both the Old Notes and the New Notes.
 
The exchange offer will expire at         p.m., New York City time, on                     , 2016 (the “Expiration Date”), unless extended. We do not currently intend to extend the Expiration Date.
 
The terms of the New Notes are identical in all material respects to the Old Notes of the same series, except that the New Notes are registered under the Securities Act of 1933, as amended (the “Securities Act”), and will not contain restrictions on transfer or provisions relating to additional interest, will bear a different CUSIP number from the Old Notes of the same series and will not entitle their holders to registration rights.
 
The New Notes will not be listed on any securities exchange or for quotation through any automated dealer quotation system.
_______________________

You should carefully consider the “Risk Factors” beginning on page 10 of this prospectus before participating in the exchange offer.
 
Neither the Securities Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.  Any representation to the contrary is a criminal offense.
_______________________

Each broker-dealer that receives New Notes for its own account pursuant to the exchange offer must acknowledge that it will deliver a prospectus in connection with any resale of such New Notes.  The letter of transmittal states that by so acknowledging and by delivering a prospectus, a broker-dealer will not be deemed to admit that it is an “underwriter” within the meaning of the Securities Act.  This prospectus, as it may be amended or supplemented from time to time, may be used by a broker-dealer in connection with resales of New Notes received in exchange for Old Notes where such Old Notes were acquired by such broker-dealer as a result of market-making activities or other trading activities.  We have agreed that, for a period of 180 days from the date of this prospectus, we will make this prospectus, as amended or supplemented, available to any broker-dealer for use in connection with any such resale.  In addition, until 180 days after the date of this prospectus, all dealers effecting transactions in the New Notes may be required to deliver a prospectus.  See “Plan of Distribution.”
 
The date of this prospectus is                   , 2016.

 
 
 

 
 
TABLE OF CONTENTS
 
Page
 
_______________________
 
This prospectus incorporates important business and financial information about us that is not included in or delivered with the document.  See “Where You Can Find More Information” for more information about these matters.  You may obtain this information, at no charge, by contacting us at the address or telephone number set forth below:
 
Nancy R. Christal
Senior Vice President, Investor Relations
CVS Health Corporation
670 White Plains Road, Suite 210
Scarsdale, New York 10583
(800) 201-0938
investorinfo@cvshealth.com
 
We have filed with the SEC a registration statement on Form S-4 under the Securities Act to register the notes offered by this prospectus.  The registration statement contains additional information about us and the notes.  We strongly encourage you to read carefully the registration statement and the exhibits and schedules thereto.
 
To obtain timely delivery of any requested information, you must request the information no later than five business days before you make your investment decision.  Please make any such requests on or before                   , 2016.
 

 
i

 

 
We are conducting this exchange offer in order to satisfy our obligations under a registration rights agreement, dated as of October 9, 2015 (the “Registration Rights Agreement”), that we entered into with the dealer managers named therein in connection with private exchange offers in which we issued $387,285,000 aggregate principal amount of Old 2022 Notes and $296,255,000 aggregate principal amount of Old 2024 Notes.  Pursuant to the Registration Rights Agreement, we agreed to consummate an exchange offer for the Old Notes pursuant to an effective registration statement. We have filed this registration statement to meet our obligations under the Registration Rights Agreement.
 
 
 
 
 
 
 
 
ii

 
 
 
We file annual, quarterly and current reports, proxy statements and other information with the SEC.  You may read and copy any document that we file at the Public Reference Room of the SEC at 100 F Street, NE, Washington, DC 20549.  You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.  In addition, the SEC maintains an Internet site at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Interested persons can electronically access our SEC filings, including the Registration Statement and the exhibits and schedules to the Registration Statement, at the SEC website.
 
The SEC allows us to “incorporate by reference” the information we file with them, which means that we can disclose important information to you by referring you to those documents.  The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information.  We incorporate by reference the documents listed below and any future filings made with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (other than, in each case, documents or information deemed to have been furnished and not filed in accordance with SEC rules), on or after the date of this prospectus until we complete or terminate the exchange offer covered by this prospectus:
 
 
·
Annual Report on Form 10-K, filed with the SEC on February 9, 2016.
 
 
·
Current Report on Form 8-K, filed with the SEC on January 26, 2016.
 
 
·
Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 8, 2016 (portions thereof incorporated by reference in Part III of the Annual Report on Form 10-K for the year ended December 31, 2015).
 
You may request a copy of any or all of the documents incorporated by reference into this prospectus at no cost, by writing or telephoning us at the following address:
 
Nancy R. Christal
Senior Vice President, Investor Relations
CVS Health Corporation
670 White Plains Road, Suite 210
Scarsdale, New York 10583
(800) 201-0938
investorinfo@cvshealth.com
 

 
iii

 

 
This summary highlights selected information appearing in other sections of, or incorporated by reference in, this prospectus.  It is not complete and does not contain all the information that you should consider before making your investment decision.  You should carefully read this prospectus and the documents incorporated by reference to understand fully the terms of the exchange offer, as well as the tax and other considerations that may be important to you.  You should pay special attention to the “Risk Factors” section beginning on page 10 of this prospectus, as well as the section entitled “Cautionary Statement Regarding Forward-Looking Statements” beginning on page 11 of this prospectus.  You should rely only on the information contained or incorporated by reference in this document or to which we have referred you.  We have not authorized anyone to provide you with information that is different.  The information in this document may only be accurate on the date of this document or, in the case of information that may be incorporated by reference into this prospectus, as of the date of such information.  For purposes of this prospectus, unless the context requires or as otherwise indicated, when we refer to “CVS Health,” the “Company,” “us,” “we,” “our” or “ours,” we are describing CVS Health Corporation and its subsidiaries.
 
Introduction
 
CVS Health, together with its subsidiaries, is a pharmacy innovation company helping people on their path to better health.  At the forefront of a changing health care landscape, we have an unmatched suite of capabilities and the expertise needed to drive innovations that will help shape the future of health.
 
We are currently the only integrated pharmacy health care company with the ability to impact consumers, payors, and providers with innovative, channel-agnostic solutions to complex challenges managing costs and care.  We have a deep understanding of their diverse needs through our unique integrated model, and we are bringing them innovative solutions that help increase access to quality care, deliver better health outcomes, and lower overall health care costs.
 
Through our approximately 9,600 retail drugstores, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 75 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, and expanding specialty pharmacy services, we enable people, businesses, and communities to manage health in more effective ways.  We are delivering break-through products and services, from advising patients on their medications at our CVS Pharmacy® locations, to introducing unique programs to help control costs for our clients at CVS CaremarkTM, to innovating how care is delivered to our patients with complex conditions through CVS SpecialtyTM, to improving pharmacy care for the senior community through Omnicare®, or by expanding access to high-quality, low-cost care at CVS MinuteClinicTM.
 
On August 18, 2015, we acquired 100% of the outstanding common shares and voting interests of Omnicare, Inc. (“Omnicare”), for $98 per share for a total of $9.6 billion and assumed long-term debt with a fair value of approximately $3.1 billion.  Omnicare is a leading pharmaceutical care company that specializes in the management of long-term care pharmacy services.  As a result of the acquisition of Omnicare, the Company’s segments have been expanded.  The Company’s Pharmacy Services Segment now also includes the specialty pharmacy operations of Omnicare.  The Company’s Retail Pharmacy Segment has been renamed the “Retail/LTC Segment” and now also includes the long-term care (“LTC”) operations, as well as the commercialization services, of Omnicare.  The LTC operations include the distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
 
On December 16, 2015, we acquired the pharmacy and clinic businesses of Target Corporation (“Target”) for approximately $1.9 billion.  This acquisition expands our pharmacy and clinic presence in existing and new markets.  It allows us to increase patient access and is an investment in our core business to drive growth.  The results of the Target pharmacies and clinics are included in our Retail/LTC Segment.
 
We currently have three reportable segments:  Pharmacy Services, Retail/LTC and Corporate.
 
Pharmacy Services Segment
 
Our Pharmacy Services Segment generates revenue from a full range of pharmacy benefit management (“PBM”) services, including plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management services and medical spend management.
 
 
1

 
 
Our clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans and other sponsors of health benefit plans, and individuals throughout the United States.  A portion of covered lives primarily within the Managed Medicaid, health plan and employer markets have access to our services through public and private exchanges.
 
As a pharmacy benefits manager, we manage the dispensing of pharmaceuticals through our mail order pharmacies, specialty pharmacies and national network of more than 68,000 retail pharmacies, consisting of approximately 41,000 chain pharmacies (which includes our CVS Pharmacy® stores) and 27,000 independent pharmacies, to eligible members in the benefit plans maintained by our clients and utilize our information systems to perform, among other things, safety checks, drug interaction screenings and brand to generic substitutions.
 
Our specialty pharmacies support individuals that require complex and expensive drug therapies.  Our specialty pharmacy business includes mail order and retail specialty pharmacies that operate under the CVS CaremarkTM, CarePlus CVS PharmacyTM, Navarro® Health Services and Advanced Care Scripts names.  In August 2015, we expanded our offerings with the acquisition of Omnicare which included its specialty pharmacy operating under the Advanced Care Scripts name.  The Pharmacy Services Segment also provides health management programs, which include integrated disease management programs for 17 conditions, through our Accordant® rare disease management offering.  In addition, through our SilverScript Insurance Company subsidiary, we are a national provider of drug benefits to eligible beneficiaries under the federal government’s Medicare Part D program.
 
The Pharmacy Services Segment operates under the CVS Caremark® Pharmacy Services, Caremark®, CVS CaremarkTM, CarePlus CVS PharmacyTM, Accordant®, SilverScript®, Coram®, CVS SpecialtyTM, NovoLogix®, Navarro® Health Services and Advanced Care Scripts names.  As of December 31, 2015, the Pharmacy Services Segment operated 24 retail specialty pharmacy stores, 11 specialty mail order pharmacies, five mail service dispensing pharmacies, and 83 branches for infusion and enteral services, including approximately 73 ambulatory infusion suites and six centers of excellence, located in 40 states, Puerto Rico and the District of Columbia.
 
Retail/LTC Segment
 
Our Retail/LTC Segment sells prescription drugs and a wide assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, photo finishing, seasonal merchandise and greeting cards.  With the acquisition of Omnicare, the Retail/LTC Segment now also includes the distribution of prescription drugs, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings, as well as commercialization services which are provided under the name RxCrossroads®.  We added approximately 1,672 pharmacies through the acquisition of Target’s pharmacies, thereby, expanding our presence in new and existing markets.  The stores within Target will only sell prescription drugs and over-the-counter drugs that are required to be behind the counter.  Our Retail/LTC Segment derives the majority of its revenues through the sale of prescription drugs, which are dispensed by our more than 30,000 retail pharmacists.
 
Our Retail/LTC Segment also provides health care services through our MinuteClinic® health care clinics.  MinuteClinics are staffed by nurse practitioners and physician assistants who utilize nationally recognized protocols to diagnose and treat minor health conditions, perform health screenings, monitor chronic conditions, and deliver vaccinations.  Through the acquisition of Target’s clinics, we added 79 clinics.
 
As of December 31, 2015, our Retail/LTC Segment included 9,655 retail drugstores (of which 7,897 were our stores that operated a pharmacy and 1,672 were our pharmacies located within Target stores) located in 49 states, the District of Columbia, Puerto Rico and Brazil operating primarily under the CVS Pharmacy®, CVS®, Longs Drugs®, Navarro Discount Pharmacy® and Drogaria OnofreTM names, 32 onsite pharmacies primarily operating under the CarePlus CVS PharmacyTM, CarePlus® and CVS Pharmacy® names, and 1,135 retail health care clinics operating primarily under the MinuteClinic® name (of which 1,049 were located in CVS Pharmacy stores), and our online retail websites, CVS.com®, Navarro.comTM and Onofre.com.brTM.  LTC operations comprise 143 spoke pharmacies that primarily handle new prescription orders, of which 32 are also hub pharmacies that use proprietary automation to support spoke pharmacies with refill prescriptions.  LTC operates primarily under the Omnicare® and NeighborCare® names.
 
 
2

 
 
Corporate Segment
 
Our Corporate Segment provides management and administrative services to support the Company.  Our Corporate Segment consists of certain aspects of our executive management, corporate relations, legal, compliance, human resources, corporate information technology and finance departments.
 
CVS Health Corporation is a Delaware corporation.  Our corporate office is located at One CVS Drive, Woonsocket, Rhode Island 02895, telephone (401) 765-1500.  Our common stock is listed on the New York Stock Exchange under the trading symbol “CVS.”  General information about CVS Health is available through our website at http://www.cvshealth.com.  Our financial press releases and filings with the SEC are available free of charge on the investor relations portion of our website at http://investors.cvshealth.com.  Our website and the information contained therein or connected thereto shall not be deemed to be incorporated into this prospectus.
 
 
 
 
 
 
 
3

 

Summary of the Terms of the Exchange Offer
 
The Exchange Offer
 
We are offering to exchange up to $387,285,000 aggregate principal amount of the Old 2022 Notes for up to $387,285,000 aggregate principal amount of the New 2022 Notes, and up to $296,255,000 aggregate principal amount of the Old 2024 Notes for up to $296,255,000 aggregate principal amount of the New 2024 Notes.  Old Notes may be exchanged only in minimum denominations of $2,000 and integral multiples of $1,000 in excess of $2,000.  New Notes will be issued only in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof.
     
   
The terms of the New Notes are identical in all material respects to the Old Notes of the same series, except that the New Notes are registered under the Securities Act and will not contain restrictions on transfer or provisions relating to additional interest, will bear a different CUSIP number from the Old Notes of the same series and will not entitle their holders to registration rights.  The New Notes and the Old Notes will be governed by the same Senior Indenture dated August 15, 2006 between CVS Health Corporation (formerly known as CVS Corporation), as issuer, and The Bank of New York Mellon Trust Company, N.A. (formerly known as “The Bank of New York Trust Company, N.A.”), as trustee (the “Indenture”).  No accrued interest will be paid at the time of the exchange.
     
Registration Rights Agreement
 
We issued an aggregate of $387,285,000 of the Old 2022 Notes and $296,255,000 of the Old 2024 Notes in connection with private exchange offers on October 9, 2015 and October 21, 2015.  In connection with the private exchange offers, we and the dealer managers entered into the Registration Rights Agreement with respect to the Old Notes in which we agreed that you, as a holder of Old Notes, would be entitled to exchange your Old Notes for the New Notes registered under the Securities Act.  This exchange offer is intended to satisfy our obligations under the Registration Rights Agreement.  After the exchange offer is completed, you will no longer be entitled to any registration rights with respect to the Old Notes.
     
CUSIPs
 
The CUSIP numbers for the Old 2022 Notes are 126650 CP3 (Rule 144A) and U15149 AE4 (Regulation S). The CUSIP number for the New 2022 Notes is 126650 CQ1.
     
    The CUSIP numbers for the Old 2024 Notes are 126650 CR9 (Rule 144A) and U15149 AF1 (Regulation S). The CUSIP number for the New 2024 Notes is 126650 CS7.
     
Expiration Date
 
The exchange offer will expire at           p.m., New York City time, on                    , 2016, unless we extend it, in which case the Expiration Date will be the latest date and time to which we extend exchange offer.  See “The Exchange Offer—Expiration Date; Extensions; Termination; Amendments.”
     
Conditions to the Exchange Offer
 
The exchange offer is subject to customary conditions, which we may waive.  See “The Exchange Offer—Conditions to the Exchange Offer.”
 
 
 
4

 
 
Procedures for Tendering Old Notes
 
If you wish to accept the exchange offer, sign and date the letter of transmittal that was delivered with this prospectus in accordance with the instructions, and deliver the letter of transmittal, along with the Old Notes and any other required documentation, to the exchange agent.  Alternatively, you can tender your outstanding Old Notes by following the procedures for book-entry transfer, as described in this prospectus.  See “The Exchange Offer—Procedures for Tendering Old Notes.”  By executing the letter of transmittal or by transmitting an agent’s message in lieu thereof, you will represent to us that, among other things:
     
   
•      the New Notes you receive will be acquired in the ordinary course of your business;
     
   
•      you are not participating, and you have no arrangement with any person or entity to participate, in the distribution of the New Notes;
     
   
•      you are not an “affiliate” (as defined in Rule 405 under the Securities Act) of ours, or, if you are such an affiliate, you will comply with the registration and prospectus delivery requirements of the Securities Act to the extent applicable;
     
   
•      you are not a broker-dealer who tendered 4.75% notes due December 1, 2022 issued by Omnicare, Inc. or 5.00% notes due December 1, 2024 issued by Omnicare, Inc. acquired directly from Omnicare, Inc. for its own account in exchange for the Old Notes;
     
   
•      if you are a broker-dealer, you have not entered into any arrangement or understanding with us or any of our “affiliates” to distribute the New Notes; and
     
   
•      you are not acting on behalf of any person or entity that could not truthfully make these representations.
     
    If the exchange offeree is a broker-dealer holding Old Notes acquired for its own account as a result of market-making activities or other trading activities, it will deliver a prospectus meeting the requirements of the Securities Act in connection with any resale of New Notes received in respect of such Old Notes pursuant to the exchange offer.
     
Special Procedures for Beneficial Owners
 
If you are a beneficial owner whose Old Notes are registered in the name of a broker, dealer, commercial bank, trust company or other nominee and wish to tender such Old Notes in the exchange offer, please contact the registered holder as soon as possible and instruct them to tender on your behalf and comply with our instructions set forth elsewhere in this prospectus.  See “The Exchange Offer—Procedures for Tendering Old Notes—Special Procedures for Beneficial Owners.”
     
Effect on Holders of Outstanding Old Notes
 
As a result of the making of, and upon acceptance for exchange of all validly tendered outstanding Old Notes pursuant to the terms of, the exchange offer, the Company will have fulfilled its obligation to consummate an exchange offer for the Old Notes under the Registration Rights Agreement. Accordingly, there will be no increase in the interest rate on the outstanding notes under the circumstances described in the Registration Rights Agreement. If you do not tender your Old Notes in the exchange offer, you will continue to be entitled to all the rights and limitations applicable to the outstanding notes as set forth in the Indenture, except the Company will not have any further obligation to you to provide for the exchange and, subject to limited exceptions, registration of untendered outstanding notes under the Registration Rights Agreement. To the extent that Old Notes are tendered and accepted in the exchange offer, the trading market for Old Notes that are not so tendered and accepted could be adversely affected.
     
 
 
5

 
 
Consequences of Failure to Exchange the Old Notes
 
All untendered outstanding Old Notes will continue to be subject to the restrictions on transfer set forth in the outstanding Old Notes and in the related Indenture.  In general, the outstanding Old Notes may not be offered or sold, unless registered under the Securities Act, except pursuant to an exemption from, or in a transaction not subject to, the Securities Act and applicable state securities laws.  Other than in connection with the exchange offer, the Company does not currently anticipate that it will register the outstanding Old Notes under the Securities Act.
     
Material U.S. Federal Income Tax Considerations
 
The exchange of outstanding Old Notes for New Notes in the exchange offer will not constitute taxable events to holders for United States federal income tax purposes.  See “Material U.S. Federal Income Tax Considerations.”
     
Use of Proceeds
 
We will not receive any cash proceeds from the issuance of the New Notes in the exchange offer.  See “Use of Proceeds.”
     
Exchange Agent
 
D.F. King & Co., Inc. is the exchange agent for the exchange offer.  The address and telephone numbers of the exchange agent are set forth in the section captioned “The Exchange Offer — Exchange Agent.”
     
Information Agent
 
D.F. King & Co., Inc. is the information agent for the exchange offer.  The address and telephone numbers of the information agent are set forth in the section captioned “The Exchange Offer — Information Agent.”
 
 
 

 
 
6

 

Summary of Terms of New Notes
 
The following is a brief summary of certain terms of the New Notes and the related Indenture.  For a more complete description of the terms of the New Notes and the Indenture, see “Description of the Notes” contained elsewhere in this prospectus.
 
Issuer
 
CVS Health Corporation
     
New Notes
 
Up to $387,285,000 aggregate principal amount of 4.75% Senior Notes due 2022 and up to $296,255,000 aggregate principal amount of 5.00% Senior Notes due 2024.
     
Maturity Dates
 
The New 2022 Notes:  December 1, 2022.
     
   
The New 2024 Notes:  December 1, 2024.
     
Interest
 
We will pay interest on the New Notes on June 1 and December 1.  The New 2022 Notes will bear interest at 4.75% per year and the New 2024 Notes will bear interest at 5.00% per year.  The New Notes will bear interest from the most recent interest payment date on the Old Notes.
     
Ranking
 
The New Notes will be our general unsecured senior obligations, will rank equally in right of payment with all of our other existing and future unsecured and unsubordinated debt and will be structurally subordinated to the secured and unsecured debt of our subsidiaries.  The New Notes will not be guaranteed by any of our future or existing subsidiaries.
     
Change of Control
 
Upon the occurrence of a Change of Control Triggering Event (as defined in the Indenture), we will be required to make an offer to purchase the New Notes at a price equal to 101% of their principal amount plus accrued and unpaid interest to, but excluding, the date of repurchase.  See “Description of the Notes—Change of Control.”
     
Optional Redemption
 
Prior to (i) with respect to the New 2022 Notes, September 1, 2022 (three months prior to the maturity date of such notes) and (ii) with respect to the New Notes, September 1, 2024 (three months prior to the maturity date of such notes), a series of New Notes will be redeemable, in whole or in part at any time, at our option upon not less than 30 nor more than 60 days’ notice at a “make-whole” premium, plus accrued and unpaid interest to the redemption date.
     
   
On or after (i) with respect to the New 2022 Notes, September 1, 2022 (three months prior to the maturity date of such notes) and (ii) with respect to the New 2024 Notes, September 1, 2024 (three months prior to the maturity date of such New Notes), a series of New Notes will be redeemable, in whole or in part at any time, at our option upon not less than 30 nor more than 60 days’ notice at a redemption price equal to 100% of the principal amount of the New Notes being redeemed plus accrued and unpaid interest on such New Notes to, but excluding, the redemption date.
     
Restrictive Covenants
 
We will issue the New Notes under the same Indenture under which the Old Notes were issued.  The Indenture under which the New Notes will be issued contains covenants that, among other things,
 
 
7

 
 
    limit our ability and the ability of our Restricted Subsidiaries (as defined in the Indenture) to secure indebtedness with a security interest on certain property or stock or engage in certain sale and leaseback transactions with respect to certain properties. See “Description of the New Notes—Certain Covenants”.
     
Governing Law
 
The New Notes will be, and the Indenture is, governed by, and construed in accordance with, the laws of the State of New York.
     
Trustee, Transfer Agent and Paying Agent
 
The Bank of New York Mellon Trust Company, N.A.

You should read the “Risk Factors” section beginning on page 10, as well as the other cautionary statements throughout this prospectus, to ensure you understand the risks involved with the exchange of the New Notes for the outstanding Old Notes.
 
 
 
 
 
 
 
8

 

 
The following tables set forth the selected historical consolidated financial and operating data for CVS Health.  The selected consolidated financial and operating data as of and for the fiscal years ended December 31, 2015, 2014, 2013, 2012 and 2011 have been derived from CVS Health’s consolidated financial statements.  The selected consolidated financial data should be read in conjunction with the consolidated financial statements and the audit reports of Ernst & Young LLP, which are incorporated herein.
 
You should not take historical results as necessarily indicative of the results that may be expected for any future period.  You should read this selected consolidated financial and operating data in conjunction with CVS Health’s Annual Report on Form 10-K for the year ended December 31, 2015, incorporated by reference herein.
 
   
Year Ended December 31,
 
   
2015
   
2014
   
2013
   
2012
   
2011
 
   
(in millions, except per share amounts, number of stores and ratios)
 
Statement of Operations Data:
                             
Net revenues
  $ 153,290     $ 139,367     $ 126,761     $ 123,120     $ 107,080  
Gross profit
    26,528       25,367       23,783       22,488       20,562  
Operating expenses
    17,074       16,568       15,746       15,278       14,231  
Operating profit
    9,454       8,799       8,037       7,210       6,331  
Interest expense, net
    838       600       509       557       584  
Loss on early extinguishment of debt
          521             348        
Income tax provision
    3,386       3,033       2,928       2,436       2,258  
Income from continuing operations
    5,230       4,645       4,600       3,869       3,489  
Income (loss) from discontinued operations, net of tax
    9       (1 )     (8 )     (7 )     (31 )
Net income
    5,239       4,644       4,592       3,862       3,458  
Net income/(loss) attributable to noncontrolling interest
    (2 )                 2       4  
Net income attributable to CVS Health
  $ 5,237     $ 4,644     $ 4,592     $ 3,864     $ 3,462  
                                         
Per Common Share Data:
                                       
Income from continuing operations attributable to CVS Health:
                                       
Basic
  $ 4.65     $ 3.98     $ 3.78     $ 3.05     $ 2.61  
Diluted
    4.62       3.96       3.75       3.02       2.59  
Income (loss) from discontinued operations attributable to CVS Health:
                                       
Basic
  $ 0.01     $     $ (0.01 )   $ (0.01 )   $ (0.02 )
Diluted
    0.01             (0.01 )     (0.01 )     (0.02 )
Net income attributable to CVS Health:
                                       
Basic
  $ 4.66     $ 3.98     $ 3.77     $ 3.04     $ 2.59  
Diluted
    4.63       3.96       3.74       3.02       2.57  
Cash dividends per common share
    1.40       1.10       0.90       0.65       0.50  
                                         
Balance Sheet:
                                       
Total working capital
  $ 7,209     $ 6,956     $ 9,900     $ 6,011     $ 6,600  
Total assets
    93,657       74,187       71,452       66,167       64,794  
Long-term debt
    26,267       11,630       12,767       9,079       9,150  
Total shareholders’ equity
    37,203       37,963       37,938       37,653       38,014  
                                         
Other Operating Data:
                                       
Ratio of earnings to fixed charges(1)
    6.26 x     6.39 x     6.81 x     5.72 x     5.26 x
Total same store sales growth
    1.70 %     2.10 %     1.70 %     5.60 %     2.30 %
Pharmacy same store sales growth
    4.50 %     4.80 %     2.60 %     6.60 %     3.00 %
Number of stores (at end of period)      9,681       7,866       7,702       7,508       7,388  
_____________
(1)
“Fixed charges” consist of interest expense, capitalized interest, amortization of debt discount, and a portion of net rental expense deemed to be representative of the interest factor.  The ratio of earnings to fixed charges is calculated as income from continuing operations, before provision for income taxes, plus fixed charges (excluding capitalized interest), plus amortization of capitalized interest, with the sum divided by fixed charges.
 
 
9

 
    
 
You should carefully consider all the information set forth below and the other documents incorporated by reference herein and therein before you decide to participate in the exchange offer.  In particular, we urge you to consider carefully the factors set forth under “Cautionary Statement Concerning Forward-Looking Statements” in this prospectus and the risk factors set forth below together with those set forth under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, incorporated by reference herein and any updates thereto in our subsequent SEC filings.
 
Risks Related to Tendering Old Notes for New Notes
 
If you do not properly tender your Old Notes, your ability to transfer such outstanding Old Notes will be adversely affected and the trading market for such Old Notes may be limited.
 
We will only issue New Notes in exchange for Old Notes that are timely received by the exchange agent, together with all required documents, including a properly completed and signed letter of transmittal or properly transferred via book entry in accordance with the procedures described in this prospectus.  Therefore, you should allow sufficient time to ensure timely delivery of the Old Notes and you should carefully follow the instructions on how to tender your Old Notes.  Neither we nor the exchange agent are required to tell you of any defects or irregularities with respect to your tender of the Old Notes.  If you do not tender your Old Notes or if your tender of Old Notes is not accepted because you did not tender your Old Notes properly, then, after consummation of the exchange offer, you will continue to hold Old Notes that are subject to the existing transfer restrictions.  After the exchange offer is consummated, if you continue to hold any Old Notes, you may have difficulty selling them because there will be fewer Old Notes remaining and the market for such Old Notes, if any, will be much more limited than it is currently.  In particular, the trading market for unexchanged Old Notes could become more limited than the existing trading market for the Old Notes and could cease to exist altogether due to the reduction in the amount of the Old Notes remaining upon consummation of the exchange offer.  A more limited trading market might adversely affect the liquidity, market price and price volatility of such untendered Old Notes.
 
If you are a broker-dealer or participating in a distribution of the New Notes, you may be required to deliver prospectuses and comply with other requirements.
 
If you tender your Old Notes for the purpose of participating in a distribution of the New Notes, you will be required to comply with the registration and prospectus delivery requirements of the Securities Act in connection with any resale of the New Notes.  If you are a broker-dealer that receives New Notes for your own account in exchange for Old Notes that you acquired as a result of market-making activities or any other trading activities, you will be required to acknowledge that you will deliver a prospectus in connection with any resale of such New Notes.
 
An active trading market for the New Notes may not develop or be sustained.
 
The New Notes are new securities for which there currently is no market.  We have not listed and do not intend to list the New Notes on any U.S. national securities exchange or quotation system.  We cannot assure you that any market for the New Notes will develop or be sustained. If an active market is not developed or sustained, the market price and liquidity of the New Notes may be adversely affected.
 
 
10

 

 
This prospectus and the information incorporated by reference herein may contain certain forward-looking statements within the meaning of federal securities laws.  In addition, the Company and its representatives may, from time to time, make written or verbal forward-looking statements, including statements contained in the Company’s filings with the SEC and in its reports to stockholders, press releases, webcasts, conference calls, meetings and other communications.  Generally, the inclusion of the words “believe,” “expect,” “intend,” “estimate,” “project,” “anticipate,” “will,” “should” and similar expressions identify statements that constitute forward-looking statements.  All statements addressing operating performance of CVS Health Corporation or any subsidiary, events or developments that the Company expects or anticipates will occur in the future, including statements relating to corporate strategy; revenue growth; earnings or earnings per common share growth; adjusted earnings or adjusted earnings per common share growth; free cash flow; debt ratings; inventory levels; inventory turn and loss rates; store development; relocations and new market entries; retail pharmacy business, sales trends and operations; PBM business, sales trends and operations; specialty pharmacy business, sales trends and operations; LTC pharmacy business, sales trends and operations; the Company’s ability to attract or retain customers and clients; Medicare Part D competitive bidding, enrollment and operations; new product development; and the impact of industry and regulatory developments, as well as statements expressing optimism or pessimism about future operating results or events, are forward-looking statements within the meaning of the federal securities laws.
 
The forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements.  The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
 
By their nature, all forward-looking statements involve risks and uncertainties.  Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our SEC filings, including those set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2015, and including, but not limited to:
 
 
·
Risks relating to the health of the economy in general and in the markets we serve, which could impact consumer purchasing power, preferences and/or spending patterns, drug utilization trends, the financial health of our PBM and LTC clients, retail and specialty pharmacy payors or other payors doing business with us and our ability to secure necessary financing, suitable store locations and sale-leaseback transactions on acceptable terms.
 
 
·
Efforts to reduce reimbursement levels and alter health care financing practices, including pressure to reduce reimbursement levels for generic drugs.
 
 
·
The possibility of PBM and LTC client loss and/or the failure to win new PBM and LTC business, including as a result of failure to win renewal of expiring contracts, contract termination rights that may permit clients to terminate a contract prior to expiration and early or periodic renegotiation of pricing by clients prior to expiration of a contract.
 
 
·
The possibility of loss of Medicare Part D business and/or failure to obtain new Medicare Part D business, whether as a result of the annual Medicare Part D competitive bidding process, a sanction or otherwise.
 
 
·
Risks related to the frequency and rate of the introduction of generic drugs and brand name prescription products.
 
 
·
Risks of declining gross margins attributable to increased competitive pressures, increased client demand for lower prices, enhanced service offerings and/or higher service levels and market dynamics and, with respect to the PBM industry, regulatory changes that impact our ability to offer plan sponsors pricing that includes the use of retail “differential” or “spread” or the use of maximum allowable cost pricing.
 
 
11

 
 
 
·
Regulatory changes, business changes and compliance requirements and restrictions that may be imposed by Centers for Medicare and Medicaid Services (“CMS”), Office of Inspector General or other government agencies relating to our  participation in Medicare, Medicaid and other federal and state government-funded programs, including sanctions and remedial actions that may be imposed by CMS on our Medicare Part D business.
 
 
·
Risks and uncertainties related to the timing and scope of reimbursement from Medicare, Medicaid and other government-funded programs, including the impact of sequestration, the impact of other federal budget, debt and deficit negotiations and legislation that could delay or reduce reimbursement from such programs and the impact of any closure, suspension or other changes affecting federal or state government funding or operations.
 
 
·
Possible changes in industry pricing benchmarks used to establish pricing in many of our PBM and LTC client contracts, pharmaceutical purchasing arrangements, retail network contracts, specialty payor agreements and other third party payor contracts.
 
 
·
A highly competitive business environment, including the uncertain impact of increased consolidation in the PBM industry, uncertainty concerning the ability of our retail and specialty pharmacy businesses to secure and maintain contractual relationships with PBMs and other payors on acceptable terms, uncertainty concerning the ability of our PBM business to secure and maintain competitive access, pricing and other contract terms from retail network pharmacies in an environment where some PBM clients are willing to consider adopting narrow or more restricted retail pharmacy networks.
 
 
·
Our ability to timely identify or effectively respond to changing consumer preferences and spending patterns, an inability to expand the products being purchased by our customers, or the failure or inability to obtain or offer particular categories of products.
 
 
·
Risks relating to our ability to secure timely and sufficient access to the products we sell from our domestic and/or international suppliers.
 
 
·
Reform of the U.S. health care system, including ongoing implementation of the Patient Protection and Affordable Care Act, continuing legislative efforts, regulatory changes and judicial interpretations impacting our health care system and the possibility of shifting political and legislative priorities related to reform of the health care system in the future.
 
 
·
Risks relating to any failure to properly maintain our information technology systems, our information security systems and our infrastructure to support our business and to protect the privacy and security of sensitive customer and business information.
 
 
·
Risks related to compliance with a broad and complex regulatory framework, including compliance with new and existing federal, state and local laws and regulations relating to health care, accounting standards, corporate securities, tax, environmental and other laws and regulations affecting our business.
 
 
·
Risks related to litigation, government investigations and other legal proceedings as they relate to our business, the pharmacy services, retail pharmacy, LTC pharmacy or retail clinic industries or to the health care industry generally.
 
 
·
The risk that any condition related to the closing of any proposed acquisition may not be satisfied on a timely basis or at all, including the inability to obtain required regulatory approvals of any proposed acquisition, or on the terms desired or anticipated; the risk that such approvals may result in the imposition of conditions that could adversely affect the resulting combined company or the expected benefits of any proposed transaction; and the risk that the proposed transactions fail to close for any other reason.
 
 
·
The possibility that the anticipated synergies and other benefits from any acquisition by us will not be realized, or will not be realized within the expected time periods.
 
 
12

 
 
 
·
The risks and uncertainties related to our ability to integrate the operations, products, services and employees of any entities acquired by us and the effect of the potential disruption of management’s attention from ongoing business operations due to any pending acquisitions.
 
 
·
The accessibility or availability of adequate financing on a timely basis and on reasonable terms in connection with any proposed acquisition.
 
 
·
Risks related to the outcome of any legal proceedings related to, or involving any entity that is a part of, any proposed acquisition contemplated by us.
 
 
·
Other risks and uncertainties detailed from time to time in our filings with the SEC.
 
The foregoing list is not exhaustive.  There can be no assurance that we have correctly identified and appropriately assessed all factors affecting its business.  Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial also may adversely impact us.  Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on our business, financial condition and results of operations.  For these reasons, you are cautioned not to place undue reliance on our forward-looking statements.
 
 
 
 
13

 
 
 
The exchange offer is intended to satisfy our obligations under the Registration Rights Agreement.  We will not receive any cash proceeds from the issuance of New Notes under the exchange offer.  In consideration for issuing the New Notes as contemplated by this prospectus, we will receive Old Notes in like principal amount, the terms of which are identical in all material respects to the New Notes of the same series, subject to limited exceptions.  Old Notes surrendered in exchange for New Notes will be retired and canceled and cannot be reissued.  Accordingly, the issuance of the New Notes will not result in any change in our indebtedness.
 
 
 
 
 
 
 
14

 
   
 
Purpose and Effect of the Exchange Offer
 
The Company entered into the Registration Rights Agreement with the dealer managers named therein in which it agreed, under certain circumstances, to use its commercially reasonable efforts to file a registration statement relating to an offer to exchange the Old Notes for New Notes and thereafter cause the registration statement to become effective under the Securities Act no later than 330 days following the closing date of the issuance of the Old Notes.  The New Notes will have terms identical in all material respects to the Old Notes, except that the New Notes are registered under the Securities Act and will not contain restrictions on transfer or provisions relating to additional interest, will bear a different CUSIP number from the Old Notes of the same series and will not entitle their holders to registration rights.  The Old Notes were issued on October 9, 2015 and October 21, 2015.
 
If you wish to exchange your outstanding Old Notes for New Notes in the exchange offer, you will be required to make the following written representations:
 
 
·
you are not our affiliate within the meaning of Rule 405 of the Securities Act or, if you are such an affiliate, you will comply with the registration and prospectus delivery requirements of the Securities Act, to the extent applicable;
 
 
·
you are not participating, and you have no arrangement or understanding with any person to participate in a distribution (within the meaning of the Securities Act) of the New Notes in violation of the provisions of the Securities Act;
  
 
·
you are not a broker-dealer who tendered 4.75% notes due December 1, 2022 issued by Omnicare, Inc. or 5.00% notes due December 1, 2024 issued by Omnicare, Inc. acquired directly from Omnicare, Inc. for your own account in exchange for the Old Notes;
  
 
·
if you are a broker dealer, you have not entered into any arrangement or understanding with us or any of our affiliates to distribute the New Notes;
  
 
·
you are acquiring the New Notes in the ordinary course of your business; and
 
 
·
you are not acting on behalf of any person or entity that could not truthfully make these representations.
    
Each broker-dealer that receives New Notes for its own account in exchange for outstanding Old Notes, where the broker-dealer acquired the outstanding Old Notes as a result of market-making activities or other trading activities, must acknowledge that it will deliver a prospectus in connection with any resale of such New Notes.  Please see “Plan of Distribution.”
 
Terms of the Exchange Offer
 
On the terms and subject to the conditions set forth in this prospectus and in the accompanying letter of transmittal, the Company will accept for exchange in the exchange offer any outstanding Old Notes that are validly tendered and not validly withdrawn prior to the Expiration Date.  Outstanding Old Notes may only be tendered in a minimum denomination of $2,000 and integral multiples of $1,000 in excess of $2,000.  No alternative, conditional or contingent tenders will be accepted.  Holders who tender less than all of their Old Notes must continue to hold Old Notes in the minimum authorized denomination of $2,000 principal amount.  The Company will issue New Notes in principal amounts identical to the outstanding Old Notes surrendered in the exchange offer.
 
The form and terms of the New Notes will be identical in all material respects to the form and terms of the Old Notes except that the New Notes will be registered under the Securities Act, will not bear legends restricting their transfer and will not provide for any additional interest upon our failure to fulfill our obligations under the Registration Rights Agreement to complete the exchange offer, or file, and cause to be effective, a shelf registration statement, if required thereby, within the specified time period.  The New Notes will evidence the same debt as the Old Notes.  The New Notes will be issued under and entitled to the benefits of the same Indenture that authorized the issuance of the Old Notes.  For a description of the Indenture, see “Description of the Notes.”
 
 
15

 
 
The exchange offer is not conditioned upon any minimum aggregate principal amount of outstanding Old Notes being tendered for exchange.
 
As of the date of this prospectus, $387,285,000 aggregate principal amount of the Old 2022 Notes and $296,255,000 aggregate principal amount of the Old 2024 Notes are outstanding.  This prospectus and the accompanying letter of transmittal are being sent to all registered holders of Old Notes.  There will be no fixed record date for determining registered holders of outstanding Old Notes entitled to participate in the exchange offer.  The Company intends to conduct the exchange offer in accordance with the provisions of the Registration Rights Agreement, the applicable requirements of the Securities Act and the Exchange Act and the rules and regulations of the SEC.  Outstanding Old Notes that are not tendered for exchange in the exchange offer will remain outstanding and continue to accrue interest and will be entitled to the rights and benefits such holders have under the Indenture relating to such holders’ outstanding Old Notes and the Registration Rights Agreement except we will not have any further obligation to you to provide for the registration of the outstanding Old Notes under the Registration Rights Agreement.
 
The Company will be deemed to have accepted for exchange properly tendered outstanding Old Notes when it has given oral or written notice of the acceptance to the exchange agent.  The exchange agent will act as agent for the tendering holders for the purposes of receiving the New Notes from us and delivering New Notes to holders.  Subject to the terms of the Registration Rights Agreement, the Company expressly reserves the right to amend or terminate the exchange offer and to refuse to accept the occurrence of any of the conditions specified below under “— Conditions to the Exchange Offer.”
 
If you tender your outstanding Old Notes in the exchange offer, you will not be required to pay brokerage commissions or fees or, subject to the instructions in the accompanying letter of transmittal, transfer taxes with respect to the exchange of Old Notes.  We will pay all charges and expenses, other than certain applicable taxes described below in connection with the exchange offer.  It is important that you read “— Fees and Expenses” below for more details regarding fees and expenses incurred in the exchange offer.
 
Expiration Date; Extensions; Termination; Amendments
 
The exchange offer expires at         p.m., New York City time, on                        , 2016, unless we extend the exchange offer, in which case the Expiration Date will be the latest date and time to which we extend the exchange offer.
 
We expressly reserve the right, so long as applicable law allows:
 
 
·
to delay our acceptance of Old Notes for exchange;
 
 
·
to terminate the exchange offer if any of the conditions set forth under “— Conditions to the Exchange Offer” exist;
 
 
·
to waive any condition to the exchange offer;
 
 
·
to amend any of the terms of the exchange offer; and
 
 
·
to extend the Expiration Date and retain all Old Notes tendered in the exchange offer, subject to your right to withdraw your tendered Old Notes as described under “— Withdrawal of Tenders.”
 
Any waiver or amendment to the exchange offer will apply to all Old Notes tendered, regardless of when or in what order the Old Notes were tendered.  If the exchange offer is amended in a manner that we think constitutes a material change, or if we waive a material condition of the exchange offer, we will promptly disclose the amendment or waiver by means of a prospectus supplement that will be distributed to the registered holders of the Old Notes, and we will extend the exchange offer to the extent required by Rule 14e-1 under the Exchange Act.
 
 
16

 
 
We will promptly follow any delay in acceptance, termination, extension or amendment by oral or written notice of the event to the exchange agent, followed promptly by oral or written notice to the registered holders.  Should we choose to delay, extend, amend or terminate the exchange offer, we will have no obligation to publish, advertise or otherwise communicate this announcement, other than by making a timely release to an appropriate news agency.
 
In the event we terminate the exchange offer, all Old Notes previously tendered and not accepted for payment will be returned promptly to the tendering holders.
 
In the event that the exchange offer is withdrawn or otherwise not completed, New Notes will not be given to holders of Old Notes who have validly tendered their Old Notes.
 
Acceptance of Old Notes for Exchange
 
In all cases, the Company will promptly issue New Notes for outstanding Old Notes that it has accepted for exchange under the exchange offer only after the exchange agent timely receives:
 
 
·
outstanding Old Notes or a timely book-entry confirmation of such outstanding Old Notes into the exchange agent’s account at the book-entry transfer facility; and
 
 
·
a properly completed and duly executed letter of transmittal and all other required documents or a properly transmitted agent’s message.
 
By tendering outstanding Old Notes pursuant to the exchange offer, you will represent to us that, among other things:
 
 
·
you are not our affiliate within the meaning of Rule 405 of the Securities Act or, if you are such an affiliate, you will comply with the registration and prospectus delivery requirements of the Securities Act, to the extent applicable;
 
 
·
you are not participating, and you have no arrangement or understanding with any person to participate in a distribution (within the meaning of the Securities Act) of the New Notes in violation of the provisions of the Securities Act;
 
 
·
you are not a broker-dealer who tendered 4.75% notes due December 1, 2022 issued by Omnicare, Inc. or 5.00% notes due December 1, 2024 issued by Omnicare, Inc. acquired directly from Omnicare, Inc. for your own account in exchange for the Old Notes;
 
 
·
if you are a broker-dealer, you have not entered into any arrangement or understanding with us or any of our affiliates to distribute the New Notes;
 
 
·
you are acquiring the New Notes in the ordinary course of your business; and
  
 
·
you are not acting on behalf of any person or entity that could not truthfully make these representations.
  
In addition, each broker-dealer that is to receive New Notes for its own account in exchange for outstanding Old Notes must represent that such outstanding Old Notes were acquired by that broker-dealer as a result of market-making activities or other trading activities and must acknowledge that it will deliver a prospectus that meets the requirements of the Securities Act in connection with any resale of the New Notes.  The letter of transmittal states that by so acknowledging and by delivering a prospectus, a broker-dealer will not be deemed to admit that it is an “underwriter” within the meaning of the Securities Act.  See “Plan of Distribution.”
 
The Company will interpret the terms and conditions of the exchange offer, including the letters of transmittal and the instructions to the letters of transmittal, and will resolve all questions as to the validity, form, eligibility, including time of receipt, and acceptance of outstanding Old Notes tendered for exchange.  Our determinations in this regard will be final and binding on all parties.  The Company reserves the absolute right to reject any and all tenders of any particular outstanding Old Notes not properly tendered or to not accept any particular Old Notes if the acceptance might, in its or its counsel’s judgment, be unlawful.  We also reserve the absolute right to waive any defects or irregularities as to any particular outstanding Old Notes prior to the Expiration Date.
 
Unless waived, any defects or irregularities in connection with tenders of outstanding Old Notes for exchange must be cured within such reasonable period of time as we determine.  Neither the Company, the exchange agent nor any other person will be under any duty to give notification of any defect or irregularity with respect to any tender of outstanding Old Notes for exchange, nor will any of them incur any liability for any failure to give notification.  Any outstanding Old Notes received by the exchange agent that are not properly tendered and as to which the irregularities have not been cured or waived will be returned by the exchange agent to the tendering holder, unless otherwise provided in the letter of transmittal, promptly after the Expiration Date.
 
 
17

 
 
Procedures for Tendering Old Notes
 
To tender your outstanding Old Notes in the exchange offer, you must comply with either of the following:
 
 
·
complete, sign and date the letter of transmittal, or a facsimile of the letter of transmittal, have the signature(s) on the letter of transmittal guaranteed if required by the letter of transmittal and mail or deliver such letter of transmittal or facsimile thereof to the exchange agent at the address set forth below under “— Exchange Agent” prior to the Expiration Date; or
 
 
·
comply with the procedures of the Automated Tender Offer Program of The Depository Trust Company (“DTC”) described below.
 
In addition, either:
 
 
·
the exchange agent must receive certificates for outstanding Old Notes along with the letter of transmittal prior to the Expiration Date; or
 
 
·
the exchange agent must receive a timely confirmation of book-entry transfer of outstanding Old Notes into the exchange agent’s account at DTC according to the procedures for book-entry transfer described below or a properly transmitted agent’s message prior to the Expiration Date.
 
Your tender, if not withdrawn prior to the Expiration Date, constitutes an agreement between us and you upon the terms and subject to the conditions described in this prospectus and in the letter of transmittal.
 
If you wish to exchange your outstanding Old Notes for New Notes in the exchange offer, you will be required to make the written representations as set forth in “—Purpose and Effect of the Exchange Offer.”
 
The method of delivery of outstanding Old Notes, letters of transmittal and all other required documents to the exchange agent is at your election and risk.  We recommend that instead of delivery by mail, you use an overnight or hand delivery service, properly insured.  In all cases, you should allow sufficient time to assure timely delivery to the exchange agent before the Expiration Date.  You should not send letters of transmittal or certificates representing outstanding Old Notes to us.  You may request that your broker, dealer, commercial bank, trust company or nominee effect the above transactions for you.
 
If you are a beneficial owner whose outstanding Old Notes are registered in the name of a broker, dealer, commercial bank, trust company or other nominee and you wish to tender your outstanding Old Notes, you should promptly contact your registered holder and instruct the registered holder to tender on your behalf.
 
Signatures on the letter of transmittal or a notice of withdrawal, as the case may be, must be guaranteed by a member firm of a registered national securities exchange or of the National Association of Securities Dealers, Inc., a commercial bank or trust company having an office or correspondent in the United States or another “eligible guarantor institution” within the meaning of Rule 17A(d)-15 under the Exchange Act unless the outstanding Old Notes surrendered for exchange are tendered:
 
 
·
by a registered holder of the outstanding Old Notes who has not completed the box entitled “Special Registration Instructions” or “Special Delivery Instructions” on the letter of transmittal; or
 
 
·
for the account of an eligible guarantor institution.
 
If the letter of transmittal is signed by a person other than the registered holder of any Old Notes listed on the outstanding Old Notes, such outstanding Old Notes must be endorsed or accompanied by a properly completed bond power.  The bond power must be signed by the registered holder as the registered holder’s name appears on the outstanding Old Notes, and an eligible guarantor institution must guarantee the signature on the bond power.
 
If the letter of transmittal, any certificates representing outstanding Old Notes or bond powers are signed by trustees, executors, administrators, guardians, attorneys-in-fact, officers of corporations or others acting in a fiduciary or representative capacity, those persons should also indicate when signing and, unless waived by us, they should also submit evidence satisfactory to us of their authority to so act.
 
 
18

 
 
The exchange agent and DTC have confirmed that any financial institution that is a participant in DTC’s system may use DTC’s Automated Tender Offer Program to tender Old Notes.  Participants in the program may, instead of physically completing and signing the letter of transmittal and delivering it to the exchange agent, electronically transmit their acceptance of the exchange by causing DTC to transfer the Old Notes to the exchange agent in accordance with DTC’s Automated Tender Offer Program procedures for transfer.  DTC will then send an agent’s message to the exchange agent.  The term “agent’s message” means a message transmitted by DTC, received by the exchange agent and forming part of the book-entry confirmation, which states that:
 
 
·
DTC has received an express acknowledgment from a participant in its Automated Tender Offer Program that is tendering outstanding Old Notes that are the subject of the book-entry confirmation;
 
 
·
the participant has received and agrees to be bound by the terms of the letter of transmittal; and
 
 
·
we may enforce that agreement against such participant.
 
DTC is referred to herein as a “book-entry transfer facility.”
 
Book-Entry Transfer
 
The exchange agent will seek to establish a new account or utilize an existing account with respect to the Old Notes at DTC promptly after the date of this prospectus.  Any financial institution that is a participant in the DTC system and whose name appears on a security position listing as the owner of the Old Notes may make book-entry delivery of Old Notes by causing DTC to transfer such Old Notes into the exchange agent’s account.  The confirmation of a book-entry transfer of Old Notes into the exchange agent’s account at DTC is referred to in this prospectus as a “book-entry confirmation.”  Delivery of documents to DTC in accordance with DTC’s procedures does not constitute delivery to the exchange agent.
 
Other Matters
 
New Notes will be issued in exchange for Old Notes accepted for exchange only after timely receipt by the exchange agent of:
 
 
·
certificates for (or a timely book-entry confirmation with respect to) your Old Notes;
 
 
·
a properly completed and duly executed letter of transmittal or facsimile thereof with any required signature guarantees, or, in the case of a book-entry transfer, an agent’s message; and
 
 
·
any other documents required by the letter of transmittal.
 
We will determine, in our sole discretion, all questions as to the form of all documents, validity, eligibility, including time of receipt, and acceptance of all tenders of Old Notes.  There will be no guaranteed delivery procedures for the offer.  Our determination will be final and binding on all parties.  Alternative, conditional or contingent tenders of Old Notes will not be considered valid.  We reserve the absolute right to reject any or all tenders of Old Notes that are not in proper form or the acceptance of which, in our opinion, would be unlawful.  We also reserve the right to waive any defects, irregularities or conditions of tender as to particular Old Notes.
 
Our interpretation of the terms and conditions of the exchange offer, including the instructions in the accompanying letter of transmittal, will be final and binding.
 
Any defect or irregularity in connection with tenders of Old Notes must be cured within the time we determine, unless waived by us.  We will not consider the tender of Old Notes to have been validly made until all defects and irregularities have been waived by us or cured.  Neither we, the exchange agent nor any other person will be under any duty to give notice of any defects or irregularities in tenders of Old Notes, or will incur any liability to holders for failure to give any such notice.
 
 
19

 
 
Withdrawal of Tenders
 
Except as otherwise provided in this prospectus, you may withdraw your tender of Old Notes at any time prior to the Expiration Date.
 
For a withdrawal to be effective:
 
 
·
the exchange agent must receive a written notice of withdrawal at the address set forth on the inside of the back cover of this prospectus; or
 
 
·
you must comply with the appropriate procedures of DTC’s Automated Tender Offer Program system.
 
Any notice of withdrawal must:
 
 
·
specify the name of the person who tendered the Old Notes to be withdrawn;
 
 
·
identify the Old Notes to be withdrawn, including the certificate numbers and principal amount of the Old Notes;
 
 
·
be signed by the person who tendered the Old Notes in the same manner as the original signature on the letter of transmittal, including any required signature guarantees; and
 
 
·
specify the name in which the Old Notes are to be re-registered, if different from that of the withdrawing holder.
 
If Old Notes have been tendered pursuant to the procedure for book-entry transfer described above, any notice of withdrawal must specify the name and number of the account at DTC to be credited with the withdrawn Old Notes and otherwise comply with the procedures of DTC.
 
We will determine all questions as to validity, form, eligibility and time of receipt of any withdrawal notices.  Our determination will be final and binding on all parties.  We will deem any Old Notes so withdrawn not to have been validly tendered for exchange for purposes of the exchange offer.
 
Any Old Notes that have been tendered for exchange but that are not exchanged for any reason will be returned to their holder without cost to the holder or, in the case of Old Notes tendered by book-entry transfer into the exchange agent’s account at DTC according to the procedures described above, such Old Notes will be credited to an account maintained with DTC for the Old Notes.  This return or crediting will take place promptly after withdrawal, rejection of tender or termination of the exchange offer.  You may retender properly withdrawn Old Notes by following one of the procedures described under “— Procedures for Tendering Old Notes” at any time on or prior to the Expiration Date.
 
Conditions to the Exchange Offer
 
Despite any other term of the exchange offer, the Company will not be required to accept for exchange, or to issue New Notes in exchange for, any outstanding Old Notes and it may terminate or amend the exchange offer as provided in this prospectus prior to the Expiration Date if in its reasonable judgment:
 
 
·
the exchange offer or the making of any exchange by a holder violates any applicable law or interpretation of the SEC; or
 
 
·
any action or proceeding has been instituted or threatened in writing in any court or by or before any governmental agency with respect to the exchange offer that, in our judgment, would reasonably be expected to impair our ability to proceed with the exchange offer.
 
In addition, the Company will not be obligated to accept for exchange the outstanding Old Notes of any holder that has not made to us:
 
 
20

 
 
 
·
the representations described under “— Purpose and Effect of the Exchange Offer,” “— Procedures for Tendering Outstanding Notes” and “Acceptance of Old Notes for Exchange”; or
 
 
·
any other representations as may be reasonably necessary under applicable SEC rules, regulations or interpretations to make available to us an appropriate form for registration of the New Notes under the Securities Act.
 
The Company expressly reserves the right at any time or at various times to extend the period of time during which the exchange offer is open.  Consequently, the Company may delay acceptance of any Old Notes by giving oral or written notice of such extension to their holders.  The Company will return any outstanding Old Notes that it does not accept for exchange for any reason without expense to their tendering holder promptly after the expiration or termination of the exchange offer.
 
The Company expressly reserves the right to amend or terminate the exchange offer and to reject for exchange any outstanding Old Notes not previously accepted for exchange, upon the occurrence of any of the conditions of the exchange offer specified above.  The Company will give oral or written notice of any extension, amendment, non-acceptance or termination of the exchange offer to the holders of the outstanding Old Notes as promptly as practicable.  In the case of any extension of the exchange offer, such notice will be issued no later than 9:00 a.m., New York City time, on the next business day after the previously scheduled Expiration Date.
 
These conditions are for our sole benefit, and the Company may assert them regardless of the circumstances that may give rise to them or waive them in whole or in part at any or at various times prior to the Expiration Date in our sole discretion.  If the Company fails at any time to exercise any of the foregoing rights, this failure will not constitute a waiver of such right.  Each such right will be deemed an ongoing right that it may assert at any time or at various times prior to the Expiration Date.
 
In addition, the Company will not accept for exchange any outstanding Old Notes tendered, and will not issue New Notes in exchange for any such outstanding Old Notes, if at such time any stop order is threatened or in effect with respect to the registration statement of which this prospectus constitutes a part or the qualification of the Indenture under the Trust Indenture Act of 1939, as amended.
 
Transfer Taxes
 
We will pay all transfer taxes applicable to the transfer and exchange of Old Notes pursuant to the exchange offer.  If, however:
 
 
·
delivery of the New Notes and/or certificates for Old Notes for principal amounts not exchanged, are to be made to any person other than the record holder of the Old Notes tendered;
 
 
·
tendered certificates for Old Notes are recorded in the name of any person other than the person signing any letter of transmittal; or
 
 
·
a transfer tax is imposed for any reason other than the transfer and exchange of Old Notes to us or our order,
 
the amount of any such transfer taxes, whether imposed on the record holder or any other person, will be payable by the tendering holder prior to the issuance of the New Notes.
 
Consequences of Failing to Exchange
 
If you do not exchange your Old Notes for New Notes in the exchange offer, you will remain subject to the restrictions on transfer of the Old Notes:
 
 
·
as set forth in the legend printed on the Old Notes as a consequence of the issuance of the Old Notes pursuant to the exemptions from, or in transactions not subject to, the registration requirements of the Securities Act and applicable state securities laws; and
 
 
21

 
 
 
·
otherwise set forth in the offering memorandum distributed in connection with the private offering of the Old Notes.
 
In general, you may not offer or sell the Old Notes unless they are registered under the Securities Act, or if the offer or sale is exempt from registration under the Securities Act and applicable state securities laws.  Upon completion of the exchange offer, except as required by the Registration Rights Agreement, we are under no obligation to, and do not intend to register resales of the outstanding Old Notes under the Securities Act.
 
Accounting Treatment
 
The New Notes will be recorded at the same carrying value as the Old Notes, as reflected in our accounting records on the date of the exchange.  Accordingly, we will not recognize any gain or loss for accounting purposes upon the consummation of the exchange offer.  We will amortize the expenses of the exchange offer over the term of the New Notes.
 
Exchange Agent
 
D.F. King & Co., Inc. has been appointed as exchange agent for the exchange offer. You should direct questions and requests for assistance, requests for additional copies of this prospectus, the letter of transmittal or any other documents to the exchange agent. You should send certificates for Old Notes, letters of transmittal and any other required documents to the exchange agent at the address set forth on the inside of the back cover of this prospectus.
 
Information Agent
 
D.F. King & Co., Inc. has been appointed as information agent for the exchange offer. Questions concerning tender procedures and requests for additional copies of this prospectus or the letter of transmittal should be directed to the information agent at the address and telephone number set forth on the inside of the back cover of this prospectus. Holders of Old Notes may also contact their commercial bank, broker, dealer, trust company or other nominee for assistance concerning the exchange offer.
 
Resale of New Notes
 
Based on interpretations by the SEC set forth in no-action letters issued to third parties, we believe that you may resell or otherwise transfer New Notes issued in the exchange offer without complying with the registration and prospectus delivery provisions of the Securities Act, if:
 
 
·
you are not our affiliate within the meaning of Rule 405 of the Securities Act;
 
 
·
you are not participating, and you have no arrangement or understanding with any person to participate in a distribution (within the meaning of the Securities Act) of the New Notes in violation of the provisions of the Securities Act;
    
 
·
you are not a broker-dealer who tendered 4.75% notes due December 1, 2022 issued by Omnicare, Inc. or 5.00% notes due December 1, 2024 issued by Omnicare, Inc. acquired directly from Omnicare, Inc. for your own account in exchange for the Old Notes;
    
 
·
if you are a broker dealer, you have not entered into any arrangement or understanding with us or any of our affiliates to distribute the New Notes; and
    
 
·
you are acquiring the New Notes in the ordinary course of your business.
 
If you are our affiliate, or are engaging in, or intend to engage in, or have any arrangement or understanding with any person to participate in, a distribution of the New Notes, or are not acquiring the New Notes in the ordinary course of your business:
 
 
·
You cannot rely on the position of the SEC set forth in Morgan Stanley & Co. Incorporated (available June 5, 1991) and Exxon Capital Holdings Corporation (available May 13, 1988), as interpreted in the SEC’s letter to Shearman & Sterling, dated July 2, 1993, and similar no-action letters; and
 
 
22

 
 
 
·
in the absence of an exception from the position stated immediately above, you must comply with the registration and prospectus delivery requirements of the Securities Act in connection with any secondary resale transaction of the New Notes, in which case the registration statement must contain the selling security holder information required by Item 507 or Item 508, as applicable, of Regulation S-K of the SEC.
 
This prospectus may be used for an offer to resell, resale or other transfer of New Notes only as specifically set forth in this prospectus.  With regard to broker-dealers, only broker-dealers that acquired the outstanding Old Notes as a result of market-making activities or other trading activities may participate in the exchange offer.  Each broker-dealer that receives New Notes for its own account in exchange for outstanding Old Notes, where such outstanding Old Notes were acquired by such broker-dealer as a result of market-making activities or other trading activities, must acknowledge that it will deliver a prospectus in connection with any resale of the New Notes.  Please read “Plan of Distribution” for more details regarding the transfer of New Notes.
 
 
 
 
 
 
 
 
23

 

 
General
 
Each series of New Notes will be issued under the Senior Indenture dated August 15, 2006 between CVS Health Corporation (formerly known as CVS Corporation), as issuer, and The Bank of New York Mellon Trust Company, N.A. (formerly known as “The Bank of New York Trust Company, N.A.”), as trustee (the “Indenture”).  The following summary of the material provisions of the Indenture does not summarize all of the provisions of the Indenture.  We urge you to read the Indenture because it, not the summaries below, defines your rights.  A copy of the Indenture has been filed as an exhibit to our current report on Form 8-K, filed with the SEC on August 15, 2006.  You may obtain a copy of the Indenture from us without charge.  See the section entitled “Where You Can Find More Information” in this prospectus.  In this description, all references to “CVS Health,” “we,” “our” and “us” mean CVS Health Corporation only.
 
The New Notes will be issued only in registered form without coupons, in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof.  No service charge will be made for any registration of transfer or any exchange of New Notes, but we may require payment of a sum sufficient to cover any transfer tax or similar governmental charge payable in connection therewith.
 
We do not intend to list the New Notes on a national securities exchange.
 
The Indenture does not contain any provisions that would limit our ability to incur indebtedness or require the maintenance of financial ratios or specified levels of net worth or liquidity, nor does it contain covenants or other provisions designed to afford holders of the New Notes protection in the event of a highly leveraged transaction, change in credit rating or other similar occurrence (except as set forth in “—Change of Control”).  However, the provisions of the Indenture do:
 
(1) provide that, subject to certain exceptions, neither we nor any of our Restricted Subsidiaries (as defined therein) will subject our property or assets to any mortgage or other encumbrance unless the New Notes are secured equally and ratably with such other indebtedness thereby secured, and
 
(2) contain certain limitations on the entry into certain sale and leaseback arrangements by us and our Restricted Subsidiaries.
 
Principal, Maturity and Interest
 
The New 2022 Notes will be issued in an aggregate principal amount of up to $387,285,000 and will mature on December 1, 2022.  The New 2022 Notes will bear interest at 4.75% per annum from the most recent date to which interest has been paid or provided for, payable semiannually in arrears to holders of record at the close of business on the May 15 or November 15 (whether or not a business day) immediately preceding the respective interest payment on June 1 or December 1 of each year.
 
The New 2024 Notes will be issued in an aggregate principal amount of up to $296,255,000 and will mature on December 1, 2024.  The New 2024 Notes will bear interest at 5.00% per annum from the most recent date to which interest has been paid or provided for, payable semiannually in arrears to holders of record at the close of business on the May 15 or November 15 (whether or not a business day) immediately preceding the respective interest payment on June 1 or December 1 of each year.
 
If any interest payment date, redemption date or the maturity date of the New Notes is not a business day, then payment of interest and/or principal will be made on the next succeeding business day.  No interest will accrue on the amount so payable for the period from such interest payment date, redemption date or maturity date, as the case may be, to the date payment is made.  Interest on the New Notes will be paid on the basis of a 360-day year consisting of twelve 30-day months.
 
The New Notes do not contain any sinking fund provisions.
 
 
24

 
 
In some circumstances, we may elect to discharge our obligations on the New Notes through defeasance or covenant defeasance.  See “Description of the New Notes—Discharge and Defeasance of New Notes and Covenants” for more information about how we may do this.
 
We may at any time purchase New Notes by tender, in the open market or by private agreement, subject to applicable law.
 
Ranking
 
The New Notes will be our general unsecured senior obligations, will rank equally in right of payment with all of our other existing and future unsecured and unsubordinated debt and will be structurally subordinated to the secured and unsecured debt of CVS Health’s subsidiaries.  The New Notes will not be guaranteed by any of our future or existing subsidiaries.
 
Optional Redemption
 
Prior to the Applicable Par Call Date, the New Notes of each series will be redeemable, in whole or in part at any time, at our option upon not less than 30 nor more than 60 days’ notice at a redemption price, plus accrued and unpaid interest to (but not including) the redemption date, equal to the greater of:
 
(1) 100% of the principal amount of the New Notes being redeemed, or
 
(2) the sum of the present values of the remaining scheduled payments of principal of and interest on the series of New Notes to be redeemed (exclusive of interest accrued to the applicable redemption date) discounted to such redemption date on a semi-annual basis, assuming a 360-day year consisting of twelve 30-day months, at the then-current Treasury Rate plus 50 basis points;
 
provided, however, that if the redemption date falls on or after the interest record date and on or prior to the related interest payment date, we will pay the full amount of accrued and unpaid interest, if any, on such redemption date to the person in whose name the note is registered at the close of business on the corresponding record date (instead of the holder surrendering its New Notes for redemption).
 
On or after the Applicable Par Call Date, the New 2022 Notes and the New 2024 Notes will be redeemable, in whole or in part at any time, at our option upon not less than 30 nor more than 60 days’ notice at a redemption price equal to 100% of the principal amount of the New Notes being redeemed plus accrued and unpaid interest on such New Notes to (but not including) the redemption date.
 
Applicable Par Call Date” means (i)  with respect to the New 2022 Notes, September 1, 2022 (three months prior to the maturity date of such notes) and (ii) with respect to the New 2024 Notes, September 1, 2024 (three months prior to the maturity date of such notes).
 
Applicable Spread” means (i) with respect to the New 2022 Notes, 50 basis points and (ii) with respect to the New 2024 Notes, 50 basis points.
 
Comparable Treasury Issue” means, with respect to each series of the New Notes offered hereby, with respect to any redemption date, the United States Treasury security selected by the Quotation Agent as having an actual or interpolated  maturity comparable to the remaining term of the series of New Notes to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the series of New Notes to be redeemed.
 
Comparable Treasury Price” means, with respect to any redemption date for a series of New Notes, (i) the average of five Reference Treasury Dealer Quotations for such redemption date, after excluding the highest and lowest such applicable Reference Treasury Dealer Quotations, (ii) if CVS Health obtains fewer than five but more than one such Reference Treasury Dealer Quotations for such redemption date, the average of all such quotations, or (iii) if CVS Health obtains only one such Reference Treasury Dealer Quotation for such redemption date, that Reference Treasury Dealer Quotation.
 
 
25

 
 
Quotation Agent” means initially Barclays Capital Inc. or Merrill Lynch, Pierce, Fenner & Smith Incorporated (or such Reference Treasury Dealer that we appoint to act as the Quotation Agent from time to time).
 
Reference Treasury Dealer means, with respect to each series of the New Notes offered hereby, (i) Barclays Capital Inc. and its successors or Merrill Lynch, Pierce, Fenner & Smith Incorporated and its successors; provided, however, that if the foregoing shall cease to be a primary United States Government securities dealer in New York City (a “Primary Treasury Dealer”), we shall substitute therefor another Primary Treasury Dealer and (ii) any other Primary Treasury Dealer selected by us.
 
Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any redemption date for a series of the New Notes, the average, as determined by the Quotation Agent, of the bid and asked prices for the Comparable Treasury Issue for such series of the New Notes (expressed in each case as a percentage of its principal amount) quoted in writing to the Quotation Agent by such Reference Treasury Dealer at 5:00 p.m., New York City time, on the third business day preceding such redemption date.
 
Treasury Rate” means, with respect to any redemption date applicable to a series of New Notes, the rate per annum equal to (i) the yield, under the heading which represents the average for the immediately preceding week, appearing in the most recently published statistical release designated “H.15(519)” or any successor publication which is published weekly by the Board of Governors of the Federal Reserve System and which establishes yields on actively traded United States Treasury securities adjusted to constant maturity under the caption “Treasury Constant Maturities,” for the maturity corresponding to the Comparable Treasury Issue (provided that, if no maturity is within three months before or after the remaining life of the New Notes to be redeemed, yields for the two published maturities most closely corresponding to the Comparable Treasury Issue will be determined and the Treasury Rate will be interpolated or extrapolated from such yields on a straight line basis, rounding to the nearest month), or (ii) if such release (or any successor release) is not published during the week preceding the calculation date or does not contain such yields, the rate per annum equal to the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, calculated using a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for the applicable redemption date.  The Treasury Rate shall be calculated on the third business day preceding the applicable redemption date.
 
A notice of redemption shall be transmitted by us (or, at our request, by the trustee on our behalf) to each holder of New Notes to be redeemed.  Such notice of redemption shall specify the principal amount of New Notes to be redeemed, the CUSIP and ISIN numbers of the New Notes to be redeemed, the date fixed for redemption, the redemption price (or if not then ascertainable, the manner of calculation thereof), the place or places of payment and that payment will be made upon presentation and surrender of such New Notes.  Once notice of redemption is sent to holders, New Notes of a series called for redemption will become due and payable on the redemption date at the redemption price for such series, plus interest accrued to the redemption date.  On or before 10:00 a.m. New York City time on the redemption date, we will deposit with the trustee or with one or more paying agents an amount of money sufficient to redeem on the redemption date all the New Notes of a series so called for redemption at the appropriate redemption price for such series, together with accrued interest to the date fixed for redemption.  Unless we default in payment of the redemption price for such series plus interest accrued to the redemption date, commencing on the redemption date interest on New Notes of a series called for redemption will cease to accrue and holders of such New Notes will have no rights with respect to such New Notes except the right to receive the redemption price for such series and any unpaid interest to the redemption date.
 
If fewer than all of the New Notes of a particular series are being redeemed, and such New Notes are represented by one or more global securities, interests in the New Notes of such series to be redeemed will be selected for redemption by The Depository Trust Company (“DTC”) in accordance with its standard procedures therefor.  Upon surrender of any note redeemed in part, the holder will receive a new note equal in principal amount to the unredeemed portion of the surrendered note.
 
In addition, we may at any time purchase New Notes by tender, in the open market or by private agreement, subject to applicable law.
 
 
26

 
 
Change of Control
 
If a Change of Control Triggering Event (as defined below) occurs, holders of New Notes will have the right to require us to repurchase all or any part (in integral multiples of $1,000 original principal amount) of their New Notes pursuant to the offer described below (Change of Control Offer) on the terms set forth in the New Notes.  In the Change of Control Offer, we will offer a cash payment equal to 101% of the aggregate principal amount of New Notes repurchased plus accrued and unpaid interest, if any, on the New Notes repurchased, to (but not including) the date of purchase (Change of Control Payment).  Within 30 days following any Change of Control Triggering Event, we will be required to mail a notice to holders of New Notes describing the transaction or transactions that constitute the Change of Control Triggering Event and offering to repurchase the New Notes on the date specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such notice is mailed (Change of Control Payment Date), pursuant to the procedures required by the New Notes and described in such notice.  We must comply with the requirements of Rule 14e-1 under the Exchange Act and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the New Notes as a result of a Change of Control Triggering Event.  To the extent that the provisions of any securities laws or regulations conflict with the Change of Control provisions of the New Notes, we will be required to comply with the applicable securities laws and regulations and will not be deemed to have breached our obligations under the Change of Control provisions of the New Notes by virtue of such conflicts and compliance with law.
 
On the Change of Control Payment Date, we will be required, to the extent lawful, to:
 
 
·
accept for payment all New Notes properly tendered pursuant to the Change of Control Offer;
 
 
·
deposit with the paying agent an amount equal to the Change of Control Payment in respect of all New Notes or portions of New Notes properly tendered; and
 
 
·
deliver or cause to be delivered to the trustee the New Notes properly accepted together with an officers’ certificate stating the aggregate principal amount of New Notes or portions of New Notes being purchased.
 
The definition of Change of Control includes a phrase relating to the direct or indirect sale, lease, transfer, conveyance or other disposition of “all or substantially all” of our properties or assets and the properties and assets of our subsidiaries taken as a whole.  Although there is a limited body of case law interpreting the phrase “substantially all” there is no precise established definition of the phrase under applicable law.  Accordingly, the ability of a holder of New Notes to require us to repurchase its New Notes as a result of a sale, lease, transfer, conveyance or other disposition of less than all of our assets and the assets of our subsidiaries taken as a whole to another person or group may be uncertain.
 
We will not be required to make a Change of Control Offer upon the occurrence of a Change of Control Triggering Event if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for an offer made by us and the third party repurchases all New Notes properly tendered and not withdrawn under its offer.  In addition, we will not repurchase any New Notes if there has occurred and is continuing on the Change of Control Payment Date an event of default under the Indenture, other than a default in the payment of the Change of Control Payment upon a Change of Control Triggering Event.
 
For purposes of the foregoing discussion of a repurchase at the option of holders, the following definitions are applicable:
 
Below Investment Grade Rating Event means that New Notes are rated below an Investment Grade Rating by each of the Rating Agencies (as defined below) on any date from the date of the public notice of an arrangement that could result in a Change of Control until the end of the 60-day period following public notice of the occurrence of the Change of Control (which 60-day period shall be extended so long as the rating of the New Notes is under publicly announced consideration for possible downgrade by any of the Rating Agencies); provided, however, that a Below Investment Grade Rating Event otherwise arising by virtue of a particular reduction in rating will not be deemed to have occurred in respect of a particular Change of Control (and thus will not be deemed a Below Investment Grade Rating Event for purposes of the definition of Change of Control Triggering Event) if the Rating Agencies making the reduction in rating to which this definition would otherwise apply do not announce or publicly confirm or inform the trustee in writing at our or its request that the reduction was the result, in whole or in part, of any event or circumstance comprised of or arising as a result of, or in respect of, the applicable Change of Control (whether or not the applicable Change of Control has occurred at the time of the Below Investment Grade Rating Event).
 
 
27

 
 
Change of Control means the occurrence of any of the following:  (1) any event requiring the filing of any report under or in response to Schedule 13D or 14D-1 pursuant to the Exchange Act disclosing beneficial ownership of either 50% or more of our common stock then outstanding or 50% or more of our voting power or our voting stock then outstanding; (2) the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the properties or our assets and the assets of our respective subsidiaries taken as a whole to one or more persons (as defined in the Indenture) other than us or one of our subsidiaries; or (3) the first day on which a majority of the members of our Board of Directors are not Continuing Directors.  Notwithstanding the foregoing, a transaction will not be deemed to involve a Change of Control if (1) we become a direct or indirect wholly-owned subsidiary of a holding company and (2)(A) the direct or indirect holders of the voting stock of such holding company immediately following that transaction are substantially the same as the holders of our voting stock immediately prior to that transaction or (B) immediately following that transaction no person (other than a holding company satisfying the requirements of this sentence) is the beneficial owner, directly or indirectly, of more than 50% of the voting stock of such holding company.
 
Under clause (3) of the definition Change of Control described above, a Change of Control will occur when a majority of our directors are not Continuing Directors.  In a decision in connection with a proxy contest, the Court of Chancery of Delaware held that the occurrence of a change of control under a similar indenture provision may nevertheless be avoided if the existing directors were to approve the slate of new director nominees (who would constitute a majority of the new board) as “continuing directors” solely for purposes of avoiding the triggering of such change of control clause, provided the incumbent directors give their approval in the good faith exercise of their fiduciary duties.  Therefore, in certain circumstances involving a significant change in the composition of our Board of Directors, including in connection with a proxy contest where our Board of Directors does not endorse a dissident slate of directors but approves them as Continuing Directors, holders of the New Notes may not be entitled to require us to make a Change of Control Offer.
 
Change of Control Triggering Event means the occurrence of both a Change of Control and a Below Investment Grade Rating Event.
 
Continuing Director means, as of any date of determination, any member of our Board of Directors who (1) was a member of such Board of Directors on the date of the issuance of the New Notes; or (2) was nominated for election or elected to such Board of Directors with the approval of majority of the Continuing Directors who were members of such Board of Directors at the time of such nomination or election (either by a specific vote or by approval of our proxy statement in which such member was named as a nominee for election as a director, without objection to such nomination).
 
Investment Grade Rating means a rating equal to or higher than Baa3 (or the equivalent) by Moody’s and BBB- (or the equivalent) by S&P.
 
Moody’s means Moody’s Investors Services, Inc., or its successor.
 
Rating Agencies means (1) each of Moody’s and S&P; and (2) if any of Moody’s or S&P ceases to rate the New Notes or fails to make a rating of the New Notes publicly available for reasons outside of our control, a “nationally recognized statistical rating organization” within the meaning of Rule 3(a)(62) under the Exchange Act selected by us (as certified by a resolution of our Board of Directors) as a replacement agency for Moody’s or S&P, or both of them, as the case may be.
 
S&P means Standard & Poor’s Ratings Services, a division of McGraw Hill Financial, Inc., or its successor.
 
 
28

 
 
Additional Notes
 
We may, without the consent of the holders of the New Notes, create and issue additional notes ranking equally with each series of New Notes offered hereby in all respects so that such additional notes shall form a single series with such New Notes and shall have the same terms as to status or otherwise as such New Notes, except for the public offering price and issue date.  No additional notes of a series may be issued if an event of default has occurred and is continuing with respect to such series of New Notes.  In addition to the New Notes, we may issue other series of New Notes under the Indenture.  There is no limit on the total aggregate principal amount of New Notes that we can issue under the Indenture.
 
Certain Covenants
 
Restrictions on Secured Funded Debt.  The Indenture provides that we will not, nor will we permit any Restricted Subsidiary to, incur, issue, assume, guarantee or create any Secured Debt, without effectively providing concurrently with the incurrence, issuance, assumption, guaranty or creation of any such Secured Debt that the New Notes (together with, if we shall so determine, any other of our Indebtedness or such Restricted Subsidiary’s Indebtedness then existing or thereafter created which is not subordinated to the New Notes) will be secured equally and ratably with (or prior to) such Secured Debt, unless, after giving effect thereto, the sum of the aggregate amount of all of our outstanding Secured Debt and the outstanding Secured Debt of our Restricted Subsidiaries together with all Attributable Debt in respect of sale and leaseback transactions relating to a Principal Property (with the exception of Attributable Debt which is excluded pursuant to clauses (1) to (8) under “Limitation on Sale/Leaseback Transactions” below), would not exceed 15% of Consolidated Net Tangible Assets.
 
This restriction will not apply to, and there will be excluded from Secured Debt in any computation under this restriction and under “Limitation on Sale/Leaseback Transactions” below, Indebtedness, secured by:
 
(1)           Liens on property, shares of capital stock or Indebtedness of any corporation existing at the time such corporation becomes a Subsidiary;
 
(2)           Liens on property, shares of capital stock or Indebtedness existing at the time of acquisition thereof or incurred within 360 days of the time of acquisition thereof (including, without limitation, acquisition through merger or consolidation) by us or any Restricted Subsidiary;
 
(3)           Liens on property, shares of capital stock or Indebtedness thereafter acquired (or constructed) by us or any Restricted Subsidiary and created prior to, at the time of, or within 360 days (or thereafter if such Lien is created pursuant to a binding commitment entered into prior to, at the time of or within 360 days) after such acquisition (including, without limitation, acquisition through merger or consolidation) (or the completion of such construction or commencement of commercial operation of such property, whichever is later) to secure or provide for the payment of all or any part of the purchase price (or the construction price) thereof;
 
(4)           Liens in favor of us or any Restricted Subsidiary;
 
(5)           Liens in favor of the United States of America, any State thereof or the District of Columbia or any foreign government, or any agency, department or other instrumentality thereof, to secure partial, progress, advance or other payments pursuant to any contract or provisions of any statute;
 
(6)           Liens incurred or assumed in connection with the issuance of revenue bonds the interest on which is exempt from federal income taxation pursuant to Section 103 (b) of the Code;
 
(7)           Liens securing the performance of any contract or undertaking not directly or indirectly in connection with the borrowing of money, the obtaining of advances or credit or the securing of Indebtedness, if made and continuing in the ordinary course of business;
 
(8)           Liens incurred (no matter when created) in connection with our or a Restricted Subsidiary’s engaging in leveraged or single investor lease transactions; provided, however, that the instrument creating or evidencing any borrowings secured by such Lien will provide that such borrowings are payable solely out of the income and proceeds of the property subject to such Lien and are not a general obligation of ours or of such Restricted Subsidiary;
 
 
29

 
 
(9)           Liens in favor of a governmental agency to qualify us or any Restricted Subsidiary to do business, maintain self insurance or obtain other benefits, or Liens under workers’ compensation laws, unemployment insurance laws or similar legislation;
 
(10)           Good faith deposits in connection with bids, tenders, contracts or deposits to secure our or any Restricted Subsidiary’s public or statutory obligations, or deposits of cash or obligations of the United States of America to secure surety and appeal bonds to which we or any Restricted Subsidiary are a party or in lieu of such bonds, or pledges or deposits for similar purposes in the ordinary course of business;
 
(11)           Liens imposed by law, such as laborers’ or other employees’, carriers’, warehousemen’s, mechanics’, materialmen’s and vendors’ Liens;
 
(12)           Liens arising out of judgments or awards against us or any Restricted Subsidiary with respect to which we or such Restricted Subsidiary at the time shall be prosecuting an appeal or proceedings for review or Liens arising out of individual final judgments or awards in amounts of less than $1,000,000; provided that the aggregate amount of all such individual final judgments or awards shall not at any one time exceed $1,000,000;
 
(13)           Liens for taxes, assessments, governmental charges or levies not yet subject to penalties for nonpayment or the amount or validity of which is being in good faith contested by appropriate proceedings by us or any Restricted Subsidiary, as the case may be;
 
(14)           Minor survey exceptions, minor encumbrances, easements or reservations of, or rights of others for, rights of way, sewers, electric lines, telegraph and telephone lines and other similar purposes, or zoning or other restrictions or Liens as to the use of real properties, which Liens, exceptions, encumbrances, easements, reservations, rights and restrictions do not, in our opinion, in the aggregate materially detract from the value of said properties or materially impair their use in the operation of our business and that of our Restricted Subsidiaries;
 
(15)           Liens incurred to finance all or any portion of the cost of construction, alteration or repair of any Principal Property or improvements thereto created prior to or within 360 days (or thereafter if such Lien is created pursuant to a binding commitment to lend entered into prior to, at the time of, or within 360 days) after completion of such construction, alteration or repair;
 
(16)           Liens existing on the date of the Indenture;
 
(17)           Liens created in connection with a project financed with, and created to secure, a Nonrecourse Obligation; or
 
(18)           Any extension, renewal, refunding or replacement of the foregoing, provided that (i) such extension, renewal, refunding or replacement Lien shall be limited to all or a part of the same property that secured the Lien extended, renewed, refunded or replaced (plus improvements on such property) and (ii) the Funded Debt secured by such Lien at such time is not increased.
 
Attributable Debt” means, in connection with any sale and leaseback transaction under which either we or any Restricted Subsidiary are at the time liable as lessee for a term of more than 12 months and at any date as of which the amount thereof is to be determined, the lesser of (A) total net obligations of the lessee for rental payments during the remaining term of the lease discounted from the respective due dates thereof to such determination date at a rate per annum equivalent to the greater of (i) the weighted average Yield to Maturity (as defined in the Indenture) of the New Notes, such average being weighted by the principal amount of each series of the New Notes and (ii) the interest rate inherent in such lease (as determined in good faith by us), both to be compounded semi-annually or (B) the sale price for the assets so sold and leased multiplied by a fraction the numerator of which is the remaining portion of the base term of the lease included in such transaction and the denominator of which is the base term of the lease.
 
 
30

 
 
Consolidated Net Tangible Assets” means, at any date, the total assets appearing on our and our Restricted Subsidiaries’ most recent consolidated balance sheet as at the end of our fiscal quarter ending not more than 135 days prior to such date, prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), less (i) all current liabilities (due within one year) as shown on such balance sheet, (ii) investments in and advances to Unrestricted Subsidiaries and (iii) Intangible Assets and liabilities relating thereto.
 
Funded Debt” means (i) any of our Indebtedness or Indebtedness of a Restricted Subsidiary maturing more than 12 months after the time of computation thereof, (ii) guarantees of Funded Debt or of dividends of others (except guarantees in connection with the sale or discount of accounts receivable, trade acceptances and other paper arising in the ordinary course of business), (iii) in the case of any Restricted Subsidiary, all preferred stock having mandatory redemption provisions of such Restricted Subsidiary as reflected on such Restricted Subsidiary’s balance sheet prepared in accordance with GAAP, and (iv) all Capital Lease Obligations (as defined in the Indenture).
 
Indebtedness” means, at any date, without duplication, all of our obligations for borrowed money or obligations for borrowed money of a Restricted Subsidiary.
 
Intangible Assets” means, at any date, the value, as shown on or reflected in our and our Restricted Subsidiaries’ most recent consolidated balance sheet as at the end of our fiscal quarter ending not more than 135 days prior to such date, prepared in accordance with GAAP, of:  (i) all trade names, trademarks, licenses, patents, copyrights, service marks, goodwill and other like intangibles; (ii) organizational and development costs; (iii) deferred charges (other than prepaid items, such as insurance, taxes, interest, commissions, rents, pensions, compensation and similar items and tangible assets being amortized); and (iv) unamortized debt discount and expense, less unamortized premium.
 
Liens” means such pledges, mortgages, security interests and other liens on any Principal Property of ours or of a Restricted Subsidiary which secure Secured Debt.
 
Nonrecourse Obligation” means indebtedness or lease payment obligations substantially related to (i) the acquisition of assets not previously owned by us or any Restricted Subsidiary or (ii) the financing of a project involving the development or expansion of our or any Restricted Subsidiary’s properties, as to which the obligee with respect to such indebtedness or obligation has no recourse to us or any Restricted Subsidiary or any of our or any of our Subsidiaries’ assets other than the assets which were acquired with the proceeds of such transaction or the project financed with the proceeds of such transaction (and the proceeds thereof).
 
Principal Property” means real and tangible property owned and operated now or hereafter by us or any Restricted Subsidiary constituting a part of any store, warehouse or, distribution center located within the United States of America or its territories or possessions (excluding current assets, motor vehicles, mobile materials handling equipment and other rolling stock, cash registers and other point-of-sale recording devices and related equipment and data processing and other office equipment), the net book value of which (including leasehold improvements and store fixtures constituting a part of such store, warehouse or distribution center) as of the date on which the determination is being made is more than 1.0% of Consolidated Net Tangible Assets.  As of the date of this prospectus, none of our stores constitutes a Principal Property.
 
Restricted Subsidiary” means each Subsidiary other than Unrestricted Subsidiaries.
 
Secured Debt” means Funded Debt which is secured by any pledge of, or mortgage, security interest or other lien on any (i) Principal Property (whether owned on the date of the Indenture or thereafter acquired or created), (ii) shares of stock owned by us or a Subsidiary in a Restricted Subsidiary or (iii) Indebtedness of a Restricted Subsidiary.
 
Subsidiary” means any corporation of which at least a majority of the outstanding stock, which under ordinary circumstances (not dependent upon the happening of a contingency) has voting power to elect a majority of the board of directors of such corporation (or similar management body), is owned directly or indirectly by us or by one or more of our Subsidiaries, or by us and one or more Subsidiaries.
 
 
31

 
 
Unrestricted Subsidiary” means Subsidiaries designated as Unrestricted Subsidiaries from time to time by our Board of Directors; provided, however, that our Board of Directors (i) will not designate as an Unrestricted Subsidiary any of our Subsidiaries that owns any Principal Property or any stock of a Restricted Subsidiary, (ii) will not continue the designation of any of our Subsidiaries as an Unrestricted Subsidiary at any time that such Subsidiary owns any Principal Property, and (iii) will not, nor will it cause or permit any Restricted Subsidiary to, transfer or otherwise dispose of any Principal Property to any Unrestricted Subsidiary (unless such Unrestricted Subsidiary will in connection therewith be redesignated as a Restricted Subsidiary and any pledge, mortgage, security interest or other lien arising in connection with any Indebtedness of such Unrestricted Subsidiary so redesignated does not extend to such Principal Property (unless the existence of such pledge, mortgage, security interest or other lien would otherwise be permitted under the Indenture)).
 
Limitation on Sale/Leaseback Transactions.    The Indenture provides that we will not, nor will we permit any Restricted Subsidiary to, enter into any arrangement with any person providing for the leasing by us or any Restricted Subsidiary of any of our or any Restricted Subsidiary’s Principal Property (which lease is required by GAAP to be capitalized on the balance sheet of such lessee), which Principal Property has been or is to be sold or transferred by us or such Restricted Subsidiary to such person (a “sale and leaseback transaction”) unless, after giving effect thereto, the aggregate amount of all Attributable Debt with respect to all such sale and leaseback transactions plus all Secured Debt (with the exception of Funded Debt secured by Liens which is excluded pursuant to clauses (1) to (18) under “Restrictions on Secured Funded Debt” above) would not exceed 15% of Consolidated Net Tangible Assets.
 
This covenant will not apply to, and there will be excluded from Attributable Debt in any computation under this restriction or under “Restrictions on Secured Funded Debt” above, Attributable Debt with respect to any sale and leaseback transaction if:
 
(1)           We or a Restricted Subsidiary are permitted to create Funded Debt secured by a Lien pursuant to clauses (1) to (18) inclusive under “Restrictions on Secured Funded Debt” above on the Principal Property to be leased, in an amount equal to the Attributable Debt with respect to such sale and leaseback transaction, without equally and ratably securing the New Notes;
 
(2)           The property leased pursuant to such arrangement is sold for a price at least equal to such property’s fair market value (as determined by our Chief Executive Officer, President, Chief Financial Officer, Treasurer or Controller) and we or a Restricted Subsidiary, within 360 days after the sale or transfer shall have been made by us or a Restricted Subsidiary, shall apply the proceeds thereof to the retirement of our or any Restricted Subsidiary’s Indebtedness or Funded Debt (other than Indebtedness or Funded Debt owned by us or any Restricted Subsidiary); provided, however, that no retirement referred to in this clause (2) may be effected by payment at maturity or pursuant to any mandatory sinking fund payment provision of Indebtedness or Funded Debt;
 
(3)           We or a Restricted Subsidiary apply the net proceeds of the sale or transfer of the Principal Property leased pursuant to such transaction to the purchase of assets (and the cost of construction thereof) within 360 days prior or subsequent to such sale or transfer;
 
(4)           The effective date of any such arrangement or the purchaser’s commitment therefor is within 36 months prior or subsequent to the acquisition of the Principal Property (including, without limitation, acquisition by merger or consolidation) or the completion of construction and commencement of operation thereof (which, in the case of a retail store, is the date of opening to the public), whichever is later;
 
(5)           The lease in such sale and leaseback transaction is for a term, including renewals, of not more than three years;
 
(6)           The sale and leaseback transaction is entered into between us and a Restricted Subsidiary or between Restricted Subsidiaries;
 
(7)           The lease secures or relates to industrial revenue or pollution control bonds; or
 
(8)           The lease payment is created in connection with a project financed with, and such obligation constitutes, a Nonrecourse Obligation.
 
 
32

 
 
Merger, Consolidation and Disposition of Assets
 
The Indenture provides that we shall not consolidate with, merge with or into, or sell, convey, transfer, lease or otherwise dispose of all or substantially all of our property and assets (as an entirety or substantially as an entirety in one transaction or a series of related transactions) to, any Person (as defined in the Indenture) (other than a consolidation with or merger with or into a Restricted Subsidiary or a sale, conveyance, transfer, lease or other disposition to a Restricted Subsidiary) or permit any Person to merge with or into us unless:  (a) either (i) we shall be the continuing Person or (ii) the Person (if other than us) formed by such consolidation or into which we are merged or that acquired or leased such of our property and assets shall be a corporation organized and validly existing under the laws of the United States of America or any jurisdiction thereof and shall expressly assume, by a supplemental indenture, executed and delivered to the trustee, all of our obligations under each series of the New Notes and the Indenture, and we shall have delivered to the trustee an opinion of counsel stating that such consolidation, merger or transfer and such supplemental indenture complies with this provision and that all conditions precedent provided for in the Indenture relating to such transaction have been complied with and that such supplemental indenture constitutes an obligation that is legal, valid and binding for us or such successor enforceable against such entity in accordance with its terms, subject to customary exceptions; and (b) we shall have delivered to the trustee an officers’ certificate to the effect that immediately after giving effect to such transaction, no Default (as defined in the Indentures) shall have occurred and be continuing and an opinion of counsel as to the matters set forth in paragraph (a) above.
 
The Indenture does not restrict, or require us to redeem or permit holders of any series of the New Notes to cause a redemption of the New Notes of that series in the event of, (i) a consolidation, merger, sale of assets or other similar transaction that may adversely affect our creditworthiness or the creditworthiness of our successor or combined entity, (ii) a change in control of the Company or (iii) a highly leveraged transaction involving us, whether or not involving a change in control.  Accordingly, the holders of the New Notes would not have protection in the event of a highly leveraged transaction, reorganization, restructuring, merger or similar transaction involving us that may adversely affect the holders of New Notes.  The existing protective covenants applicable to the New Notes would continue to apply to us, or our successor, in the event of such a transaction initiated or supported by us, our management, or any of our affiliates or their management, but may not prevent such a transaction from taking place.
 
Events of Default, Waiver and Notice
 
“Event of Default” with respect to a series of New Notes is defined in the Indenture to be if:
 
(1)           We default in the payment of all or any part of the principal of such series of the New Notes when the same becomes due and payable at maturity, upon acceleration, redemption or mandatory repurchase, including as a sinking fund installment, or otherwise;
 
(2)           We default in the payment of any interest on such series of the New Notes when the same becomes due and payable, and such default continues for a period of 30 days;
 
(3)           We default in the performance of or breach any of our other covenants or agreements in the Indenture and such default or breach continues for a period of 60 consecutive days after written notice thereof has been given to us by the trustee or to us and the trustee by the holders of 25% or more in aggregate principal amount of the affected series of the New Notes;
 
(4)           An involuntary case or other proceeding shall be commenced against us with respect to us or our debts under any bankruptcy, insolvency or other similar law now or hereafter in effect seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official or for any substantial part of our property and assets, and such involuntary case or other proceeding shall remain undismissed and unstayed for a period of 60 days; or an order for relief shall be entered against us under any bankruptcy, insolvency or other similar law now or hereafter in effect;
 
(5)           We (i) commence a voluntary case under any applicable bankruptcy, insolvency or other similar law now or hereafter in effect, or consent to the entry of an order for relief in an involuntary case under any such law, (ii) consent to the appointment of or taking possession by a receiver, liquidator, assignee, custodian, trustee, sequestrator or similar official of us or for all or substantially all of our property and assets or (iii) effect any general assignment for the benefit of creditors;
 
 
33

 
 
(6)           An event of default as defined in any one or more indentures or instruments evidencing or under which we have at the date of the Indenture or shall thereafter have outstanding an aggregate of at least $50,000,000 aggregate principal amount of indebtedness for borrowed money, shall happen and be continuing and such indebtedness shall have been accelerated so that the same shall be or become due and payable prior to the date on which the same would otherwise have become due and payable, and such acceleration shall not be rescinded or annulled within ten days after notice thereof shall have been given to us by the trustee (if such event be known to it), or to us and the trustee by the holders of at least 25% in aggregate principal amount of the outstanding New Notes of such series; provided that if such event of default under such indentures or instruments shall be remedied or cured by us or waived by the holders of such indebtedness, then the Event of Default under the Indenture by reason thereof shall be deemed likewise to have been thereupon remedied, cured or waived without further action upon the part of either the trustee or any of the holders of such series; or
 
(7)           Failure by us to make any payment at maturity, including any applicable grace period, in respect of at least $50,000,000 aggregate principal amount of indebtedness for borrowed money and such failure shall have continued for a period of ten days after notice thereof shall have been given to us by the trustee (if such event be known to it), or to us and the trustee by the holders of at least 25% in aggregate principal amount of the outstanding New Notes of such series; provided that if such failure shall be remedied or cured by us or waived by the holders of such indebtedness, then the Event of Default under the Indenture by reason thereof shall be deemed likewise to have been thereupon remedied, cured or waived without further action upon the part of either the trustee or any of the holders of such series.
 
If an Event of Default occurs and is continuing with respect to a series of the New Notes, then, and in each and every such case, either the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding New Notes of such series by notice in writing to us (and to the trustee if given by holders), may declare the entire outstanding principal amount of the New Notes of such series, and the interest accrued thereon, if any, to be due and payable immediately, and upon any such declaration the same shall become immediately due and payable.  If an Event of Default described in clauses (4) or (5) occurs and is continuing with respect to a series of the New Notes, then the principal amount of all the New Notes of such series then outstanding and interest accrued thereon, if any, shall be and become immediately due and payable, without any notice or other action by any holder of New Notes of such series or the trustee to the full extent permitted by applicable law.
 
Subject to provisions in the Indenture for the indemnification of the trustee and certain other limitations, the holders of at least a majority in aggregate principal amount of the outstanding New Notes of any series may direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee by the Indenture with respect to the New Notes of such series;  provided that the trustee may refuse to follow any direction that conflicts with law or the Indenture, that may involve the trustee in personal liability, or that the trustee determines in good faith may be unduly prejudicial to the rights of holders of the New Notes of such series not joining in the giving of such direction; and provided further that the trustee may take any other action it deems proper that is not inconsistent with any directions received from holders of New Notes of such series pursuant to this paragraph.
 
Subject to various provisions in the Indenture, the holders of at least a majority in principal amount of the outstanding New Notes of any series, by notice to the trustee, may waive an existing Default or Event of Default with respect to such series and its consequences, except a Default in the payment of principal of or interest on any New Notes of such series as specified in clauses (1) or (2) of the first paragraph of this section or in respect of a covenant or provision of the Indenture which cannot be modified or amended without the consent of the holder of each outstanding New Notes of such series affected.  Upon any such waiver, such Default shall cease to exist with respect to such series, and any Event of Default arising therefrom shall be deemed to have been cured, for every purpose of the Indenture; but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereto.
 
The Indenture provides that no holder of New Notes of any series may institute any proceeding, judicial or otherwise, with respect to the Indenture or the New Notes of such series, or for the appointment of a receiver or trustee, or for any other remedy under the Indenture, unless:  (i) such holder has previously given to the trustee written notice of a continuing Event of Default;
 
 
34

 
 
(ii) the holders of at least 25% in aggregate principal amount of outstanding New Notes of such series shall have made written request to the trustee to institute proceedings in respect of such Event of Default in its own name as trustee under the Indenture; (iii) such holder or holders have offered to the trustee indemnity reasonably satisfactory to the trustee against any costs, liabilities or expenses to be incurred in compliance with such request; (iv) the trustee for 60 days after its receipt of such notice, request and offer of indemnity has failed to institute any such proceeding; and (v) during such 60-day period, the holders of a majority in aggregate principal amount of the outstanding New Notes of such series have not given the trustee a direction that is inconsistent with such written request.  A holder of New Notes of any series may not use the Indenture to prejudice the rights of another holder of such series or to obtain a preference or priority over such other holder.
 
Information
 
The Indenture provides that we shall file with the trustee and transmit to holders of the New Notes such information, documents and other reports, and such summaries thereof, as may be required pursuant to the Trust Indenture Act at the time and in the manner provided pursuant to such Act.
 
The Company will be required to file with the trustee annually, within four months of the end of each fiscal year of the Company, a certificate as to the compliance with all conditions and covenants of the Indenture.
 
Discharge and Defeasance of New Notes and Covenants
 
The Indenture provides that we may terminate our obligations under any series of New Notes if:  (i) all New Notes of such series previously authenticated and delivered, with certain exceptions, have been delivered to the trustee for cancellation and we have paid all sums payable by us with respect to that series of New Notes under the Indenture; or (ii) (a) the New Notes of such series mature within one year or all of them are to be called for redemption within one year under arrangements satisfactory to the trustee for giving the notice of redemption, (b) we irrevocably deposit in trust with the trustee, as trust funds solely for the benefit of the holders of the New Notes of such series for that purpose, money or U.S. government obligations or a combination thereof sufficient (unless such funds consist solely of money, in the opinion of a nationally recognized firm of independent public accountants expressed in a written certification thereof delivered to the trustee), without consideration of any reinvestment, to pay the principal of and interest on the New Notes of such series to maturity or redemption, as the case may be, and to pay all other sums payable by us under the Indenture, and (c) we deliver to the trustee an officers’ certificate and an opinion of counsel, in each case stating that all conditions precedent provided for in the Indenture relating to the satisfaction and discharge of our obligations under the Indenture with respect to the New Notes of such series have been complied with.  The following obligations will survive until the New Notes of such series are no longer outstanding:  our obligations to execute and deliver the New Notes of such series for authentication, to set the terms of the New Notes of such series, to maintain an office or agency in respect of the New Notes of such series, to have moneys held for payment in trust, to register the transfer or exchange of the New Notes of such series, to compensate and indemnify the trustee and to appoint a successor trustee, and our right to recover excess money held by the trustee.  Thereafter, only our obligations to compensate and indemnify the trustee, and our right to recover excess money held by the trustee shall survive.
 
The Indenture provides that we (i) will be deemed to have paid and will be discharged from any and all obligations in respect of the New Notes of such series, and the provisions of the Indenture will, except as noted below, no longer be in effect with respect to the New Notes of such series (“legal defeasance”) or (ii) may omit to comply with other specific covenants relating to the New Notes of such series in the Indenture, and with respect to the Indenture, such omission shall be deemed not to be an Event of Default under clause (3) of the first paragraph of “Events of Default, Waiver and Notice” (“covenant defeasance”); provided that the following conditions shall have been satisfied:  (a) we have irrevocably deposited in trust with the trustee as trust funds solely for the benefit of the holders of the New Notes of such series, for payment of the principal of and interest on the New Notes of such series, money or U.S. government obligations or a combination thereof sufficient (unless such funds consist solely of money, in the opinion of a nationally recognized firm of independent public accountants expressed in a written certification thereof delivered to the trustee) without consideration of any reinvestment and after payment of all federal, state and local taxes or other charges and assessments in respect thereof payable by the trustee, to pay and discharge the principal of and accrued interest on the outstanding New Notes of such series to maturity or earlier redemption (irrevocably provided for under arrangements satisfactory to the trustee), as the case may be; (b) such deposit will not result in a breach or violation of, or constitute a default under, the Indenture or any other material agreement or instrument to which we are a party or by which we are bound;
 
 
35

 
 
(c) no Default with respect to the New Notes of such series shall have occurred and be continuing on the date of such deposit; (d) we shall have delivered to the trustee an opinion of counsel that (1) the holders of the New Notes of such series will not recognize income, gain or loss for federal income tax purposes as a result of our exercise of our option under this provision of the Indenture and will be subject to federal income tax on the same amount and in the same manner and at the same times as would have been the case if such deposit and defeasance had not occurred and (2) the holders of the New Notes of such series have a valid security interest in the trust funds, and (e) we have delivered to the trustee an officers’ certificate and an opinion of counsel, in each case stating that all conditions precedent provided for in the Indenture relating to the defeasance contemplated have been complied with.  In the case of legal defeasance under clause (i) above, the opinion of counsel referred to in clause (d) (1) above may be replaced by a ruling directed to the trustee received from the Internal Revenue Service to the same effect.  Notwithstanding legal or covenant defeasance, the following obligations will survive until the New Notes of such series are no longer outstanding:  our obligations to execute and deliver the New Notes of such series for authentication, to set the terms of the New Notes of such series, to maintain an office or agency in respect of the New Notes of such series, to have moneys held for payment in trust, to register the transfer or exchange of the New Notes of such series, to compensate and indemnify the trustee and to appoint a successor trustee, and our right to recover excess money held by the trustee.  Thereafter, only our obligations to compensate and indemnify the trustee, and our right to recover excess money held by the trustee shall survive.
 
Modification and Waiver
 
The Indenture provides that we and the trustee may amend or supplement the Indenture or any series of the New Notes without notice to or the consent of any holder of such series:
 
(1)           to cure any ambiguity, defect or inconsistency in the Indenture; provided that such amendments or supplements shall not materially and adversely affect the interests of the holders of New Notes of such series;
 
(2)           to provide for the assumption of our obligations to the holders of the New Notes of such series in connection with a consolidation or merger of our company or the sale, conveyance, transfer, lease or other disposal of all or substantially all of our property and assets;
 
(3)           to comply with any requirements of the SEC in connection with the qualification of the Indenture under the Trust Indenture Act;
 
(4)           to evidence and provide for the acceptance of appointment under the Indenture by a successor trustee; and
 
(5)           to make any change that does not materially and adversely affect the rights of any holder of New Notes of such series, provided that any change to conform the terms of the New Notes to the Indenture and to the Description of New Notes contained in this prospectus relating to the New Notes shall not be deemed to be adverse to any holder of such New Notes.
 
The Indenture also contains provisions whereby we and the trustee, subject to certain conditions, may amend the Indenture and the outstanding New Notes of such series with the written consent of the holders of a majority in principal amount of the New Notes of such series then outstanding, and the holders of a majority in principal amount of the outstanding New Notes of any series may waive future compliance by us with any provision of the Indenture or the New Notes of such series.
 
Notwithstanding the foregoing provisions, without the consent of each holder of a series of the New Notes affected thereby, an amendment or waiver may not:
 
(1)           extend the stated maturity of the principal of, or any installment of interest on, such holder’s New Notes, or reduce the principal thereof or the rate of interest thereon, or any premium payable with respect thereto, or change any place or currency of payment where any New Note of that series or any premium or the interest thereon is payable, or impair the right to institute suit for the enforcement of any such payment on or after the due date therefor;
 
 
36

 
 
(2)           reduce the percentage in principal amount of outstanding New Notes of that series the consent of whose holders is required for any such supplemental indenture, for any waiver of compliance with certain provisions of the Indenture or certain Defaults and their consequences provided for in the Indenture;
 
(3)           waive a Default in the payment of principal of or interest on any New Note of that series of such holder; or
 
(4)           modify any of the provisions of this provision of the Indenture, except to increase any such percentage or to provide that certain other provisions of the Indenture cannot be modified or waived without the consent of the holder of each outstanding New Note of that series thereunder affected thereby.
 
It shall not be necessary for the consent of any holder under this provision of the Indenture to approve the particular form of any proposed amendment, supplement or waiver, but it shall be sufficient if such consent approves the substance thereof.  After an amendment, supplement or waiver under this section of the Indenture becomes effective, we shall give to the holders of the series of the New Notes affected thereby a notice briefly describing the amendment, supplement or waiver.  Any failure by us to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental indenture or waiver.
 
Book-Entry System
 
Upon closing of the exchange offer, each series of the New Notes will be represented by one or more fully registered global securities.  Each such global security will be deposited with, or on behalf of, DTC and registered in the name of DTC or a nominee thereof.  Unless and until it is exchanged in whole or in part for New Notes in definitive form, no global security may be transferred except as a whole by DTC to a nominee of DTC or by a nominee of DTC to DTC or another nominee of DTC or by DTC or any such nominee to a successor of DTC or a nominee of such successor.  Accountholders in the Euroclear Bank S.A./N.V. or Clearstream Banking, société anonyme clearance systems may hold beneficial interests in the New Notes through the accounts that each of these systems maintain as participants in DTC.
 
So long as DTC or its nominee is the registered owner of the global securities, DTC or its nominee, as the case may be, will be the sole holder of the New Notes represented thereby for all purposes under the Indenture.  Except as otherwise provided in this section, the beneficial owners of the global securities representing the New Notes will not be entitled to receive physical delivery of certificated New Notes and will not be considered the holders thereof for any purpose under the Indenture, and the global securities representing the New Notes shall not be exchangeable or transferable.  Accordingly, each person owning a beneficial interest in a global security must rely on the procedures of DTC and, if such person is not a participant, on the procedures of the participant through which such person owns its interest, in order to exercise any rights of a holder under the Indenture.  The laws of some jurisdictions require that certain purchasers of securities take physical delivery of such securities in certificated form.  Such limits and such laws may impair the ability to transfer beneficial interests in the global securities representing the New Notes.
 
The global securities representing the New Notes are exchangeable for certificated New Notes of like tenor and terms and of differing authorized denominations aggregating a like amount only if:
 
 
·
DTC notifies us that it is unwilling, unable or ineligible to continue as depositary for the global securities and a successor depositary is not appointed by us within 90 days of such notification or of our becoming aware of DTC’s ineligibility;
 
 
·
there shall have occurred and be continuing an Event of Default under the Indenture with respect to any of the global securities and the outstanding New Notes of the series represented by such global securities shall have become due and payable pursuant to the Indenture and the trustee has requested that certificated New Notes be issued; or
 
 
·
we have decided to discontinue use of book-entry transfers through DTC.  DTC has advised us that, under its current practices, it would notify its participants of our request, but would only withdraw beneficial interests from the global securities at the request of its participants.
 
 
 
37

 
 
Upon any such exchange, the certificated New Notes shall be registered in the names of the beneficial owners of the global securities representing the New Notes of the applicable series as provided by DTC’s relevant participants (as identified by DTC).
 
The description of the operations and procedures of DTC set forth below are provided solely as a matter of convenience.  These operations and procedures are solely within the control of the respective settlement systems and are subject to change by them from time to time.  Neither we nor the Dealer Managers take any responsibility for these operations or procedures, and investors are urged to contact the relevant system or its participants directly to discuss these matters.
 
The following is based on information furnished by DTC:
 
 
·
DTC is a limited-purpose trust company organized under the laws of the State of New York, a “banking organization” within the meaning of the New York Banking Law, a member of the Federal Reserve System, a “clearing corporation” within the meaning of the New York Uniform Commercial Code, and a “clearing agency” registered pursuant to the provisions of Section 17A of the Exchange Act.  DTC holds securities that its participants deposit with DTC.  DTC also facilitates the settlement among participants of securities transactions, such as transfers and pledges, in deposited securities through electronic computerized book entry changes in participants’ accounts, thereby eliminating the need for physical movement of securities certificates.  Direct participants include securities brokers and dealers, banks, trust companies, clearing corporations and certain other organizations.  Access to DTC’s system is available to securities brokers and dealers, banks and trust companies that clear through or maintain a custodial relationship with a direct participant, either directly or indirectly.
 
 
·
Persons who are not participants may beneficially own the New Notes held by DTC only through direct participants or indirect participants.  Purchases of the New Notes under DTC’s system must be made by or through direct participants, which will receive a credit for such New Notes on DTC’s records.  The ownership interest of each actual purchaser of each note represented by a global security (a “Beneficial Owner”) is in turn to be recorded on the direct participants’ and indirect participants’ records.  Beneficial Owners will not receive written confirmation from DTC of their purchase, but Beneficial Owners are expected to receive written confirmations providing details of the transaction, as well as periodic statements of their holdings, from the direct participants or indirect participants through which such Beneficial Owner entered into the transaction.  Transfers of ownership interests in the global securities representing the New Notes are to be accomplished by entries made on the books of participants acting on behalf of Beneficial Owners.  Beneficial Owners of the global securities representing the New Notes will not receive certificated New Notes representing their ownership interests therein, except in the event that use of the book-entry system for such New Notes is discontinued and in certain other limited circumstances.
 
 
·
Principal, premium, if any, and interest payments on the global securities representing the New Notes will be made to DTC.  DTC’s practice is to credit direct participants’ accounts on the applicable payment date in accordance with their respective holdings shown on DTC’s records unless DTC has reason to believe that it will not receive payment on such date.  Payments by participants to Beneficial Owners will be governed by standing instructions and customary practices, as is the case with securities held for the accounts of customers in bearer form or registered in “street name,” and will be the responsibility of such participant and not of DTC, the trustee or ours, subject to any statutory or regulatory requirements as may be in effect from time to time.  Payment of principal, premium, if any, and interest to DTC is our and the trustee’s responsibility, disbursement of such payments to direct participants is the responsibility of DTC, and disbursement of such payments to the Beneficial Owners is the responsibility of direct participants and indirect participants.
 
 
·
DTC may discontinue providing its services as securities depository with respect to the New Notes at any time by giving reasonable notice to us or the trustee.  Under such circumstances, in the event that a successor securities depository is not obtained, certificated New Notes are required to be printed and delivered.
 
 
38

 
 
The information in this section concerning DTC and DTC’s system has been obtained from sources that we believe to be reliable, but we take no responsibility for the accuracy thereof.  Transfers between participants in DTC will be effected in accordance with DTC’s procedures and will be settled in same-day funds.
 
Governing Law
 
The Indenture and the New Notes shall be governed by and construed in accordance with the laws of the State of New York.
 
The Trustee
 
We maintain ordinary banking and trust relationships with The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.), a national banking association, and its affiliates.
 
 
 
 
 
 
39

 
 
 
The following discussion summarizes the material U.S. federal income tax consequences of an exchange of Old Notes for New Notes pursuant to this exchange offer.  This discussion is based upon the provisions of the Internal Revenue Code of 1986, as amended, the Treasury regulations promulgated thereunder, judicial authority and administrative interpretations, all as of the date hereof and all of which are subject to change, possibly with retroactive effect, or different interpretations.  This discussion does not address all of the tax considerations that may be relevant to a particular holder in light of the holder’s circumstances, or to certain categories of holders that may be subject to special rules.  This summary does not consider any tax consequences arising under U.S. alternative minimum tax law, U.S. federal gift and estate tax law, the Medicare tax on certain net investment income or under the laws of any foreign, state, local or other jurisdiction.  Each holder should consult its own independent tax advisor regarding its particular situation and the U.S. federal, state, local and foreign tax consequences of exchanging the Old Notes for New Notes and purchasing, holding and disposing of the New Notes, including the consequences of any proposed change in applicable laws.
 
The exchange of Old Notes for New Notes in the exchange offer will not constitute a taxable event for U.S. federal income tax purposes.  Consequently, for such purposes, a holder will not recognize gain upon receipt of a New Note in exchange for an Old Note in the exchange offer, the holder’s adjusted tax basis (and adjusted issue price) in the New Note received in the exchange offer will be the same as its adjusted tax basis (and adjusted issue price) in the corresponding Old Note immediately before the exchange, and the holder’s holding period in the New Note will include its holding period in the Old Note.
 
 
 
 
 
 
 
 
40

 
  
 
We entered into the Registration Rights Agreement with the dealer managers named therein on October 9, 2015.  In the Registration Rights Agreement, we agreed for the benefit of the holders of the Old Notes that we will use our commercially reasonable efforts to file with the SEC and cause to become effective this exchange offer registration statement relating to offers to exchange Old 2022 Notes and Old 2024 Notes for an issue of SEC-registered New 2022 Notes and New 2024 Notes respectively, with terms identical to the respective series of Old Notes (except that each series of New Notes will not be subject to restrictions on transfer or to any increase in annual interest rate as described below).
 
When the SEC declares this exchange offer registration statement effective, we will offer New Notes in return for Old Notes.  Each exchange offer will remain open for at least 20 business days after the date we mail notice of such exchange offer to noteholders.  For each Old Note surrendered to us under an exchange offer, the holder who surrendered such Old Note will receive a New Note of equal principal amount.  Interest on each New Note will accrue from the last interest payment date on which interest was paid on the notes or, if no interest has been paid on the notes, from the original issue date of the notes.
 
If applicable interpretations of the staff of the SEC do not permit us to effect the exchange offers, we will use our commercially reasonable efforts to cause to become effective a shelf registration statement relating to resales of Old Notes and to keep that shelf registration statement effective until the date that is one year after the original issue date of the Old Notes, or such shorter period that will terminate when all Old Notes covered by the shelf registration statement have been sold.  We will, in the event of such a shelf registration, provide to each noteholder copies of a prospectus, notify each noteholder when the shelf registration statement has become effective and take certain other actions to permit resales of Old Notes.  A noteholder that sells Old Notes under the shelf registration statement generally will be required to be named as a selling security holder in the related prospectus and to deliver a prospectus to purchasers, will be subject to certain of the civil liability provisions under the Securities Act in connection with those sales and will be bound by the provisions of the Registration Rights Agreement that are applicable to such noteholder (including certain indemnification obligations).
 
If the exchange offer with respect to a series of notes is not completed (or, if required, the shelf registration statement is not declared effective) on or before the date that is 365 days after the original issue date of the notes (each such event, a “registration default”), the annual interest rate borne by such series of notes will be increased by 0.25% per annum for the first 90-day period immediately following such date and by an additional 0.25% per annum for each subsequent 90-day period, up to a maximum additional rate of 0.50% per annum, until the exchange offer is completed or the shelf registration statement is declared effective.  Following the cure of all registration defaults, additional interest will cease to accrue and the interest rate shall revert to the original interest rate unless a new registration default shall occur.
 
 
41

 
 
If we effect the exchange offers, we will be entitled to close the exchange offers 20 business days after their commencement, provided that we have accepted all Old Notes validly surrendered in accordance with the terms of the applicable exchange offer.  Old Notes not tendered in an exchange offer shall bear interest at the rate set forth on the cover page of this prospectus and be subject to all the terms and conditions specified in the applicable supplemental indenture, including transfer restrictions.
 
This summary of the provisions of the Registration Rights Agreement does not purport to be complete and is subject to, and is qualified in its entirety by reference to, all the provisions of the Registration Rights Agreement, copies of which are available from us upon request.
 
 
Each broker-dealer that receives New Notes for its own account pursuant to the exchange offer must acknowledge that it will deliver a prospectus in connection with any resale of such New Notes.  This prospectus, as it may be amended or supplemented from time to time, may be used by a broker-dealer in connection with resales of New Notes received in exchange for unregistered Old Notes where such unregistered Old Notes were acquired as a result of market-making activities or other trading activities.  We have agreed that, for a period of 180 days from the date of this prospectus, we will make this prospectus, as amended or supplemented, available to any broker-dealer for use in connection with any such resale.  In addition, until 180 days after the date of this prospectus, all dealers effecting transactions in the New Notes may be required to deliver a prospectus.
 
We will not receive any proceeds from any sale of New Notes by broker-dealers.  New Notes received by broker-dealers for their own account pursuant to the exchange offer may be sold from time to time in one or more transactions in the over-the-counter market, in negotiated transactions, through the writing of options on the New Notes or a combination of such methods of resale, at market prices prevailing at the time of resale, at prices related to such prevailing market prices or at negotiated prices.  Any such resale may be made directly to purchasers or to or through brokers or dealers that may receive compensation in the form of commissions or concessions from any such broker-dealer or the purchasers of any such New Notes.  Any broker-dealer that resells New Notes that were received by it for its own account pursuant to the exchange offer and any broker or dealer that participates in a distribution of such New Notes may be deemed to be an “underwriter” within the meaning of the Securities Act and any profit on any such resale of New Notes and any commission or concessions received by any such persons may be deemed to be underwriting compensation under the Securities Act.  The letter of transmittal states that, by acknowledging that it will deliver and by delivering a prospectus, a broker-dealer will not be deemed to admit that it is an “underwriter” within the meaning of the Securities Act.
 
For a period of 180 days after the date of this prospectus, we will promptly send additional copies of this prospectus to any broker-dealer that requests such documents in the letter of transmittal.  We have agreed to pay all expenses incident to the exchange offer (including the expenses of one counsel for the holders of the Old Notes) other than commissions or concessions of any brokers or dealers and will indemnify the holders of the notes (including any broker-dealers) against certain liabilities, including liabilities under the Securities Act.
 
 
 
42

 
 
 
The validity and enforceability of the notes offered hereby will be passed upon for CVS Health Corporation by Shearman & Sterling LLP, New York, New York.
 
 
The consolidated financial statements of CVS Health Corporation incorporated by reference in CVS Health Corporation’s Annual Report (Form 10-K) for the year ended December 31, 2015, and the effectiveness of CVS Health Corporation’s internal control over financial reporting as of December 31, 2015, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their reports thereon, incorporated by reference therein, and incorporated herein by reference.  Such consolidated financial statements and CVS Health Corporation management’s assessment of the effectiveness of internal control over financial reporting as of December 31, 2015 are incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing.
 
 
 
 
 
 
 

 
 
43

 

The information agent and exchange agent for the exchange offer is:
 
D.F. King & Co., Inc.
48 Wall Street, 22nd Floor
New York, New York 10005
 
or
 
Banks and Brokers Call Collect: (212) 269-5550
All Others Call Toll Free: (866) 745-0265
Email: cvs@dfking.com
 

 
By Regular, Registered or Certified Mail, Hand or Overnight Delivery:
 
D.F. King & Co., Inc.
48 Wall Street, 22nd Floor
New York, New York 10005
Attn: Peter Aymar
 
By Facsimile (for Eligible Institutions only):
(212) 709-3328
Attn:  Peter Aymar
 
For Confirmation:
(212) 232-3235

Any questions or requests for assistance or for additional copies of the prospectus or the letter of transmittal may be directed to the information agent at the telephone numbers set forth above.
 


 
 
 

 
 


 
We have not authorized any dealer, salesperson or other person to give you written information other than this prospectus or to make representations as to matters not stated in this prospectus.  You must not rely on unauthorized information.  This prospectus is not an offer to sell the notes or our solicitation of your offer to buy the notes in any jurisdiction where that would not be permitted or legal.  Neither the delivery of this prospectus nor any sales made hereunder after the date of this prospectus shall create an implication that the information contained herein or the affairs of the Company have not changed since the date of this prospectus.
 
Until                       , 2016, all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus.  This is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriters and with respect to their unused allotments or subscriptions.
 
CVS Health Corporation
 
Offer to Exchange
$387,285,000 Outstanding 4.75% Senior Notes due 2022
for
Registered 4.75% Senior Notes due 2022
and
$296,255,000 Outstanding 5.00% Senior Notes due 2024
for
Registered 5.00% Senior Notes due 2024

 
 
 
PROSPECTUS
_______________________










                , 2016
 




 
 
 
 

PART II
 
Item 20.                 Indemnification of Directors and Officers.
 
Exculpation.  Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for unlawful payments of dividends or unlawful stock repurchases, redemptions or other distributions, or (iv) for any transaction from which the director derived an improper personal benefit.  The CVS Health Corporation Amended and Restated Certificate of Incorporation, as amended, (the “CVS Health Charter”) limits the personal liability of a director to CVS Health and its stockholders for monetary damages for a breach of fiduciary duty as a director to the fullest extent permitted by law.
 
Indemnification.  Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent to the Registrant.  The Delaware General Corporation Law provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise.  Expenses, including attorneys’ fees, incurred by any such person in defending any such action, suit or proceeding shall be paid or reimbursed by CVS Health in advance of the final disposition of such action, suit or proceeding upon receipt by it of an undertaking of such person to repay such expenses if it shall ultimately be determined that such person is not entitled to be indemnified by CVS Health.  The CVS Health Charter provides for indemnification of directors and officers of CVS Health against liability they may incur in their capacities as such to the fullest extent permitted under the Delaware General Corporation Law.
 
Insurance.  CVS Health has in effect Directors and Officers insurance, inclusive of Fiduciary Liability, with a combined limit of $475,000,000.  Our Employment Practices Liability insurance is subject to a limit of $125,000,000.  The Fiduciary Liability and Employment Practices Liability insurance covers actions of directors and officers as well as other employees of CVS Health.
 
 
 
 
II-1

 

Item 21.                 Exhibits and Financial Statement Schedules.
 
 
(a)
Exhibits.
 
The following exhibits are included as exhibits to this Registration Statement.
 
Exhibit
Number
 
Description
4.1
Senior Indenture, dated as of August 15, 2006, between CVS Health Corporation (formerly CVS Corporation) and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.) (incorporated by reference to Exhibit 4.1 to CVS Health Corporation’s (formerly CVS Corporation) Current Report on Form 8-K filed August 15, 2006).
4.2
Form of 4.75% Senior Note due 2022 (incorporated by reference to Exhibit 4.1 to CVS Health Corporation’s Current Report on Form 8-K filed October 14, 2015).
4.3
Form of 5.00% Senior Note due 2024 (incorporated by reference to Exhibit 4.2 to CVS Health Corporation’s Current Report on Form 8-K filed October 14, 2015).
4.4
Registration Rights Agreement dated October 9, 2015 among the Company and the dealer managers named therein (incorporated by reference to Exhibit 4.3 to CVS Health Corporation’s Current Report on Form 8-K filed October 14, 2015).
5.1*
Opinion of Shearman & Sterling LLP as to the legality of the securities offered hereby.
12.1*
Statement regarding Computation of Ratio of Earnings to Fixed Charges.
23.1*
Consent of Shearman & Sterling LLP (Included in Exhibit 5.1).
23.2*
Consent of Ernst & Young LLP.
24.1*
Powers of Attorney (included on signature page of this Registration Statement).
25.1*
Statement of Eligibility of The Bank of New York Mellon Trust Company, N.A. on Form T-1 for the Senior Indenture, dated as of August 15, 2006.
99.1*
Form of Letter of Transmittal (with accompanying IRS Form W-9 and related Guidelines).
99.2*
Form of Letter to Registered Holders and The Depository Trust Company Participants.
99.3*
Form of Letter to Clients (with form of Instructions to Registered Holder and/or The Depository Trust Company Participant).
_______________
 
*
Filed herewith.
     
All supporting schedules have been omitted because they are not required or the information required to be set forth therein is included in the consolidated financial statements or in the notes thereto.
 
Item 22.                 Undertakings.
 
(A) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
 
(B) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.  In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
 
 
II-2

 
 
(C) The undersigned Registrant hereby undertakes:
 
(1) To respond to requests for information that is incorporated by reference in the prospectus pursuant to Item 4, 10(b), 11, 13 of this Form S-4, within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means.  This includes information contained in documents filed subsequent to the effective date of the Registration Statement through the date of responding to the request.
 
(2) To supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the Registration Statement when it became effective.
 
 
 
 
 
 
II-3

 

SIGNATURES AND POWER OF ATTORNEY
 
Pursuant to the requirements of the Securities Act of 1933, the Registrant, CVS Health Corporation, has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Woonsocket, State of Rhode Island, on April 22, 2016.
 
 
CVS Health Corporation
 
       
 
By:
/s/ David M. Denton
 
   
David M. Denton
 
   
Executive Vice President and Chief Financial Officer
 
       
 
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David M. Denton as such person’s true and lawful attorney-in-fact and agent, with full power to act separately and full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorney-in-fact and agent or such person’s substitute or substitutes may lawfully do or cause to be done by virtue hereof.
    
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
 
Signature
 
Title
Date
/s/ Eva C. Boratto
 
Senior Vice President – Controller and Chief Accounting Officer (Principal Accounting Officer)
April 22, 2016
Eva C. Boratto
     
       
/s/ Richard M. Bracken
 
Director
 April 22, 2016
Richard M. Bracken
     
       
/s/ C. David Brown II
 
Director
April 22, 2016
C. David Brown II
     
       
/s/ Alecia A. DeCoudreaux
 
Director
April 22, 2016
Alecia A. DeCoudreaux
     
       
/s/ David M. Denton
 
Executive Vice President and Chief Financial Officer (Principal Financial Officer)
April 22, 2016
David M. Denton
     
       
/s/ Nancy-Ann M. DeParle
 
Director
April 22, 2016
Nancy-Ann M. DeParle
     
       
/s/ David W. Dorman
 
Director
April 22, 2016
David W. Dorman
     
       
/s/ Anne M. Finucane
 
Director
April 22, 2016
Anne M. Finucane
     
       
/s/ Larry J. Merlo
 
President and Chief Executive Officer (Principal Executive Officer) and Director
April 22, 2016
Larry J. Merlo
     
       
/s/ Jean-Pierre Millon
 
Director
April 22, 2016
Jean-Pierre Millon
     
       
/s/ Richard J. Swift
 
Director
April 22, 2016
Richard J. Swift
     
       
/s/ William C. Weldon
 
Director
April 22, 2016
William C. Weldon
     
       
/s/ Tony L. White
 
Director
April 22, 2016
Tony L. White
     
 
 
II-4

 
 
EXHIBIT INDEX
 
Exhibit Number
 
Description
4.1
Senior Indenture, dated as of August 15, 2006, between CVS Health Corporation (formerly CVS Corporation) and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.) (incorporated by reference to Exhibit 4.1 to CVS Health Corporation’s (formerly CVS Corporation) Current Report on Form 8-K filed August 15, 2006).
4.2
Form of 4.75% Senior Note due 2022 (incorporated by reference to Exhibit 4.1 to CVS Health Corporation’s Current Report on Form 8-K filed October 14, 2015).
4.3
Form of 5.00% Senior Note due 2024 (incorporated by reference to Exhibit 4.2 to CVS Health Corporation’s Current Report on Form 8-K filed October 14, 2015).
4.4
Registration Rights Agreement dated October 9, 2015 among the Company and the dealer managers named therein (incorporated by reference to Exhibit 4.3 to CVS Health Corporation’s Current Report on Form 8-K filed October 14, 2015).
5.1*
Opinion of Shearman & Sterling LLP as to the legality of the securities offered hereby.
12.1*
Statement regarding Computation of Ratio of Earnings to Fixed Charges.
23.1*
Consent of Shearman & Sterling LLP (Included in Exhibit 5.1).
23.2*
Consent of Ernst & Young LLP.
24.1*
Powers of Attorney (included on signature page of this Registration Statement).
25.1*
Statement of Eligibility of The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.) on Form T-1 for the Senior Indenture, dated as of August 15, 2006.
99.1*
Form of Letter of Transmittal (with accompanying IRS Form W-9 and related Guidelines).
99.2*
Form of Letter to Registered Holders and The Depository Trust Company Participants.
99.3*
Form of Letter to Clients (with form of Instructions to Registered Holder and/or The Depository Trust Company Participant).
__________________
 
*
Filed herewith.

 
 
 
 
 
 

EX-5.1 2 ss1454292_ex0501.htm OPINION OF SHEARMAN & STERLING LLP
  
Exhibits 5.1 and 23.1
 

 
OPINION OF SHEARMAN & STERLING LLP
 
April 22, 2016
 
CVS Health Corporation
One CVS Drive
Woonsocket, RI 02895
 
CVS Health Corporation
Registration Statement on Form S-4
 
Ladies and Gentlemen:
 
We have acted as counsel to CVS Health Corporation, a Delaware corporation (the “Company”), in connection with the preparation and filing by the Company of a registration statement on Form S4 (the “Registration Statement”) with the United States Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), relating to the issuance of the Company’s 4.75% Senior Notes due 2022 (the “Exchange 2022 Notes”) and 5.00% Senior Notes due 2024 (the “Exchange 2024 Notes” and, together with the Exchange 2022 Notes, the “Exchange Notes”). Pursuant to the prospectus forming a part of the Registration Statement (the “Prospectus”), the Company is offering to exchange (the “Exchange Offer”) up to $387,285,000 aggregate principal amount of Exchange 2022 Notes for a like principal amount of its outstanding 4.75% Senior Notes due 2022 issued on October 9, 2015 and October 21, 2015 (the “Old 2022 Notes”) and up to $296,255,000 aggregate principal amount of Exchange 2024 Notes for a like principal amount of its outstanding 5.00% Senior Notes due 2024 issued on October 9, 2015 and October 21, 2015 (the “Old 2024 Notes” and, together with the 2022 Notes, the “Old Notes”).  The Exchange Notes will be registered under the Securities Act as set forth in the Registration Statement and will be issued upon consummation of the Exchange Offer pursuant to the Senior Indenture, dated as of August 15, 2006 (as amended or supplemented from time to time, the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.), as trustee (the “Trustee”).
 
In our capacity as counsel to the Company, we have reviewed originals or copies of the following documents:
 
 
(a)
The Indenture.
 
 
(b)
The form of the Exchange Notes.
 
The documents described in the foregoing clauses (a) and (b) are collectively referred to herein as the “Opinion Documents.
 
 
 
 

 
 
We have also reviewed the following:
 
 
(a)
The Registration Statement.
 
 
(b)
The Prospectus.
 
 
(d)
The registration rights agreement, dated as of October 9, 2015, among the Company and the dealer managers named therein.
 
 
(e)
Originals or copies of such other corporate records of the Company, certificates of public officials and of officers of the Company and agreements and other documents as we have deemed necessary as a basis for the opinions expressed below.
 
In our review of the Opinion Documents and other documents, we have assumed:
 
 
(a)
The genuineness of all signatures.
 
 
(b)
The authenticity of the originals of the documents submitted to us.
 
 
(c)
The conformity to authentic originals of any documents submitted to us as copies.
 
 
(d)
As to matters of fact, the truthfulness of the representations made in the Opinion Documents and in certificates of public officials and officers of the Company.
 
 
(e)
That each of the Opinion Documents is the legal, valid and binding obligation of each party thereto, other than the Company, enforceable against each such party in accordance with its terms.
 
 
(f)
That:
 
(i)           The execution, delivery and performance by the Company of the Opinion Documents will be duly authorized by all necessary action (corporate or otherwise) and do not:
 
(A)           except with respect to Generally Applicable Law, violate any law, rule or regulation applicable to it; or
 
(B)           except with respect to any documents and agreements filed as exhibits to the Registration Statement, result in any conflict with, or breach of, any agreement or document binding on it.
 
(ii)           Except with respect to Generally Applicable Law, no authorization, approval or other action by, and no notice to or filing with, any governmental authority or regulatory body or any other third party is required for the due execution, delivery or performance by the Company of any Opinion Document to which it is a party or, if any such authorization, approval, consent, action, notice or filing is required, it has been duly obtained, taken, given or made and is in full force and effect.
 
 
2

 
 
We have not independently established the validity of the foregoing assumptions.
 
Generally Applicable Law” means the federal law of the United States of America, and the law of the State of New York (including the rules and regulations promulgated thereunder or pursuant thereto) that a New York lawyer exercising customary professional diligence would reasonably be expected to recognize as being applicable to the Company, the Opinion Documents or the transactions governed by the Opinion Documents, and for purposes of assumption paragraph (f) above and our opinion below, the General Corporation Law of the State of Delaware.  Without limiting the generality of the foregoing definition of Generally Applicable Law, the term “Generally Applicable Law” does not include any law, rule or regulation that is applicable to the Company, the Opinion Documents or such transactions solely because such law, rule or regulation is part of a regulatory regime applicable to the specific assets or business of any party to any of the Opinion Documents or any of its affiliates.
 
Based upon the foregoing and upon such other investigation as we have deemed necessary and subject to the qualifications set forth below, we are of the opinion that the Exchange Notes have been duly authorized by the Company and when duly executed and delivered by the Company and authenticated by the Trustee in accordance with the terms of the Indenture and if and when issued upon consummation of the Exchange Offer as set forth in the Registration Statement, will be the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms and entitled to the benefits of the Indenture.
 
Our opinions expressed above are subject to the following qualifications:
 
 
(a)
Our opinions are subject to the effect of any applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally (including without limitation all laws relating to fraudulent transfers).
 
 
(b)
Our opinions are also subject to the effect of general principles of equity, including without limitation concepts of materiality, reasonableness, good faith and fair dealing (regardless of whether considered in a proceeding in equity or at law).
 
 
(c)
Our opinions are limited to Generally Applicable Law and we do not express any opinion herein concerning any other law.
 
This opinion letter is rendered to you in connection with the Exchange Offer.
 
This opinion letter speaks only as of the date hereof.  We expressly disclaim any responsibility to advise you of any development or circumstance of any kind, including any change of law or fact, that may occur after the date of this opinion letter that might affect the opinions expressed herein.
 
 
3

 
 
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the use of our name under the heading “Legal Matters” in the Prospectus.  In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act and the rules and regulations promulgated thereunder.
 
Very truly yours,
 
/s/ Shearman & Sterling LLP
 
 
 
 
 
 
 

4

EX-12.1 3 ss1454292_ex1201.htm STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
 
Exhibit 12.1
 
CVS HEALTH CORPORATION
  
Computation of Ratio of Earnings to Fixed Charges

 
                               
                               
   
Fiscal Years
 
In millions
 
2015
   
2014
   
2013
   
2012
   
2011
 
Earnings:
                             
Earnings from continuing operations before income taxes and extraordinary items
  $ 8,613.5     $ 7,677.1     $ 7,527.1     $ 6,307.1     $ 5,750.5  
Interest portion of net rental expense
    763.7       785.3       750.3       741.7       715.8  
Interest expense (net of interest capitalized)
    859.5       615.4       517.5       561.2       588.5  
Adjusted earnings
  $ 10,236.7     $ 9,077.8     $ 8,794.9     $ 7,610.0     $ 7,054.8  
Fixed Charges:
                                       
Interest portion of net rental expense
    763.7       785.3       750.3       741.7       715.8  
Interest expense (net of interest capitalized)
    859.5       615.4       517.5       561.2       588.5  
Interest capitalized
    11.8       18.9       24.6       28.6       36.5  
Total fixed charges
  $ 1,635.0     $ 1,419.6     $ 1,292.4     $ 1,331.5     $ 1,340.8  
Ratio of earnings to fixed charges
    6.26 x     6.39 x     6.81 x     5.72 x     5.26 x
 
 
 
 
 
 
 


EX-23.2 4 ss1454292_ex2302.htm CONSENT OF ERNST & YOUNG LLP
  
Exhibit 23.2
 
 
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We consent to the reference to our firm under the caption “Experts” in this Registration Statement (Form S-4) and related Prospectus of CVS Health Corporation for the registration of debt securities and to the incorporation by reference therein of our reports dated February 9, 2016 with respect to the consolidated financial statements of CVS Health Corporation and the effectiveness of internal control over financial reporting of CVS Health Corporation incorporated by reference in its Annual Report (Form 10-K) for the year ended December 31, 2015, filed with the Securities and Exchange Commission.
 

 
 
/s/ Ernst & Young LLP

Boston, Massachusetts
April 22, 2016

 
 
 
 

EX-25.1 5 ss1454292_ex2501.htm STATEMENT OF ELIGIBILITY
    
Exhibit 25.1
 
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
  
FORM T-1
  
STATEMENT OF ELIGIBILITY
UNDER THE TRUST INDENTURE ACT OF 1939 OF A
CORPORATION DESIGNATED TO ACT AS TRUSTEE
 
CHECK IF AN APPLICATION TO DETERMINE
ELIGIBILITY OF A TRUSTEE PURSUANT TO
SECTION 305(b)(2)           |__|
___________________________
 
THE BANK OF NEW YORK MELLON
TRUST COMPANY, N.A.
(Exact name of trustee as specified in its charter)
 
(Jurisdiction of incorporation
if not a U.S. national bank)
95-3571558
(I.R.S. employer
identification no.)
   
400 South Hope Street
Suite 500
Los Angeles, California
(Address of principal executive offices)
90071
(Zip code)

 
___________________________
 
CVS Health Corporation
(Exact name of obligor as specified in its charter)
    
Delaware
(State or other jurisdiction of
incorporation or organization)
05-0494040
(I.R.S. employer
identification no.)
   
One CVS Drive
Woonsocket, Rhode Island
(Address of principal executive offices)
02895
(Zip code)
___________________________
 
4.75% Senior Notes due 2022
and 5.00% Senior Notes due 2024
(Title of the indenture securities)
 
 
 


 
 
 
 
    
1.
General information.  Furnish the following information as to the trustee:
 
 
(a)
Name and address of each examining or supervising authority to which it is subject.
 
Name
Address
Comptroller of the Currency
United States Department of the Treasury
   
Washington, DC 20219
Federal Reserve Bank
   
San Francisco, CA 94105
 
Federal Deposit Insurance Corporation
   
Washington, DC 20429
  
  
 
(b)
Whether it is authorized to exercise corporate trust powers.
 
Yes.
 
2.
Affiliations with Obligor.
 
If the obligor is an affiliate of the trustee, describe each such affiliation.
 
None.
 
16.
List of Exhibits.
 
Exhibits identified in parentheses below, on file with the Commission, are incorporated herein by reference as an exhibit hereto, pursuant to Rule 7a-29 under the Trust Indenture Act of 1939 (the “Act”) and 17 C.F.R. 229.10(d).
 
 
1.
A copy of the articles of association of The Bank of New York Mellon Trust Company, N.A., formerly known as The Bank of New York Trust Company, N.A. (Exhibit 1 to Form T-1 filed with Registration Statement No. 333-121948 and Exhibit 1 to Form T-1 filed with Registration Statement No. 333-152875).
  
 
2.
A copy of certificate of authority of the trustee to commence business. (Exhibit 2 to Form T-1 filed with Registration Statement No. 333-121948).
  
 
3.
A copy of the authorization of the trustee to exercise corporate trust powers (Exhibit 3 to Form T-1 filed with Registration Statement No. 333-152875).
   
 
 
- 2 -

 
   
 
4.
A copy of the existing by-laws of the trustee (Exhibit 4 to Form T-1 filed with Registration Statement No. 333-162713).
 
 
6.
The consent of the trustee required by Section 321(b) of the Act (Exhibit 6 to Form T-1 filed with Registration Statement No. 333-152875).
 
 
7.
A copy of the latest report of condition of the Trustee published pursuant to law or to the requirements of its supervising or examining authority.
 
 
 
 
 
 
 
 
 
 
 
 
- 3 -

 
     
SIGNATURE
 
Pursuant to the requirements of the Act, the trustee, The Bank of New York Mellon Trust Company, N.A., a banking association organized and existing under the laws of the United States of America, has duly caused this statement of eligibility to be signed on its behalf by the undersigned, thereunto duly authorized, all in the City of Chicago, and State of Illinois, on the 19th day of April, 2016.
         
  THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.
           
           
  By:  /s/ R. Tarnas  
  Name: R. Tarnas  
  Title: Vice President  
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 4 -

 
   
EXHIBIT 7

Consolidated Report of Condition of
THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.
of 400 South Hope Street, Suite 400, Los Angeles, CA 90071

At the close of business December 31, 2015, published in accordance with Federal regulatory authority instructions.


   
Dollar amounts
in thousands
 
ASSETS
     
       
Cash and balances due from depository institutions:
     
Noninterest-bearing balances
and currency and coin
    6,117  
Interest-bearing balances
    272,045  
Securities:
       
Held-to-maturity securities
    0  
Available-for-sale securities
    679,285  
Federal funds sold and securities
purchased under agreements to resell:
       
Federal funds sold
    0  
Securities purchased under agreements to resell
    0  
Loans and lease financing receivables:
       
Loans and leases held for sale
    0  
Loans and leases,
net of unearned income
    0  
LESS: Allowance for loan and
lease losses
    0  
Loans and leases, net of unearned
income and allowance
    0  
Trading assets
    0  
Premises and fixed assets
(including capitalized leases)
    11,408  
Other real estate owned
    0  
Investments in unconsolidated
subsidiaries and associated
companies
    0  
Direct and indirect investments in real estate ventures
    0  
Intangible assets:
       
Goodwill
    856,313  
Other intangible assets
    77,335  
Other assets
    118,036  
Total assets
  $ 2,020,539  
         
    
 
1

 
    
LIABILITIES
       
         
Deposits:
       
In domestic offices
    505  
Noninterest-bearing
    505  
Interest-bearing
    0  
Not applicable
       
Federal funds purchased and securities
sold under agreements to repurchase:
       
Federal funds purchased
    0  
Securities sold under agreements to repurchase
    0  
Trading liabilities
    0  
Other borrowed money:
       
(includes mortgage indebtedness and obligations under capitalized leases)
    0  
Not applicable
       
Not applicable
       
Subordinated notes and debentures
    0  
Other liabilities
    276,953  
Total liabilities
    277,458  
Not applicable
       
         
EQUITY CAPITAL
       
         
Perpetual preferred stock and related surplus
    0  
Common stock
    1,000  
Surplus (exclude all surplus related to preferred stock)
    1,122,455  
Not available
       
Retained earnings
    620,521  
Accumulated other comprehensive income
    895  
Other equity capital components
    0  
Not available
       
Total bank equity capital
    1,743,081  
Noncontrolling (minority) interests in consolidated subsidiaries
    0  
Total equity capital
    1,743,081  
Total liabilities and equity capital
    2,020,539  


I, Matthew J. McNulty, CFO of the above-named bank do hereby declare that the Reports of Condition and Income (including the supporting schedules) for this report date have been prepared in conformance with the instructions issued by the appropriate Federal regulatory authority and are true to the best of my knowledge and belief.

Matthew J. McNulty
)
CFO


We, the undersigned directors (trustees), attest to the correctness of the Report of Condition (including the supporting schedules) for this report date and declare that it has been examined by us and to the best of our knowledge and belief has been prepared in conformance with the instructions issued by the appropriate Federal regulatory authority and is true and correct.

Antonio I. Portuondo, President
)
 
William D. Lindelof, Director
)
Directors (Trustees)
Alphonse J. Briand, Director
)
 
 

 
 
 
2

EX-99.1 6 ss1454292_ex9901.htm FORM OF LETTER OF TRANSMITTAL
Exhibit 99.1
 
LETTER OF TRANSMITTAL
 
CVS Health Corporation
 
OFFER TO EXCHANGE
 
$387,285,000 OUTSTANDING 4.75% SENIOR NOTES DUE 2022
AND
$296,255,000 OUTSTANDING 5.00% SENIOR NOTES DUE 2024
 
FOR
 
A LIKE PRINCIPAL AMOUNT OF CORRESPONDING NEW NOTES
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
 
PURSUANT TO THE PROSPECTUS
DATED                 , 2016
 

THE EXCHANGE OFFER WILL EXPIRE AT        P.M., NEW YORK CITY TIME, ON                  , 2016, UNLESS EXTENDED (THE “EXPIRATION DATE”). TENDERS IN THE EXCHANGE OFFER MAY BE WITHDRAWN AT ANY TIME PRIOR TO         P.M., NEW YORK CITY TIME, ON THE EXPIRATION DATE.

The information agent and exchange agent for the exchange offer is:
 
D.F. King & Co., Inc.
48 Wall Street, 22nd Floor
New York, New York 10005
   
or
   
Banks and Brokers Call Collect:
(212) 269-5550
All Others Call Toll Free: (866) 745-0265
Email: cvs@dfking.com
 
 
By Regular, Registered or Certified Mail, Hand or Overnight Delivery:
D.F. King & Co., Inc.
48 Wall Street, 22nd Floor
New York, New York 10005
Attn: Peter Aymar
 
By Facsimile (for Eligible Institutions only):
(212) 709-3328
Attn:  Peter Aymar
 
For Confirmation:
(212) 232-3235
     
DELIVERY OF THIS LETTER OF TRANSMITTAL TO AN ADDRESS OR TRANSMISSION OF INSTRUCTIONS VIA A FACSIMILE NUMBER, OTHER THAN AS SET FORTH ABOVE, WILL NOT CONSTITUTE A VALID DELIVERY. THE INSTRUCTIONS ACCOMPANYING THIS LETTER OF TRANSMITTAL SHOULD BE READ CAREFULLY BEFORE THIS LETTER OF TRANSMITTAL IS COMPLETED. YOU MUST SIGN THIS LETTER OF TRANSMITTAL IN THE APPROPRIATE SPACE PROVIDED THEREFOR, WITH SIGNATURE GUARANTEE IF REQUIRED.
 
 
 

 
 
The undersigned hereby acknowledges receipt of the prospectus dated                        , 2016 (the “Prospectus”) of CVS Health Corporation, a Delaware corporation (“CVS Health”), and this Letter of Transmittal (or a facsimile thereof, the “Letter of Transmittal”), which together constitute CVS Health’s offer (the “exchange offer”) to exchange all of its issued and outstanding 4.75% Senior Notes due 2022 (the “Old 2022 Notes”) and issued and outstanding 5.00% Senior Notes due 2024 (the “Old 2024 Notes” and together with the Old 2022 Notes, the “Old Notes”), for a like principal amount of its 4.75% Senior Notes due 2022 (the “New 2022 Notes”) and 5.00% Senior Notes due 2024 (the “New 2024 Notes” and together with the New 2022 Notes, the “New Notes”), respectively, which have been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to a registration statement of which the Prospectus is a part. The Old Notes were issued in connection with private exchange offers on October 9, 2015 and October 21, 2015. Certain terms used but not defined herein have the respective meanings given to them in the Prospectus.
 
CVS Health reserves the right, at any time or from time to time, to extend the exchange offer at its discretion, in which event the term “Expiration Date” shall mean the latest date and time to which the exchange offer is extended.
 
This Letter of Transmittal is to be used by a holder of Old Notes if (i) Old Notes are to be physically forwarded herewith to the exchange agent or (ii) delivery of Old Notes is to be made by book-entry transfer to the account maintained by the exchange agent at The Depository Trust Company (“DTC”) pursuant to the procedures set forth in the Prospectus under the caption “The Exchange Offer — Procedures for Tendering Old Notes.” Tenders by book-entry transfer may also be made by delivering an agent’s message (as defined in the Prospectus) pursuant to DTC’s Automated Tender Offer Program in lieu of this Letter of Transmittal. DELIVERY OF DOCUMENTS TO THE BOOK-ENTRY TRANSFER FACILITY DOES NOT CONSTITUTE DELIVERY TO THE EXCHANGE AGENT.
 
The term “holder” with respect to the exchange offer means any person in whose name Old Notes are registered on the books of CVS Health or any other person who has obtained a properly completed bond power from the registered holder. The undersigned has completed, executed and delivered this Letter of Transmittal to indicate the action the undersigned desires to take with respect to the exchange offer. Holders who wish to tender their Old Notes must complete this Letter of Transmittal in its entirety.
 
Please read the entire Letter of Transmittal and the Prospectus carefully before checking any box below.
 
The instructions included with this Letter of Transmittal must be followed. Questions and requests for assistance for additional copies of the Prospectus and this Letter of Transmittal may be directed to the exchange agent.
 
 
 
 
 
2

 
 
List below the Old Notes to which this Letter of Transmittal relates. If the space below is inadequate, list the registered numbers and principal amounts on a separate signed schedule and affix the list to this Letter of Transmittal.
 
DESCRIPTION OF OLD NOTES TENDERED
 
Tendered
Old Note(s)
Name(s) and Address(es) of Registered Holder(s)
Exactly as Name(s) Appear(s)
on the Old Notes.
(Please Fill in, if Blank).
Series of Old Notes (Please check applicable boxes)
Certificate
Number(s)*
Aggregate Principal Amount Represented
by Old Notes*
Principal
Amount
Tendered**
 
4.75% Senior Notes Due 2022
 
     
 
5.00% Senior Notes Due 2024
 
     
 
Total Principal Amount
     
 
*   Need not be completed if Old Notes are being transferred by book-entry transfer. Such holders should check the boxes below as appropriate and provide the requested information.
** Unless otherwise indicated, any tendering holder of Old Notes will be deemed to have tendered the entire aggregate principal amount represented by such Old Notes. Notes may be tendered and accepted for payment only in principle amounts equal to minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof. No alternative, conditional or contingent tenders will be accepted.
 
¨
CHECK HERE IF TENDERED OLD NOTES ARE ENCLOSED HEREWITH.
 
¨
CHECK HERE IF TENDERED OLD NOTES ARE BEING DELIVERED BY BOOK-ENTRY TRANSFER MADE TO THE ACCOUNT MAINTAINED BY THE EXCHANGE AGENT WITH DTC AND COMPLETE THE FOLLOWING (FOR USE BY ELIGIBLE INSTITUTIONS ONLY):
 
 
Name of Tendering Institution:
 
Account Number:
 
Transaction Code Number:

¨
CHECK HERE IF YOU ARE A BROKER-DEALER AND WISH TO RECEIVE 10 ADDITIONAL COPIES OF THE PROSPECTUS AND 10 COPIES OF ANY AMENDMENTS OR SUPPLEMENTS THERETO:
 
 
Name:
 
Address:
 
 
 
 
3

 
 
SIGNATURES MUST BE PROVIDED BELOW
PLEASE READ THE ACCOMPANYING INSTRUCTIONS CAREFULLY
 
Ladies and Gentlemen:
 
Subject to the terms and conditions of the exchange offer, the undersigned hereby tenders to CVS Health for exchange the principal amount of Old Notes indicated above. Subject to and effective upon the acceptance for exchange of the principal amount of Old Notes tendered in accordance with this Letter of Transmittal, the undersigned hereby exchanges, assigns and transfers to CVS Health all right, title and interest in and to the Old Notes tendered for exchange hereby. The undersigned hereby irrevocably constitutes and appoints the exchange agent, as its agent, attorney-in-fact and proxy (with full knowledge that the exchange agent also is acting as the agent of CVS Health in connection with the exchange offer) with respect to the tendered Old Notes with full power of substitution to:
 
 
·
deliver such Old Notes, or transfer ownership of such Old Notes on the account books maintained by DTC, to CVS Health and deliver all accompanying evidence of transfer and authenticity, and
 
 
·
present such Old Notes for transfer on the books of CVS Health and receive all benefits and otherwise exercise all rights of beneficial ownership of such Old Notes,
 
all in accordance with the terms of the exchange offer. The power of attorney granted in this paragraph shall be deemed to be irrevocable and coupled with an interest.
 
The undersigned hereby represents and warrants that the undersigned has full power and authority to tender, exchange, assign and transfer the Old Notes tendered hereby and to acquire the New Notes issuable upon the exchange of such tendered Old Notes, and that CVS Health will acquire good and unencumbered title to the Old Notes, free and clear of all liens, restrictions, charges and encumbrances and not subject to any adverse claim, when the same are accepted for exchange by CVS Health.
 
The undersigned acknowledge(s) that this exchange offer is being made in reliance upon interpretations contained in no-action letters issued to third parties by the staff of the Securities and Exchange Commission (the “SEC”), including Exxon Capital Holdings Corporation, SEC No-Action Letter (available April 13, 1988), Morgan Stanley & Co. Incorporated, SEC No-Action Letter (available June 5, 1991), Shearman & Sterling, SEC No-Action Letter (available July 2, 1993) and Brown & Wood LLP (available February 7, 1997), that the New Notes issued in exchange for the Old Notes pursuant to the exchange offer may be offered for resale, resold and otherwise transferred by holders thereof (other than a broker-dealer who purchased Old Notes exchanged for such New Notes directly from CVS Health to resell pursuant to Rule 144A or any other available exemption under the Securities Act or a person that is an “affiliate” of CVS Health within the meaning of Rule 405 under the Securities Act), without compliance with the registration and prospectus delivery provisions of the Securities Act, provided that such New Notes are acquired in the ordinary course of such holders’ business and such holders are not participating in, and have no arrangement with any person to participate in, the distribution of such New Notes. The undersigned specifically represent(s) to CVS Health that:
 
 
·
it is not an affiliate of CVS Health within the meaning of Rule 405 of the Securities Act or, if it is such an affiliate, it will comply with the registration and prospectus delivery requirements of the Securities Act, to the extent applicable;
 
 
·
it is not participating, and it has no arrangement or understanding with any person to participate in a distribution (within the meaning of the Securities Act) of the New Notes in violation of the provisions of the Securities Act;
 
 
·
it is not a broker-dealer who tendered 4.75% notes due December 1, 2022 issued by Omnicare, Inc. or 5.00% notes due December 1, 2024 issued by Omnicare, Inc. acquired directly from Omnicare, Inc. for its own account in exchange for the Old Notes;
 
 
·
if it is a broker dealer, it has not entered into any arrangement or understanding with CVS Health or any of CVS Health’s affiliates to distribute the New Notes;
 
 
·
it is acquiring the New Notes in the ordinary course of its business; and
 
 
· 
it is not acting on behalf of any person or entity that could not truthfully make these representations.
 
 
 
4

 
 
If the exchange offeree is a broker-dealer holding Old Notes acquired for its own account as a result of market-making activities or other trading activities, it will deliver a prospectus meeting the requirements of the Securities Act in connection with any resale of New Notes received in respect of such Old Notes pursuant to the exchange offer.
    
If the undersigned is a broker-dealer that will receive New Notes for its own account in exchange for Old Notes, it acknowledges and represents that (i) such outstanding Old Notes were acquired by it as a result of market-making activities or other trading activities and (ii) it will deliver a prospectus meeting the requirements of the Securities Act in connection with any resale of such New Notes; however, by so acknowledging and by delivering a prospectus, the undersigned will not be deemed to admit that it is an “underwriter” within the meaning of the Securities Act.
    
The undersigned acknowledges that if the undersigned is participating in the exchange offer for the purpose of distributing the New Notes:
 
 
·
the undersigned cannot rely on the position of the staff of the SEC enunciated in Morgan Stanley and Co., Inc. (available June 5, 1991) and Exxon Capital Holdings Corporation (available May 13, 1988), as interpreted in the SEC’s letter to Shearman & Sterling dated July 2, 1993, and similar no-action letters, and, in the absence of an exemption therefrom, must comply with the registration and prospectus delivery requirements of the Securities Act in connection with any secondary resale transaction of the New Notes, in which case the registration statement must contain the selling security holder information required by Item 507 or Item 508, as applicable, of Regulation S-K of the SEC; and
 
 
·
failure to comply with such requirements in such instance could result in the undersigned incurring liability for which the undersigned is not indemnified by CVS Health.
 
The undersigned will, upon request, execute and deliver any additional documents deemed by the exchange agent or CVS Health to be necessary or desirable to complete the exchange, assignment and transfer of the Old Notes tendered hereby, including the transfer of such Old Notes on the account books maintained by DTC.
 
For purposes of the exchange offer, CVS Health shall be deemed to have accepted for exchange validly tendered Old Notes when, as and if CVS Health gives oral or written notice thereof to the exchange agent. Any tendered Old Notes that are not accepted for exchange pursuant to the exchange offer for any reason will be returned, without expense (subject to Instruction 6), to the undersigned at the address shown below or at a different address as may be indicated herein under “Special Delivery Instructions” as promptly as practicable after the expiration date.
 
All authority conferred or agreed to be conferred by this Letter of Transmittal shall survive the death, incapacity or dissolution of the undersigned, and every obligation of the undersigned under this Letter of Transmittal shall be binding upon the undersigned’s heirs, personal representatives, successors and assigns.
 
The undersigned acknowledges that the acceptance of properly tendered Old Notes by CVS Health pursuant to the procedures described under the caption “The Exchange Offer — Procedures for Tendering Old Notes” in the Prospectus and in the instructions hereto will constitute a binding agreement between the undersigned and CVS Health upon the terms and subject to the conditions of the exchange offer.
 
Unless otherwise indicated under “Special Issuance Instructions,” please issue the New Notes issued in exchange for the Old Notes accepted for exchange, and return any Old Notes not tendered or not exchanged, in the name(s) of the undersigned. Similarly, unless otherwise indicated under “Special Delivery Instructions,” please mail or deliver the New Notes issued in exchange for the Old Notes accepted for exchange and any Old Notes not tendered or not exchanged (and accompanying documents, as appropriate) to the undersigned at the address shown below the undersigned’s signature(s). In the event that both “Special Issuance Instructions” and “Special Delivery Instructions” are completed, please issue the New Notes issued in exchange for the Old Notes accepted for exchange in the name(s) of, and return any Old Notes not tendered or not exchanged to, the person(s) so indicated. The undersigned recognizes that CVS Health has no obligation pursuant to the “Special Issuance Instructions” and “Special Delivery Instructions” to transfer any Old Notes from the name of the registered holder(s) thereof if CVS Health does not accept for exchange any of the Old Notes so tendered for exchange.
 
 
 
5

 
 

SPECIAL ISSUANCE INSTRUCTIONS
(See Instructions 4 and 5)
 

To be completed ONLY (i) if Old Notes in a principal amount not tendered, or New Notes issued in exchange for Old Notes accepted for exchange, are to be issued in the name of someone other than the undersigned, or (ii) if Old Notes tendered by book-entry transfer that are not exchanged are to be returned by credit to an account maintained at DTC other than the account indicated above.
 
Issue New Notes and/or Old Notes to:
 
Name:
(Please Print or Type)
 
Address:
 
 
(Include Zip Code)
 
 
(Tax Identification or Social Security Number)
(See IRS Form W-9 Included Herein)

¨
Credit unexchanged Old Notes delivered by book-entry transfer to DTC account number set forth below:
 
DTC account number:
 
(Please Complete IRS Form W-9 Herein, See Instruction 7)
 
 

SPECIAL DELIVERY INSTRUCTIONS
(See Instructions 4 and 5)
 
To be completed ONLY if Old Notes in a principal amount not tendered, or New Notes issued in exchange for Old Notes accepted for exchange, are to be mailed or delivered to someone other than the undersigned, or to the undersigned at an address other than that shown below the undersigned’s signature.
 
Mail or deliver New Notes and/or Old Notes to:
 
Name:
(Please Print or Type)
 
Address:
 
 
(Include Zip Code)
 
 
(Tax Identification or Social Security Number)
(See IRS Form W-9 Included Herein)
 
 
 
 
 
6

 
 
IMPORTANT
PLEASE SIGN HERE WHETHER OR NOT OLD NOTES
ARE BEING PHYSICALLY TENDERED HEREBY
(Complete Accompanying Substitute Form W-9 on Reverse Side)
 
X:
 
X
(Signature(s) of Registered Holder(s) of Old Notes)

Dated: ____________________________________, 2016
 
(The above lines must be signed by the registered holder(s) of Old Notes as name(s) appear(s) on the Old Notes or on a security position listing, or by person(s) authorized to become registered holder(s) by a properly completed bond power from the registered holder(s), a copy of which must be transmitted with this Letter of Transmittal. If Old Notes to which this Letter of Transmittal relate are held of record by two or more joint holders, then all such holders must sign this Letter of Transmittal. If signature is by a trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation or other person acting in a fiduciary or representative capacity, then such person must set forth his or her or her full title below and, unless waived by CVS Health, submit evidence satisfactory to CVS Health of such person’s authority so to act. See Instruction 4 regarding the completion of this Letter of Transmittal, printed below.)
 
Name:
(Please Type or Print)
 
Capacity:
 
Address:
 
 
(Include Zip Code)
 
Address Code and Telephone Number:
 

SIGNATURE GUARANTEE
(If Required by Instruction 4)
 
Certain signatures must be guaranteed by an eligible institution.                                                                                                                                          
 
Signature(s) guaranteed by an eligible institution:  
 
(Authorized Signature)
 
(Title)
 
(Name of Firm)
 
(Address, Include Zip Code)
 
(Area Code and Telephone Number)

Dated: ____________________________________, 2016
 
 
 
7

 
 
INSTRUCTIONS
 
FORMING PART OF THE TERMS AND CONDITIONS OF THE EXCHANGE OFFER
 
1.           Delivery of this Letter of Transmittal and Old Notes or Book-Entry Confirmations. All physically delivered Old Notes or any confirmation of a book-entry transfer to the exchange agent’s account at DTC of Old Notes tendered by book-entry transfer (a “book-entry confirmation”), as well as a properly completed and duly executed copy of this Letter of Transmittal (or facsimile hereof) or agent’s message (as defined in the Prospectus) in lieu thereof, and any other documents required by this Letter of Transmittal, must be received by the exchange agent at its address set forth herein prior to       p.m., New York City time, on the expiration date. The method of delivery of the tendered Old Notes, this Letter of Transmittal and all other required documents to the exchange agent is at the election and risk of the holder and, except as otherwise provided below, the delivery will be deemed made only when actually received or confirmed by the exchange agent. Instead of delivery by mail, it is recommended that the holder use an overnight or hand delivery service. In all cases, sufficient time should be allowed to assure delivery to the exchange agent before the expiration date. No Letter of Transmittal or Old Notes should be sent to CVS Health.
 
2.           Tender by Holder. Only a holder of Old Notes may tender such Old Notes in the exchange offer. Any beneficial owner of Old Notes who is not the registered holder and who wishes to tender should arrange with the registered holder to execute and deliver this Letter of Transmittal on his or her behalf or must, prior to completing and executing this Letter of Transmittal and delivering his or her Old Notes, either make appropriate arrangements to register ownership of the Old Notes in such beneficial owner’s name or obtain a properly completed bond power from the registered holder.
 
3.           Partial Tenders. Tenders of Old Notes will be accepted only in a minimum denomination of $2,000 and integral multiples of $1,000 in excess of $2,000. Holders who tender less than all of their Old Notes must continue to hold Old Notes in the minimum denomination of $2,000. If less than the entire principal amount of any Old Notes is tendered, the tendering holder should fill in the principal amount tendered in the third column of the box titled “Description of Old Notes Tendered” above. The entire principal amount of Old Notes delivered to the exchange agent will be deemed to have been tendered unless otherwise indicated. If the entire principal amount of all Old Notes is not tendered, then Old Notes for the principal amount of Old Notes not tendered and New Notes issued in exchange for any Old Notes accepted will be sent to the holder at his or her registered address, unless a different address is provided in the appropriate box on this Letter of Transmittal, promptly after the Old Notes are accepted for exchange.
 
4.           Signatures on this Letter of Transmittal; Bond Powers and Endorsements; Guarantee of Signatures. If this Letter of Transmittal (or facsimile hereof) is signed by the record holder(s) of the Old Notes tendered hereby, the signature must correspond with the name(s) as written on the face of the Old Notes without alteration, enlargement or any change whatsoever. If this Letter of Transmittal (or facsimile hereof) is signed by a participant in DTC, the signature must correspond with the name as it appears on the security position listing as the holder of the Old Notes.
 
If this Letter of Transmittal (or facsimile hereof) is signed by the registered holder or holders of Old Notes listed and tendered hereby and the New Notes issued in exchange therefor are to be issued (or any untendered principal amount of Old Notes is to be reissued) to the registered holder, the said holder need not and should not endorse any tendered Old Notes, nor provide a separate bond power. In any other case, such holder must either properly endorse the Old Notes tendered or transmit a properly completed separate bond power with this Letter of Transmittal, with the signatures on the endorsement or bond power guaranteed by an eligible institution.
 
If this Letter of Transmittal (or facsimile hereof) is signed by a person other than the registered holder or holders of any Old Notes listed, such Old Notes must be endorsed or accompanied by appropriate bond powers, in each case signed as the name of the registered holder (or holders) appears on the Old Notes.
 
If this Letter of Transmittal (or facsimile hereof) or any Old Notes or bond powers are signed by trustees, executors, administrators, guardians, attorneys-in-fact, officers of corporations or others acting in a fiduciary or representative capacity, such persons should so indicate when signing, and, unless waived by CVS Health, evidence satisfactory to CVS Health of their authority to act must be submitted with this Letter of Transmittal.
 
 
8

 
 
Endorsements on Old Notes or signatures on bond powers required by this Instruction 4 must be guaranteed by an eligible institution.
 
No signature guarantee is required if:
 
 
·
this Letter of Transmittal (or facsimile hereof) is signed by the registered holder(s) of the Old Notes tendered herein (or by a participant in DTC whose name appears on a security position listing as the owner of the tendered Old Notes) and the New Notes are to be issued directly to such registered holder(s) (or, if signed by a participant in DTC, deposited to such participant’s account at DTC) and neither the box entitled “Special Delivery Instructions” nor the box entitled “Special Issuance Instructions” has been completed; or
 
 
·
such Old Notes are tendered for the account of an eligible institution.
 
In all other cases, all signatures on this Letter of Transmittal (or facsimile hereof) must be guaranteed by an eligible institution.
 
5.           Special Issuance and Delivery Instructions. Tendering holders should indicate, in the applicable box or boxes, the name and address (or account at the book-entry transfer facility) to which New Notes or substitute Old Notes for principal amounts not tendered or not accepted for exchange are to be issued or sent, if different from the name and address of the person signing this Letter of Transmittal. In the case of issuance in a different name, the taxpayer identification or social security number of the person named must also be indicated.
 
6.           Transfer Taxes. CVS Health will pay all transfer taxes, if any, applicable to the exchange of Old Notes pursuant to the exchange offer. If, however, New Notes or Old Notes for principal amounts not tendered or accepted for exchange are to be delivered to, or are to be registered or issued in the name of, any person other than the registered holder of the Old Notes tendered hereby, or if tendered Old Notes are registered in the name of any person other than the person signing this Letter of Transmittal, or if a transfer tax is imposed for any reason other than the exchange of Old Notes pursuant to the exchange offer, then the amount of any such transfer taxes (whether imposed on the registered holder or any other persons) will be payable by the tendering holder. If satisfactory evidence of payment of such taxes or exemption therefrom is not submitted with this Letter of Transmittal, the amount of such transfer taxes will be billed directly to such tendering holder.
 
EXCEPT AS PROVIDED IN THIS INSTRUCTION 6, IT WILL NOT BE NECESSARY FOR TRANSFER TAX STAMPS TO BE AFFIXED TO THE OLD NOTES LISTED IN THIS LETTER OF TRANSMITTAL.
 
7.           Taxpayer Identification Number; Backup Withholding; IRS Form W-9. U.S. federal income tax laws generally require that a tendering holder provides the exchange agent with such holder’s correct Taxpayer Identification Number (“TIN”) on IRS Form W-9, Request for Taxpayer Identification Number and Certification, below (the “IRS Form W-9”), which in the case of a holder who is an individual, is his or her social security number. If the tendering holder is a non-resident alien or a foreign entity, other requirements (as described below) will apply. If the exchange agent is not provided with the correct TIN or an adequate basis for an exemption from backup withholding, such tendering holder may be subject to a $50 penalty imposed by the Internal Revenue Service (the “IRS”). In addition, failure to provide the exchange agent with the correct TIN or an adequate basis for an exemption from backup withholding may result in backup withholding on payments made to the tendering holder pursuant to the exchange offer at a current rate of 28%. If withholding results in an overpayment of taxes, the holder may obtain a refund from the IRS.
 
Exempt holders of the Old Notes (including, among others, all corporations) are not subject to these backup withholding and reporting requirements. See the enclosed Instructions for the Requester of Form W-9 (the “W-9 Guidelines”) for additional instructions.
 
To prevent backup withholding, each tendering holder that is a U.S. person (including a resident alien) must provide its correct TIN by completing the IRS Form W-9 set forth below, certifying, under penalties of perjury, that such holder is a U.S. person (including a resident alien), that the TIN provided is correct (or that such Holder is awaiting a TIN) and that (i) such holder is exempt from backup withholding, or (ii) such holder has not been notified by the IRS that such holder is subject to backup withholding as a result of a failure to report all interest or dividends, or (iii) the IRS has notified such holder that such holder is no longer subject to backup withholding. If the Old Notes are in more than one name or are not in the name of the actual owner, such holder should consult the W-9 Guidelines for information on which TIN to report. If such holder does not have a TIN, such Holder should consult the W-9 Guidelines for instructions on applying for a TIN, write “Applied For” in the space reserved for the TIN, as shown on IRS Form W-9.
 
 
9

 
    
Note: Writing “Applied For” on the IRS Form W-9 means that such holder has already applied for a TIN or that such holder intends to apply for one in the near future. If such holder does not provide its TIN to the exchange agent within 60 days, backup withholding will begin and continue until such holder furnishes its TIN to the exchange agent.
 
A tendering holder that is a non-resident alien or a foreign entity must submit the appropriate completed IRS Form W-8 (generally IRS Form W-8BEN or W-8BEN-E, as applicable, Certificate of Foreign Status of Beneficial Owner for United States Tax Withholding and Reporting) to avoid backup withholding. The appropriate form may be obtained via the IRS website at www.irs.gov or by contacting the exchange agent at the address on the face of this Letter of Transmittal.
 
FAILURE TO COMPLETE IRS FORM W-9, IRS FORM W-8BEN OR ANOTHER APPROPRIATE FORM MAY RESULT IN BACKUP WITHHOLDING AT THE RATE DESCRIBED ABOVE ON ANY PAYMENTS MADE TO YOU PURSUANT TO THE EXCHANGE OFFER.
 
8.           Validity of Tenders. All questions as to the validity, form, eligibility (including time of receipt), acceptance and withdrawal of tendered Old Notes will be determined by CVS Health in its sole discretion, which determination will be final and binding. CVS Health reserves the absolute right to reject any and all Old Notes not properly tendered or any Old Notes the acceptance of which would, in the opinion of CVS Health or its counsel, be unlawful. CVS Health also reserves the absolute right to waive any conditions of the exchange offer or defects or irregularities in tenders as to particular Old Notes. The interpretation of the terms and conditions by CVS Health of the exchange offer (which includes this Letter of Transmittal and the instructions hereto) shall be final and binding on all parties. Unless waived, any defects or irregularities in connection with tenders of Old Notes must be cured within such time as CVS Health shall determine. Neither CVS Health, the exchange agent nor any other person shall be under any duty to give notification of defects or irregularities with regard to tenders of Old Notes nor shall any of them incur any liability for failure to give such information.
 
9.           Waiver of Conditions. CVS Health reserves the absolute right to waive, in whole or in part, any of the conditions to the exchange offer set forth in the Prospectus.
 
10.           No Conditional Tender. No alternative, conditional, irregular or contingent tender of Old Notes or transmittal of this Letter of Transmittal will be accepted.
 
11.           Mutilated, Lost, Stolen or Destroyed Old Notes. Any holder whose Old Notes have been mutilated, lost, stolen or destroyed should contact the exchange agent at the address indicated above for further instructions.
 
12.           Requests for Assistance or Additional Copies. Requests for assistance or for additional copies of the Prospectus or this Letter of Transmittal may be directed to the exchange agent at the address or telephone number set forth on the cover page of this Letter of Transmittal. Holders may also contact their broker, dealer, commercial bank, trust company or other nominee for assistance concerning the exchange offer.
 
13.           Withdrawal. Tenders may be withdrawn only pursuant to the withdrawal rights set forth in the Prospectus under the caption “The Exchange Offer — Withdrawal of Tenders.”
 
IMPORTANT: THIS LETTER OF TRANSMITTAL OR A MANUALLY SIGNED FACSIMILE HEREOF OR AN AGENT’S MESSAGE IN LIEU THEREOF (TOGETHER WITH THE OLD NOTES DELIVERED BY BOOK-ENTRY TRANSFER OR IN ORIGINAL HARD COPY FORM) MUST BE RECEIVED BY THE EXCHANGE AGENT ON OR PRIOR TO THE EXPIRATION DATE.
 
 
 
10

 
 
Form  W-9
(Rev. December 2014)
Department of the Treasury
Internal Revenue Service
 
Request for Taxpayer
Identification Number and Certification
 
Give Form to the
requester. Do not
send to the IRS.
   
1  Name (as shown on your income tax return). Name is required on this line; do not leave this line blank.
 
   
   
2  Business name/disregarded entity name, if different from above
 
   
   
3  Check appropriate box for federal tax classification; check only one of the following seven boxes:
 
4  Exemptions (codes apply only
Print or type
See Specific
  o
lndividual/sole proprietor or single-member LLC
o
C Corporation
o
S Corporation
o
Partnership
o
Trust/estate
 
to certain entities, not individuals; see
instructions on page 3):
Instructions
on page 2.
  o
Limited liability company. Enter the tax classification (C=C corporation, S=S corporation, P=partnership)  _____________
Note. For a single-member LLC that is disregarded, do not check LLC; check the appropriate box In the line above for the tax classification of the single-member owner
 
Exempt payee code (if any) ____________
Exemption from FATCA reporting
code (if any)  ________________________
    o
Other (see instructions)
 
(Applies to accounts maintained outside the U.S.)
   
5  Address (number, street, and apt. or suite no.)
 
  Requester’s name and address (optional)
   
6  City, state, and ZIP code
 
 
   
7  List account number(s) here (optional)
 
 
Part I
  
Taxpayer Identification Number (TIN)
Enter your TIN in the appropriate box. The TIN provided must match the name given on line 1 to avoid
 
Social security number
backup withholding. For individuals, this is generally your social security number (SSN). However, for a
       
   
       
resident alien, sole proprietor, or disregarded entity, see the Part I instructions on page 3. For other entities,
  or                    
it is your employer identification number (EIN). If you do not have a number, see How to get a TIN on page 3.
  Employer identification number  
Note. If the account is in more than one name, see the instructions for line 1 and the chart on page 4 for guidelines on whose number to enter.
                     
Part II
  
Certification
Under penalties of perjury, I certify that:
1.
 
The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me); and
2.  
I am not subject to backup withholding because: (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and
3.  
I am a U.S. citizen or other U.S. person (defined below); and
4.  
The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.
Certification instructions. You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions on page 3.
Sign
Here
 
Signature of
U.S. person  u
 
Date  u
 
General Instructions
Section references are to the Internal Revenue Code unless otherwise noted.
Future developments. Information about developments affecting Form W-9 (such as legislation enacted after we release it) is at www.irs.gov/fw9.
 
Purpose of Form
An individual or entity (Form W-9 requester) who is required to file an information return with the IRS must obtain your correct taxpayer identification number (TIN) which may be your social security number (SSN), individual taxpayer identification number (ITIN), adoption taxpayer identification number (ATIN), or employer identification number (EIN), to report on an information return the amount paid to you, or other amount reportable on an information return. Examples of information returns include, but are not limited to, the following:
• Form 1099-INT (interest earned or paid)
• Form 1099-DIV (dividends, including those from stocks or mutual funds)
• Form 1099-MISC (various types of income, prizes, awards, or gross proceeds)
• Form 1099-B (stock or mutual fund sales and certain other transactions by brokers)
• Form 1099-S (proceeds from real estate transactions)
• Form 1099-K (merchant card and third party network transactions)
 
 
• Form 1098 (home mortgage interest), 1098-E (student loan interest), 1098-T (tuition)
• Form 1099-C (canceled debt)
• Form 1099-A (acquisition or abandonment of secured property)
Use Form W-9 only if you are a U.S. person (including a resident alien), to provide your correct TIN.
If you do not return Form W-9 to the requester with a TIN, you might be subject to backup withholding. See What is backup withholding? on page 2.
By signing the filled-out form, you:
1. Certify that the TIN you are giving is correct (or you are waiting for a number to be issued),
2. Certify that you are not subject to backup withholding, or
3. Claim exemption from backup withholding if you are a U.S. exempt payee. If applicable, you are also certifying that as a U.S. person, your allocable share of any partnership income from a U.S. trade or business is not subject to the withholding tax on foreign partners’ share of effectively connected income, and
4. Certify that FATCA code(s) entered on this form (if any) indicating that you are exempt from the FATCA reporting, is correct. See What Is FATCA reporting? on page 2 for further information.
 
 
   
Cat. No. 10231X
 
Form W-9 (Rev. 12-2014)
 
 
 

 
 
Form W-9 (Rev. 12-2014)
Page 2
 
Note. If you are a U.S. person and a requester gives you a form other than Form W-9 to request your TIN, you must use the requester’s form if it is substantially similar to this Form W-9.
Definition of a U.S. parson. For federal tax purposes, you are considered a U.S. person if you are:
• An individual who is a U.S. citizen or U.S. resident alien;
• A partnership, corporation, company, or association created or organized in the United States or under the laws of the United States;
• An estate (other than a foreign estate); or
• A domestic trust (as defined in Regulations section 301.7701-7).
Special rules for partnerships. Partnerships that conduct a trade or business in the United States are generally required to pay a withholding tax under section 1446 on any foreign partners’ share of effectively connected taxable income from such business. Further, in certain cases where a Form W-9 has not been received, the rules under section 1446 require a partnership to presume that a partner is a foreign person, and pay the section 1446 withholding tax. Therefore, if you are a U.S. person that is a partner in a partnership conducting a trade or business in the United States, provide Form W-9 to the partnership to establish your U.S. status and avoid section 1446 withholding on your share of partnership income.
In the cases below, the following person must give Form W-9 to the partnership for purposes of establishing its U.S. status and avoiding withholding on its allocable share of net income from the partnership conducting a trade or business in the United States:
• In the case of a disregarded entity with a U.S. owner, the U.S. owner of the disregarded entity and not the entity;
• In the case of a grantor trust with a U.S. grantor or other U.S. owner, generally, the U.S. grantor or other U.S. owner of the grantor trust and not the trust; and
• In the case of a U.S. trust (other than a grantor trust), the U.S. trust (other than a grantor trust) and not the beneficiaries of the trust.
Foreign person. If you are a foreign person or the U.S. branch of a foreign bank that has elected to be treated as a U.S. person, do not use Form W-9. Instead, use the appropriate Form W-8 or Form 8233 (see Publication 515, Withholding of Tax on Nonresident Aliens and Foreign Entities).
Nonresident alien who becomes a resident alien. Generally, only a nonresident alien individual may use the terms of a tax treaty to reduce or eliminate U.S. tax on certain types of income. However, most tax treaties contain a provision known as a “saving clause.” Exceptions specified in the saving clause may permit an exemption from tax to continue for certain types of income even after the payee has otherwise become a U.S. resident alien for tax purposes.
If you are a U.S. resident alien who is relying on an exception contained in the saving clause of a tax treaty to claim an exemption from U.S. tax on certain types of income, you must attach a statement to Form W-9 that specifies the following five items:
1. The treaty country. Generally, this must be the same treaty under which you claimed exemption from tax as a nonresident alien.
2. The treaty article addressing the income.
3. The article number (or location) in the tax treaty that contains the saving clause and its exceptions.
4. The type and amount of income that qualifies for the exemption from tax.
5. Sufficient facts to justify the exemption from tax under the term of the treaty article.
Example. Article 20 of the U.S.-China income tax treaty allows an exemption from tax for scholarship income received by a Chinese student temporarily present in the United States. Under U.S. law, this student will become a resident alien for tax purposes if his or her stay in the United States exceeds 5 calendar years. However, paragraph 2 of the first Protocol to the U.S.-China treaty (dated April 30, 1984) allows the provisions of Article 20 to continue to apply even after the Chinese student becomes a resident alien of the United States. A Chinese student who qualifies for this exception (under paragraph 2 of the first protocol) and is relying on this exception to claim an exemption from tax on his or her scholarship or fellowship income would attach to Form W-9 a statement that includes the information described above to support that exemption.
If you are a nonresident alien or a foreign entity, give the requester the appropriate completed Form W-8 or Form 8233.
 
Backup Withholding
What is backup withholding? Persons making certain payments to you must under certain conditions withhold and pay to the IRS 28% of such payments. This is called “backup withholding.” Payments that may be subject to backup withholding include interest, tax-exempt interest, dividends, broker and barter exchange transactions, rents, royalties, nonemployee pay, payments made in settlement of payment card and third party network transactions, and certain payments from fishing boat operators. Real estate transactions are not subject to backup withholding.
You will not be subject to backup withholding on payments you receive if you give the requester your correct TIN, make the proper certifications, and report all your taxable interest and dividends on your tax return.
Payments you receive will be subject to backup withholding if:
1. You do not furnish your TIN to the requester,
2. You do not certify your TIN when required (see the Part II instructions on page 3 for details),
 
3. The IRS tells the requester that you furnished an incorrect TIN,
4. The IRS tells you that you are subject to backup withholding because you did not report all your interest and dividends on your tax return (for reportable interest and dividends only), or
5. You do not certify to the requester that you are not subject to backup withholding under 4 above (for reportable interest and dividend accounts opened after 1983 only).
Certain payees and payments are exempt from backup withholding. See Exempt payee code on page 3 and the separate Instructions for the Requester of Form W-9 for more information.
Also see Special rules for partnerships above.
 
What is FATCA reporting?
The Foreign Account Tax Compliance Act (FATCA) requires a participating foreign financial institution to report all United States account holders that are specified United States persons. Certain payees are exempt from FATCA reporting. See Exemption from FATCA reporting code on page 3 and the Instructions for the Requester of Form W-9 for more information.
 
Updating Your Information
You must provide updated information to any person to whom you claimed to be an exempt payee if you are no longer an exempt payee and anticipate receiving reportable payments in the future from this person. For example, you may need to provide updated information if you are a C corporation that elects to be an S corporation, or if you no longer are tax exempt. In addition, you must furnish a new Form W-9 if the name or TIN changes for the account; for example, if the grantor of a grantor trust dies.
 
Penalties
Failure to furnish TIN. If you fail to furnish your correct TIN to a requester, you are subject to a penalty of $50 for each such failure unless your failure is due to reasonable cause and not to willful neglect.
Civil penalty for false information with respect to withholding. If you make a false statement with no reasonable basis that results in no backup withholding, you are subject to a $500 penalty.
Criminal penalty for falsifying information. Willfully falsifying certifications or affirmations may subject you to criminal penalties including fines and/or imprisonment.
Misuse of TINs. If the requester discloses or uses TINs in violation of federal law, the requester may be subject to civil and criminal penalties.
 
Specific Instructions
Line 1
You must enter one of the following on this line; do not leave this line blank. The name should match the name on your tax return.
If this Form W-9 is for a joint account, list first, and then circle, the name of the person or entity whose number you entered in Part I of Form W-9.
a. Individual. Generally, enter the name shown on your tax return. If you have changed your last name without informing the Social Security Administration (SSA) of the name change, enter your first name, the last name as shown on your social security card, and your new last name.
Note. ITIN applicant: Enter your individual name as it was entered on your Form W-7 application, line 1a. This should also be the same as the name you entered on the Form 1040/1040A/1040EZ you filed with your application.
b. Sole proprietor or single-member LLC. Enter your individual name as shown on your 1040/1040A/1040EZ on line 1. You may enter your business, trade, or “doing business as” (DBA) name on line 2.
c. Partnership, LLC that is not a single-member LLC, C Corporation, or S Corporation. Enter the entity’s name as shown on the entity’s tax return on line 1 and any business, trade, or DBA name on line 2.
d. Other entities. Enter your name as shown on required U.S. federal tax documents on line 1. This name should match the name shown on the charter or other legal document creating the entity. You may enter any business, trade, or DBA name on line 2.
e. Disregarded entity. For U.S. federal tax purposes, an entity that is disregarded as an entity separate from its owner is treated as a “disregarded entity.” See Regulations section 301.7701-2(c)(2)(iii). Enter the owner’s name on line 1. The name of the entity entered on line 1 should never be a disregarded entity. The name on line 1 should be the name shown on the income tax return on which the income should be reported. For example, if a foreign LLC that is treated as a disregarded entity for U.S. federal tax purposes has a single owner that is a U.S. person, the U.S. owner’s name is required to be provided on line 1. If the direct owner of the entity is also a disregarded entity, enter the first owner that is not disregarded for federal tax purposes. Enter the disregarded entity’s name on line 2, “Business name/disregarded entity name.” If the owner of the disregarded entity is a foreign person, the owner must complete an appropriate Form W-8 instead of a Form W-9. This is the case even if the foreign person has a U.S. TIN.
 
 
 

 
 
Form W-9 (Rev. 12-2014)
Page 3
 
Line 2
If you have a business name, trade name, DBA name, or disregarded entity name, you may enter it on line 2.
 
Line 3
Check the appropriate box in line 3 for the U.S. federal tax classification of the person whose name is entered on line 1. Check only one box in line 3.
Limited Liability Company (LLC). If the name on line 1 is an LLC treated as a partnership for U.S. federal tax purposes, check the “Limited Liability Company” box and enter “P” in the space provided. If the LLC has filed Form 8832 or 2553 to be taxed as a corporation, check the “Limited Liability Company” box and in the space provided enter “C” for C corporation or “S” for S corporation. If it is a single-member LLC that is a disregarded entity, do not check the “Limited Liability Company” box; instead check the first box in line 3 “Individual/sole proprietor or single-member LLC.”
 
Line 4, Exemptions
If you are exempt from backup withholding and/or FATCA reporting, enter in the appropriate space in line 4 any code(s) that may apply to you.
Exempt payee code.
• Generally, individuals (including sole proprietors) are not exempt from backup withholding.
• Except as provided below, corporations are exempt from backup withholding for certain payments, including interest and dividends.
• Corporations are not exempt from backup withholding for payments made in settlement of payment card or third party network transactions.
• Corporations are not exempt from backup withholding with respect to attorneys’ fees or gross proceeds paid to attorneys, and corporations that provide medical or health care services are not exempt with respect to payments reportable on Form 1099-MISC.
The following codes identify payees that are exempt from backup withholding. Enter the appropriate code in the space in line 4.
1—An organization exempt from tax under section 501(a), any IRA, or a custodial account under section 403(b)(7) if the account satisfies the requirements of section 401(f)(2)
2—The United States or any of its agencies or instrumentalities
3—A state, the District of Columbia, a U.S. commonwealth or possession, or any of their political subdivisions or instrumentalities
4—A foreign government or any of its political subdivisions, agencies, or instrumentalities
5—A corporation
6—A dealer in securities or commodities required to register in the United States, the District of Columbia, or a U.S. commonwealth or possession
7—A futures commission merchant registered with the Commodity Futures Trading Commission
8—A real estate investment trust
9—An entity registered at all times during the tax year under the Investment Company Act of 1940
10—A common trust fund operated by a bank under section 584(a)
11—A financial institution
12—A middleman known in the investment community as a nominee or custodian
13—A trust exempt from tax under section 664 or described in section 4947
The following chart shows types of payments that may be exempt from backup withholding. The chart applies to the exempt payees listed above, 1 through 13.
 
2 However, the following payments made to a corporation and reportable on Form 1099-MISC are not exempt from backup withholding: medical and health care payments, attorneys’ fees, gross proceeds paid to an attorney reportable under section 6045(f), and payments for services paid by a federal executive agency.
Exemption from FATCA reporting code. The following codes identify payees that are exempt from reporting under FATCA. These codes apply to persons submitting this form for accounts maintained outside of the United States by certain foreign financial institutions. Therefore, if you are only submitting this form for an account you hold in the United States, you may leave this field blank. Consult with the person requesting this form If you are uncertain If the financial institution is subject to these requirements. A requester may indicate that a code is not required by providing you with a Form W-9 with “Not Applicable” (or any similar indication) written or printed on the line for a FATCA exemption code.
A—An organization exempt from tax under section 501(a) or any individual retirement plan as defined in section 7701 (a)(37)
B—The United States or any of its agencies or instrumentalities
C—A state, the District of Columbia, a U.S. commonwealth or possession, or any of their political subdivisions or instrumentalities
D—A corporation the stock of which is regularly traded on one or more established securities markets, as described in Regulations section 1.1472-1(c)(1)(i)
E—A corporation that is a member of the same expanded affiliated group as a corporation described in Regulations section 1.1472-1 (c)(1)(i)
F—A dealer in securities, commodities, or derivative financial instruments (including notional principal contracts, futures, forwards, and options) that is registered as such under the laws of the United States or any state
G—A real estate investment trust
H—A regulated investment company as defined in section 851 or an entity registered at all times during the tax year under the Investment Company Act of 1940
I—A common trust fund as defined in section 584(a)
J—A bank as defined in section 581
K—A broker
L—A trust exempt from tax under section 664 or described in section 4947(a)(1)
M—A tax exempt trust under a section 403(b) plan or section 457(g) plan
Note. You may wish to consult with the financial institution requesting this form to determine whether the FATCA code and/or exempt payee code should be completed.
 
Line 5
Enter your address (number, street, and apartment or suite number). This is where the requester of this
Form W-9 will mail your information returns.
 
Line 6
Enter your city, state, and ZIP code.
 
Part I. Taxpayer Identification Number (TIN)
Enter your TIN in the appropriate box. If you are a resident alien and you do not have and are not eligible to get an SSN, your TIN is your IRS individual taxpayer Identification number (ITIN). Enter it in the social security number box. If you do not have an ITIN, see How to get a TIN below.
If you are a sole proprietor and you have an EIN, you may enter either your SSN or EIN. However, the IRS prefers that you use your SSN.
If you are a single-member LLC that is disregarded as an entity separate from Its owner (see Limited Liability Company (LLC) on this page), enter the owner’s SSN (or EIN, if the owner has one). Do not enter the disregarded entity’s EIN. If the LLC is classified as a corporation or partnership, enter the entity’s EIN.
IF the payment is for...
THEN the payment is exempt for...
 
Note. See the chart on page 4 for further clarification of name and TIN combinations.
How to get a TIN. If you do not have a TIN, apply for one immediately, To apply for an SSN, get Form SS-5, Application for a Social Security Card, from your local SSA office or get this form online at www.ssa.gov. You may also get this form by calling 1-800-772-1213. Use Form W-7, Application for IRS Individual Taxpayer Identification Number, to apply for an ITIN, or Form SS-4, Application for Employer Identification Number, to apply for an EIN. You can apply for an EIN online by accessing the IRS website at www.irs.gov/businesses and clicking on Employer Identification Number (EIN) under Starting a Business. You can get Forms W-7 and SS-4 from the IRS by visiting IRS.gov or by calling 1-800-TAX-FORM (1-800-829-3676).
If you are asked to complete Form W-9 but do not have a TIN, apply for a TIN and write “Applied For” in the space for the TIN, sign and date the form, and give it to the requester. For interest and dividend payments, and certain payments made with respect to readily tradable instruments, generally you will have 60 days to get a TIN and give it to the requester before you are subject to backup withholding on payments. The 60-day rule does not apply to other types of payments. You will be subject to backup withholding on all such payments until you provide your TIN to the requester.
Note. Entering “Applied For” means that you have already applied for a TIN or that you intend to apply for one soon.
Interest and dividend payments
All exempt payees except for 7
 
Broker transactions
Exempt payees 1 through 4 and 6 through 11 and all C corporations. S corporations must not enter an exempt payee code because they are exempt only for sales of noncovered securities acquired prior to 2012.
 
Barter exchange transactions and patronage dividends
Exempt payees 1 through 4
 
Payments over $600 required to be reported and direct sales over $5,0001
Generally, exempt payees 1 through 52
 
Payments made in settlement of payment card or third party network transactions
Exempt payees 1 through 4
 
1 See Form 1099-MISC, Miscellaneous Income, and its instructions.
 
Caution: A disregarded U.S. entity that has a foreign owner must use the appropriate Form W-8.
 
 
 

 
 
Form W-9 (Rev. 12-2014)
Page 4
 
Part II. Certification
 
To establish to the withholding agent that you are a U.S. person, or resident alien, sign Form W-9. You may be requested to sign by the withholding agent even if items I, 4, or 5 below indicate otherwise.
For a joint account, only the person whose TIN is shown in Part I should sign (when required). In the case of a disregarded entity, the person identified on line 1 must sign. Exempt payees, see Exempt payee code earlier.
Signature requirements. Complete the certification as indicated in items 1 through 5 below.
1. Interest, dividend, and barter exchange accounts opened before 1984 and broker accounts considered active during 1983. You must give your correct TIN, but you do not have to sign the certification.
2. Interest, dividend, broker, and barter exchange accounts opened after 1983 and broker accounts considered inactive during 1983. You must sign the certification or backup withholding will apply. If you are subject to backup withholding and you are merely providing your correct TIN to the requester, you must cross out item 2 in the certification before signing the form.
3. Real estate transactions. You must sign the certification. You may cross out item 2 of the certification.
4. Other payments. You must give your correct TIN, but you do not have to sign the certification unless you have been notified that you have previously given an incorrect TIN. “Other payments” include payments made in the course of the requester’s trade or business for rents, royalties, goods (other than bills for merchandise), medical and health care services (including payments to corporations), payments to a nonemployee for services, payments made in settlement of payment card and third party network transactions, payments to certain fishing boat crew members and fishermen, and gross proceeds paid to attorneys (including payments to corporations).
5. Mortgage interest paid by you, acquisition or abandonment of secured property, cancellation of debt, qualified tuition program payments (under section 529), IRA, Coverdell ESA, Archer MSA or HSA contributions or distributions, and pension distributions. You must give your correct TIN, but you do not have to sign the certification.
 
What Name and Number To Give the Requester
 
3   You must show your individual name and you may also enter your business or DBA name on the “Business name/disregarded entity” name line. You may use either your SSN or EIN (if you have one), but the IRS encourages you to use your SSN.
4   List first and circle the name of the trust, estate, or pension trust. (Do not furnish the TIN of the personal representative or trustee unless the legal entity itself is not designated in the account title.) Also see Special rules for partnerships on page 2.
* Note. Grantor also must provide a Form W-9 to trustee of trust.
Note. If no name is circled when more than one name is listed, the number will be considered to be that of the first name listed.
 
Secure Your Tax Records from Identity Theft
 
Identity theft occurs when someone uses your personal information such as your name, SSN, or other identifying information, without your permission, to commit fraud or other crimes. An identity thief may use your SSN to get a job or may file a tax return using your SSN to receive a refund.
To reduce your risk:
• Protect your SSN,
• Ensure your employer is protecting your SSN, and
• Be careful when choosing a tax preparer.
If your tax records are affected by identity theft and you receive a notice from the IRS, respond right away to the name and phone number printed on the IRS notice or letter.
If your tax records are not currently affected by identity theft but you think you are at risk due to a lost or stolen purse or wallet, questionable credit card activity or credit report, contact the IRS identity Theft Hotline at 1-800-908-4490 or submit Form 14039.
For more information, see Publication 4535, Identity Theft Prevention and Victim Assistance.
Victims of identity theft who are experiencing economic harm or a system problem, or are seeking help in resolving tax problems that have not been resolved through normal channels, may be eligible for Taxpayer Advocate Service (TAS) assistance. You can reach TAS by calling the TAS toll-free case intake line at 1-877-777-4778 or TTY/TDD 1-800-829-4059.
 
For this type of account:
Give name and SSN of:
 
Protect yourself from suspicious emails or phishing schemes. Phishing is the creation and use of email and websites designed to mimic legitimate business emails and websites. The most common act is sending an email to a user falsely claiming to be an established legitimate enterprise in an attempt to scam the user into surrendering private information that will be used for identity theft.
The IRS does not initiate contacts with taxpayers via emails. Also, the IRS does not request personal detailed information through email or ask taxpayers for the PIN numbers, passwords, or similar secret access information for their credit card, bank, or other financial accounts.
If you receive an unsolicited email claiming to be from the IRS, forward this message to phishing@irs.gov. You may also report misuse of the IRS name, logo, or other IRS property to the Treasury Inspector General for Tax Administration (TIGTA) at 1-800-366-4484. You can forward suspicious emails to the Federal Trade Commission at: spam@uce.gov or contact them at www.ftc.gov/idtheft or 1-877-IDTHEFT (1-877-438-4338).
Visit IRS.gov to learn more about identity theft and how to reduce your risk.
1.
Individual
The individual
 
2.
Two or more individuals (joint account)
The actual owner of the account or, if combined funds, the first individual on the account1
 
3.
Custodian account of a minor (Uniform Gift to Minors Act)
The minor2
 
4.
a. The usual revocable savings trust (grantor is
also trustee)
b.So-called trust account that is not a legal or valid trust under state law
The grantor-trustee1

The actual owner1
 
5.
Sole proprietorship or disregarded entity owned by an individual
The owner3
 
Privacy Act Notice
 
Section 6109 of the Internal Revenue Code requires you to provide your correct TIN to persons (including federal agencies) who are required to file information returns with the IRS to report interest, dividends, or certain other income paid to you; mortgage interest you paid; the acquisition or abandonment of secured property; the cancellation of debt; or contributions you made to an IRA, Archer MSA, or HSA. The person collecting this form uses the information on the form to file information returns with the IRS, reporting the above information. Routine uses of this information include giving it to the Department of Justice for civil and criminal litigation and to cities, states, the District of Columbia, and U.S. commonwealths and possessions for use in administering their laws. The information also may be disclosed to other countries under a treaty, to federal and state agencies to enforce civil and criminal laws, or to federal law enforcement and intelligence agencies to combat terrorism. You must provide your TIN whether or not you are required to file a tax return. Under section 3406, payers must generally withhold a percentage of taxable interest, dividend, and certain other payments to a payee who does not give a TIN to the payer. Certain penalties may also apply for providing false or fraudulent information.
 
 
6.
Grantor trust filing under Optional Form 1099 Filing Method 1 (see Regulations section 1.671-4(b)(2)(i)(A))
The grantor*
 
 
For this type of account:
Give name and EIN of:
 
7.
Disregarded entity not owned by an individual
The owner
 
8.
A valid trust, estate, or pension trust
Legal entity4
 
9.
Corporation or LLC electing corporate status on Form 8832 or Form 2553
The corporation
 
10.
Association, club, religious, charitable, educational, or other tax­exempt organization
The organization
 
11.
Partnership or multi-member LLC
The partnership
 
12.
A broker or registered nominee
The broker or nominee
 
13.
Account with the Department of Agriculture in the name of a public entity (such as a state or local government, school district, or prison) that receives agricultural program payments
The public entity
 
14.
Grantor trust filing under the Form 1041 Filing Method or the Optional Form 1099 Filing Method 2 (see Regulations section 1.671-4(b)(2)(i)(B))
The trust
 
 
1 List first and circle the name of the person whose number you furnish. If only one person on a joint account has an SSN, that person’s number must be furnished.
2 Circle the minor’s name and furnish the minor’s SSN.
 
       
 
 
 
 
 

 
 
 
Instructions for the
Requester of Form W-9
(Rev. December 2014)
 
Request for Taxpayer Identification Number
and Certification
   
Department of the Treasury
Internal Revenue Service
 
Section references are to the Internal Revenue Code unless otherwise noted.
 
Future Developments
For the latest developments related to Form W-9 and its instructions, such as legislation enacted after they were published, go to www.irs.gov/w9.
 
Reminders
Foreign Account Tax Compliance Act (FATCA). FATCA requires a participating foreign financial institution to report all U.S. account holders that are specified U.S. persons. Form W-9 and the Instructions for the Requester of Form W-9 have an Exemptions box on the front of the form that includes entry for the Exempt payee code (if any) and Exemption from FATCA Reporting Code (if any). The references for the appropriate codes are in the Exemptions section of Form W-9, and in the Payees Exempt from Backup Withholding and Payees and Account Holders Exempt From FATCA Reporting sections of these instructions.
 
The Certification section in Part II of Form W-9 includes certification relating to FATCA reporting.
 
Payment card and third party network transactions. References to payments made in settlement of payment card and third party network transactions are included in the Purpose of Form section of Form W-9. For more information, see the Instructions for Form 1099-K, Payment Card and Third Party Network Transactions on IRS.gov. Also, visit www.irs.gov/1099k.
 
Backup withholding rate.  The backup withholding rate is 28% for reportable payments.
 
TIN matching e-services.  The IRS website offers TIN Matching e-services for certain payers to validate name and TIN combinations. See Taxpayer Identification Number (TIN) Matching on page 4.
 
How Do I Know When To Use Form W-9?
Use Form W-9 to request the taxpayer identification number (TIN) of a U.S. person (including a resident alien) and to request certain certifications and claims for exemption.
(See Purpose of Form on Form W-9.) Withholding agents may require signed Forms W-9 from U.S. exempt recipients to overcome a presumption of foreign status. For federal purposes, a U.S. person includes but is not limited to:
  An individual who is a U.S. citizen or U.S. resident alien,
  A partnership, corporation, company, or association created or organized in the United States or under the laws of the United States,
  Any estate (other than a foreign estate), or
 
  A domestic trust (as defined in Regulations section 301.7701-7).
 
A partnership may require a signed Form W-9 from its U.S. partners to overcome a presumption of foreign status and to avoid withholding on the partner’s allocable share of the partnership’s effectively connected income. For more information, see Regulations section 1.1446-1.
 
Advise foreign persons to use the appropriate Form W-8 or Form 8233, Exemption From Withholding on Compensation for Independent (and Certain Dependent) Personal Services of a Nonresident Alien Individual. See Pub. 515, Withholding of Tax on Nonresident Aliens and Foreign Entities, for more information and a list of the W-8 forms.
 
Also, a nonresident alien individual may, under certain circumstances, claim treaty benefits on scholarships and fellowship grant income. See Pub. 515 or Pub. 519, U.S. Tax Guide for Aliens, for more information.
 
Electronic Submission of Forms W-9
Requesters may establish a system for payees and payees’ agents to submit Forms W-9 electronically, including by fax. A requester is anyone required to file an information return. A payee is anyone required to provide a taxpayer identification number (TIN) to the requester.
 
Payee’s agent.  A payee’s agent can be an investment advisor (corporation, partnership, or individual) or an introducing broker. An investment advisor must be registered with the Securities and Exchange Commission (SEC) under the Investment Advisers Act of 1940. The introducing broker is a broker-dealer that is regulated by the SEC and the National Association of Securities Dealers, Inc., and that is not a payer. Except for a broker who acts as a payee’s agent for “readily tradable instruments,” the advisor or broker must show in writing to the payer that the payee authorized the advisor or broker to transmit the Form W-9 to the payer.
 
Electronic system.  Generally, the electronic system must:
  Ensure the information received is the information sent, and document all occasions of user access that result in the submission;
  Make reasonably certain that the person accessing the system and submitting the form is the person identified on Form W-9, the investment advisor, or the introducing broker;
  Provide the same information as the paper Form W-9;
  Be able to supply a hard copy of the electronic Form W-9 if the Internal Revenue Service requests it; and
  Require as the final entry in the submission an electronic signature by the payee whose name is on Form W-9 that authenticates and verifies the submission. The electronic signature must be under penalties of perjury and the perjury statement must contain the language of the paper Form W-9.
 
 
Dec 15, 2014
 
Cat. No. 20479P
   
 
 
 

 
 
 
         
  For Forms W-9 that are not required to be signed, the electronic system need not provide for an electronic signature or a perjury statement.  
A substitute Form W-9 that contains a separate signature line just for the certifications satisfies the requirement that the certifications be clearly stated.
For more details, see the following.
  Announcement 98-27, which is on page 30 of Internal Revenue Bulletin 1998-15 at www.irs.gov/pub/irs-irbs/irb98-15.pdf.
  Announcement 2001-91, which is on page 221 of Internal Revenue Bulletin 2001-36 at www.irs.gov/pub/irs-irbs/irb01-36.pdf.
 
Individual Taxpayer Identification Number (ITIN)
Form W-9 (or an acceptable substitute) is used by persons required to file information returns with the IRS to get the payee’s (or other person’s) correct name and TIN. For individuals, the TIN is generally a social security number (SSN).
 
However, in some cases, individuals who become U.S. resident aliens for tax purposes are not eligible to obtain an SSN. This includes certain resident aliens who must receive information returns but who cannot obtain an SSN.
 
These individuals must apply for an ITIN on Form W-7, Application for IRS Individual Taxpayer Identification Number, unless they have an application pending for an SSN. Individuals who have an ITIN must provide it on Form W-9.
 
Substitute Form W-9
You may develop and use your own Form W-9 (a substitute Form W-9) if its content is substantially similar to the official IRS Form W-9 and it satisfies certain certification requirements.
 
You may incorporate a substitute Form W-9 into other business forms you customarily use, such as account signature cards. However, the certifications on the
substitute Form W-9
must clearly state (as shown on the official Form W-9) that under penalties of perjury:
 
1.  The payee’s TIN is correct,
2.  The payee is not subject to backup withholding due to failure to report interest and dividend income,
3.  The payee is a U.S. person, and
4.  The FATCA code entered on this form (if any) indicating that the payee is exempt from FATCA reporting is correct.
 
You may provide certification instructions on a substitute Form W-9 in a manner similar to the official form. If you are not collecting a FATCA exemption code by omitting that field from the substitute Form W-9 (see Payees and Account Holders Exempt From FATCA Reporting, later), you may notify the payee that item 4 does not apply.
 
You may not:
1.  Use a substitute Form W-9 that requires the payee, by signing, to agree to provisions unrelated to the required certifications, or
 
If a single signature line is used for the required certifications and other provisions, the certifications must be highlighted, boxed, printed in bold-face type, or presented in some other manner that causes the language to stand out from all other information contained on the substitute form. Additionally, the following statement must be presented to stand out in the same manner as described above and must appear immediately above the single signature line:
 
“The Internal Revenue Service does not require your consent to any provision of this document other than the certifications required to avoid backup withholding.”
 
If you use a substitute form, you are required to provide the Form W-9 instructions to the payee only if he or she requests them. However, if the IRS has notified the payee that backup withholding applies, then you must instruct the payee to strike out the language in the certification that relates to underreporting. This instruction can be given orally or in writing. See item 2 of the Certification on Form W-9. You can replace “defined below” with “defined in the instructions” in item 3 of the Certification on Form W-9 when the instructions will not be provided to the payee except upon request. For more information, see Rev. Proc. 83-89,1983-2 C.B. 613; amplified by Rev. Proc. 96-26, which is on page 22 of Internal Revenue Bulletin 1996-8 at www.irs.gov/pub/irs-irbs/irb96-08.pdf.
 
TIN Applied for
For interest and dividend payments and certain payments with respect to readily tradable instruments, the payee may return a properly completed, signed Form W-9 to you with “Applied For” written in Part I. This is an “awaiting-TIN” certificate. The payee has 60 calendar days, from the date you receive this certificate, to provide a TIN. If you do not receive the payee’s TIN at that time, you must begin backup withholding on payments.
 
Reserve rule. You must backup withhold on any reportable payments made during the 60-day period if a payee withdraws more than $500 at one time, unless the payee reserves an amount equal to the current year’s backup withholding rate on all reportable payments made to the account.
 
Alternative rule.  You may also elect to backup withhold during this 60-day period, after a 7-day grace period, under one of the two alternative rules discussed below.
Option 1.  Backup withhold on any reportable payments if the payee makes a withdrawal from the account after the close of 7 business days after you receive the awaiting-TIN certificate. Treat as reportable payments all cash withdrawals in an amount up to the reportable payments made from the day after you receive the awaiting-TIN certificate to the day of withdrawal.
Option 2.  Backup withhold on any reportable payments made to the payee’s account, regardless of whether the payee makes any withdrawals, beginning no later than 7 business days after you receive the awaiting-TIN certificate.

2. Imply that a payee may be subject to backup withholding unless the payee agrees to provisions on the substitute form that are unrelated to the required certifications.
   
The 60-day exemption from backup withholding does not apply to any payment other than interest, dividends, and certain payments relating
to readily tradable instruments. Any other reportable payment, such as nonemployee compensation, is subject to backup
 
 
 
-2-
 
Instr. for Req. of Form W-9 (Rev.  12-2014)
 
 
 

 
 
 
withholding immediately, even if the payee has applied for and is awaiting a TIN.
 
Even if the payee gives you an awaiting-TIN certificate, you must backup withhold on reportable interest and dividend payments if the payee does not certify, under penalties of perjury, that the payee is not subject to backup withholding.
 
If you do not collect backup withholding from affected payees as required, you may become liable for any uncollected amount.
 
Payees Exempt From Backup Withholding
The following payees are exempt from backup withholding with respect to the payments below, and should enter the corresponding exempt payee code on Form W-9. If a payee is not exempt, you are required to backup withhold on reportable
payments if the payee does not provide a TIN in the manner required or sign the certification, if required.
1.  An organization exempt from tax under section 501(a), any IRA, or a custodial account under section 403(b)(7) if the account satisfies the requirements of section 401(f)(2);
2.  The United States or any of its agencies or instrumentalities;
3.  A state, the District of Columbia, a U.S. commonwealth or possession, or any of their political subdivisions, agencies, or instrumentalities;
4.  A foreign government or any of its political subdivisions, agencies, or instrumentalities; or
5.  A corporation;
6.  A dealer in securities or commodities required to register in the United States, the District of Columbia, or a U.S. commonwealth or possession;
7.  A futures commission merchant registered with the Commodity Futures Trading Commission;
8.  A real estate investment trust;
9.  An entity registered at all times during the tax year under the Investment Company Act of 1940;
10. A common trust fund operated by a bank under section 584(a);
11. A financial institution;
12. A middleman known in the investment community as a nominee or custodian; or
13. A trust exempt from tax under section 664 or described in section 4947.
 
The following types of payments are exempt from backup withholding as indicated for payees listed in 1 through 13, above.
 
Interest and dividend payments.  All listed payees are exempt except the payee in item 7.
Broker transactions.  All payees listed in items 1 through 4 and 6 through 11 are exempt. Also, C corporations are exempt. A person registered under the Investment Advisers Act of 1940 who regularly acts as a broker is also exempt.
Barter exchange transactions and patronage dividends.  Only payees listed in items 1 through 4 are exempt.
Payments reportable under sections 6041 and 6041A.  Payees listed in items 1 through 5 are generally exempt.
 
However, the following payments made to a corporation and reportable on Form 1099-MISC, Miscellaneous Income, are not exempt from backup withholding.
● Medical and health care payments.
● Attorneys’ fees (also gross proceeds paid to an attorney, reportable under section 6045(f)).
●  Payments for services paid by a federal executive agency. (See Rev. Rul. 2003-66, which is on page 1115 of Intenal Revenue Bulletin 2003-26 at www.irs.gov/pub/irs-irbs/irb03-26.pdf.)
 
Payments made in settlement of payment card or third party network transactions.  Only payees listed in items 1 through 4 are exempt.
 
Payments Exempt From Backup Withholding
Payments that are not subject to information reporting also are not subject to backup withholding. For details, see sections 6041, 6041A, 6042, 6044, 6045, 6049, 6050A, 6050N, and 6050W and their regulations. The following payments are generally exempt from backup withholding.
 
Dividends and patronage dividends
●  Payments to nonresident aliens subject to withholding under section 1441.
●  Payments to partnerships not engaged in a trade or business in the United States and that have at least one nonresident alien partner.
●  Payments of patronage dividends not paid in money.
●  Payments made by certain foreign organizations.
●  Section 404(k) distributions made by an ESOP.
 
Interest payments
●  Payments of interest on obligations issued by individuals. However, if you pay $600 or more of interest in the course of your trade or business to a payee, you must report the payment. Backup withholding applies to the reportable payment if the payee has not provided a TIN or has provided an incorrect TIN.
●  Payments described in section 6049(b)(5) to nonresident aliens.
●  Payments on tax-free covenant bonds under section 1451.
●  Payments made by certain foreign organizations.
●  Mortgage or student loan interest paid to you.
 
Other types of payment
●  Wages.
●  Distributions from a pension, annuity, profit-sharing or stock bonus plan, any IRA, an owner-employee plan, or other deferred compensation plan.
●  Distributions from a medical or health savings account and long-term care benefits.
●  Certain surrenders of life insurance contracts.
●  Distribution from qualified tuition programs or Coverdell ESAs.
●  Gambling winnings if regular gambling winnings withholding is required under section 3402(q). However, if regular gambling winnings withholding is not required under section 3402(q), backup withholding applies if the payee fails to furnish a TIN.
●  Real estate transactions reportable under section 6045(e).
●  Cancelled debts reportable under section 6050P.
 
Instr. for Req. of Form W-9 (Rev. 12-2014)
 
-3-
   
 
 
 

 
 
●  Fish purchases for cash reportable under section 6050R.
 
Payees and Account Holders Exempt From FATCA Reporting
Reporting under chapter 4 (FATCA) with respect to U.S. persons generally applies only to foreign financial institutions (FFI) (including a branch of a U.S. financial institution that is treated as an FFI under an applicable intergovernmental agreement (IGA)). Thus, for example, a U.S. financial institution maintaining an account in the United States does not need to collect an exemption code for FATCA reporting. If you are providing a Form W-9, you may pre-populate the FATCA exemption code with “Not Applicable,” “N/A,” or a similar indication that an exemption from FATCA reporting does not apply. Any payee that provides such a form, however, cannot be treated as exempt from FATCA reporting. For details on the FATCA reporting requirements, including specific information regarding which financial institutions are required to report, see sections 1471 to 1474 and related regulations. See Regulations section 1.1471-3(d)(2) for when an FFI may rely on documentary evidence to treat a U.S. person as other than a specified U.S. person and see Regulations section 1.1471-3(f)(3) for when an FFI may presume a U.S. person as other than a specified U.S. person.
 
If you receive a Form W-9 with a FATCA exemption code and you know or have reason to know the person is a specified U.S. person, you may not rely on the Form W-9 to treat the person as exempt from FATCA reporting. However, you may still rely on an otherwise completed Form W-9 to treat a person as a specified U.S. person. An exemption from FATCA reporting (or lack thereof) does not affect backup withholding as described earlier in these instructions. The following are not specified U.S. persons and are thus exempt from FATCA reporting:
 
K.  A broker;
L.  A trust exempt from tax under section 664 or described in section 4947; or
M.  A tax-exempt trust under a section 403(b) plan or section 457(g) plan.
 
Joint Foreign Payees
If the first payee listed on an account gives you a Form W-8 or a similar statement signed under penalties of perjury, backup withholding applies unless:
 
1.  Every joint payee provides the statement regarding foreign status, or
2.  Any one of the joint payees who has not established foreign status gives you a TIN.
If any one of the joint payees who has not established foreign status gives you a TIN, use that number for purposes of backup withholding and information reporting.
 
For more information on foreign payees, see the Instructions for the Requester of Forms W-8BEN, W-8ECI, W-8EXP, and W-8IMY.
 
Names and TINs To Use for Information Reporting
Show the full name and address as provided on Form W-9 on the information return filed with the IRS and on the copy furnished to the payee. If you made payments to more than one payee or the account is in more than one name, enter on the
first name line of the information return only the name of the payee whose TIN is shown on Form W-9. You may show the names of any other individual payees in the area below the first name line on the information return. Forms W-9 showing an ITIN must have the name exactly as shown on line 1a of the Form W-7 application.
 
A.  An organization exempt from tax under section 501(a), or any individual retirement plan as defined in section 7701(a)(37);
B. The United States or any of its agencies or instrumentalities;
   
For more information on the names and TINs to use for information reporting, see section J of the General Instructions for Certain Information Returns.
C.  A state, the District of Columbia, a U.S. commonwealth or possession, or any of their political subdivisions, agencies, or instrumentalities;
D.  A corporation the stock of which is regularly traded on one or more established securities markets, as described in Reg, section 1.1472-1(c)(1)(i);
E.  A corporation that is a member of the same expanded affiliated group as a corporation described in Reg. section 1.1472-1(c)(1)(i);
F.  A dealer in securities, commodities, or derivative financial instruments (including notional principal contracts, futures, forwards, and options) that is registered as such under the laws of the United States or any State;
G.  A real estate investment trust;
H.  A regulated investment company as defined in section 851 or an entity registered at all times during the tax year under the Investment Company Act of 1940;
I.  A common trust fund as defined in section 584(a);
J.  A bank as defined in section 581;
 
Notices From the IRS
The IRS will send you a notice if the payee’s name and TIN on the information return you filed do not match the IRS’s records. (See Taxpayer Identification Number (TIN) Matching.) You may have to send a “B” notice to the payee to solicit another TIN. Pub. 1281, Backup Withholding for Missing and Incorrect Name/TIN(s), contains copies of the two types of “B” notices.
 
Taxpayer Identification Number (TIN) Matching
TIN Matching allows a payer or authorized agent who is required to file Forms 1099-B, DIV, INT, K, MISC, OID, and/or PATR to match TIN and name combinations with IRS records before submitting the forms to the IRS. TIN Matching is one of the e-services products that is offered and is accessible through the IRS website. Go to IRS.gov and enter e-services in the search box. It is anticipated that payers who validate the TIN and name combinations before filing information returns will receive fewer backup withholding (CP2100) notices and penalty notices.
 
Additional Information
For more information on backup withholding, see Pub. 1281.
 
 
 
-4-
 
Instr. for Req. of Form W-9 (Rev. 12-2014)
 
 
 

 
Questions and requests for assistance may be directed to the information agent and exchange agent at its address and telephone number set forth below. Additional copies of the Prospectus, this Letter of Transmittal or other materials related to the exchange offer may be obtained from the information agent and exchange agent or from brokers, dealers, commercial banks or trust companies.

The information agent and exchange agent for the exchange offer is:
 
D.F. King & Co., Inc.
48 Wall Street, 22nd Floor
New York, New York 10005
  
or
  
Banks and Brokers Call Collect:
(212) 269-5550
All Others Call Toll Free: (866) 745-0265
Email: cvs@dfking.com
 
 
By Regular, Registered or Certified Mail, Hand or Overnight Delivery:
D.F. King & Co., Inc.
48 Wall Street, 22nd Floor
New York, New York 10005
Attn: Peter Aymar
 
By Facsimile (for Eligible Institutions only):
(212) 709-3328
Attn:  Peter Aymar
 
For Confirmation:
(212) 232-3235

 
 
 
 
 
 

 
 
EX-99.2 7 ss1454292_ex9902.htm FORM OF LETTER TO REGISTERED HOLDERS
Exhibit 99.2
 
CVS Health Corporation
 
OFFER TO EXCHANGE
 
$387,285,000 OUTSTANDING 4.75% SENIOR NOTES DUE 2022
AND
$296,255,000 OUTSTANDING 5.00% SENIOR NOTES DUE 2024
 
FOR
 
A LIKE PRINCIPAL AMOUNT OF CORRESPONDING NEW NOTES
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
 
PURSUANT TO THE PROSPECTUS
DATED                 , 2016
 
 
THE EXCHANGE OFFER WILL EXPIRE AT         P.M., NEW YORK CITY TIME, ON                  , 2016 UNLESS EXTENDED (THE “EXPIRATION DATE”). TENDERS IN THE EXCHANGE OFFER MAY BE WITHDRAWN AT ANY TIME PRIOR TO         P.M., NEW YORK CITY TIME, ON THE EXPIRATION DATE.
 
To Registered Holders and Depository Trust Company Participants:
 
We are enclosing herewith the material listed below relating to the offer by CVS Health Corporation, a Delaware corporation (“CVS Health”), to exchange all of its issued and outstanding 4.75% Senior Notes due 2022 (the “Old 2022 Notes”) and issued and outstanding 5.00% Senior Notes due 2024 (the “Old 2024 Notes” and together with the Old 2022 Notes, the “Old Notes”), for a like principal amount of its 4.75% Senior Notes due 2022 (the “New 2022 Notes”) and 5.00% Senior Notes due 2024 (the “New 2024 Notes” and together with the New 2022 Notes, the “New Notes”), respectively, which have been registered under the Securities Act of 1933, as amended (the “Securities Act”), upon the terms and subject to the conditions set forth in the prospectus, dated                    , 2016 (the “Prospectus”), and the related Letter of Transmittal (which together constitute the “exchange offer”).
 
Enclosed herewith are copies of the following documents:
 
1.           Prospectus, dated                    , 2016;
 
2.           Letter of Transmittal (together with accompanying IRS Form W-9 and related Guidelines);
 
3.           Letter that may be sent to your clients for whose account you hold Old Notes in your name or in the name of your nominee;
 
4.           Letter that may be sent from your clients to you with such clients’ instruction with regard to the exchange offer (included in item 3 above); and
 
5.           Letter to the holders of Old Notes.
 
We urge you to contact your clients promptly. Please note that the exchange offer will expire on the Expiration Date unless extended. The exchange offer is not conditioned upon any minimum number of Old Notes being tendered.
 
 
 

 
 
Pursuant to the Letter of Transmittal, each holder of Old Notes will represent to CVS Health that:
 
 
·
it is not an affiliate of CVS Health within the meaning of Rule 405 of the Securities Act or, if it is such an affiliate, it will comply with the registration and prospectus delivery requirements of the Securities Act, to the extent applicable;
 
 
·
it is not participating, and it has no arrangement or understanding with any person to participate in a distribution (within the meaning of the Securities Act) of the New Notes in violation of the provisions of the Securities Act;
 
 
·
it is not a broker-dealer who tendered 4.75% notes due December 1, 2022 issued by Omnicare, Inc. or 5.00% notes due December 1, 2024 issued by Omnicare, Inc. acquired directly from Omnicare, Inc. for its own account in exchange for the Old Notes;
 
 
·
if it is a broker dealer, it has not entered into any arrangement or understanding with CVS Health or any of CVS Health’s affiliates to distribute the New Notes;
 
 
·
it is acquiring the New Notes in the ordinary course of its business; and
    
 
·
it is not acting on behalf of any person or entity that could not truthfully make these representations.
    
If the exchange offeree is a broker-dealer holding Old Notes acquired for its own account as a result of market-making activities or other trading activities, it will deliver a prospectus meeting the requirements of the Securities Act in connection with any resale of New Notes received in respect of such Old Notes pursuant to the exchange offer.
         
If the holder is a broker-dealer that will receive New Notes for its own account in exchange for Old Notes, it acknowledges that it will deliver a prospectus in connection with any resale of such New Notes.
          
The enclosed Letter to Clients contains an authorization by the beneficial owners of the Old Notes for you to make the foregoing representations.
 
CVS Health will not pay any fee or commission to any broker or dealer or to any other persons (other than the exchange agent) in connection with the solicitation of tenders of Old Notes pursuant to the exchange offer. CVS Health will pay or cause to be paid any transfer taxes payable on the transfer of Old Notes to it, except as otherwise provided in Instruction 6 of the enclosed Letter of Transmittal.
 
Additional copies of the enclosed materials may be obtained from the information agent and exchange agent by calling D.F. King & Co., Inc. at (866) 745-0265 (bankers and brokers call: (212) 269-5550).
     
 
Very truly yours,
   
   
 
CVS HEALTH CORPORATION

 
 
 2

EX-99.3 8 ss1454292_ex9903.htm FORM OF LETTER TO CLIENTS
Exhibit 99.3
 
CVS Health Corporation
 
OFFER TO EXCHANGE
 
$387,285,000 OUTSTANDING 4.75% SENIOR NOTES DUE 2022
AND
$296,255,000 OUTSTANDING 5.00% SENIOR NOTES DUE 2024
 
FOR
 
A LIKE PRINCIPAL AMOUNT OF CORRESPONDING NEW NOTES
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
 
PURSUANT TO THE PROSPECTUS
DATED                 , 2016
 
THE EXCHANGE OFFER WILL EXPIRE AT         P.M., NEW YORK CITY TIME, ON                      , 2016 UNLESS EXTENDED (THE “EXPIRATION DATE”). TENDERS IN THE EXCHANGE OFFER MAY BE WITHDRAWN AT ANY TIME PRIOR TO        P.M., NEW YORK CITY TIME, ON THE EXPIRATION DATE.

To Our Clients:
 
We are enclosing a prospectus, dated                     , 2016 (the “Prospectus”) of CVS Health Corporation, a Delaware corporation (“CVS Health”), and a related Letter of Transmittal (which together constitute the “exchange offer”) relating to the offer by CVS Health to exchange all of its issued and outstanding 4.75% Senior Notes due 2022 (the “Old 2022 Notes”) and issued and outstanding 5.00% Senior Notes due 2024 (the “Old 2024 Notes” and together with the Old 2022 Notes, the “Old Notes”), for a like principal amount of its 4.75% Senior Notes due 2022 (the “New 2022 Notes”) and 5.00% Senior Notes due 2024 (the “New 2024 Notes” and together with the New 2022 Notes, the “New Notes”), respectively, which have been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to a registration statement of which the Prospectus is a part, upon the terms and subject to the conditions set forth in the exchange offer.
 
The exchange offer is not conditioned upon any minimum number of Old Notes being tendered.
 
We are the holder of record of Old Notes held by us for your account. A tender of such Old Notes can be made only by us as the record holder and pursuant to your instructions. The enclosed Letter of Transmittal is furnished to you for your information only and cannot be used by you to tender Old Notes held by us for your account.
 
We request instructions as to whether you wish to tender any or all of the Old Notes held by us for your account pursuant to the terms and conditions of the exchange offer. We also request that you confirm that we may on your behalf make the representations and warranties contained in the Letter of Transmittal.
 
PLEASE RETURN YOUR INSTRUCTIONS TO US IN THE ENCLOSED ENVELOPE WITHIN AMPLE TIME TO PERMIT US TO SUBMIT A TENDER ON YOUR BEHALF PRIOR TO THE EXPIRATION DATE.
 
 
 
 

 
 
INSTRUCTIONS TO REGISTERED HOLDER AND/OR
DEPOSITORY TRUST COMPANY PARTICIPANT
 
To Registered Holder and/or Participant of The Depository Trust Company:
 
The undersigned hereby acknowledges receipt of the prospectus, dated                       , 2016 (the “Prospectus”) of CVS Health Corporation, a Delaware corporation (“CVS Health”), and the accompanying Letter of Transmittal, that together constitute the offer by CVS Health (the “exchange offer”) to exchange all of its issued and outstanding 4.75% Senior Notes due 2022 (the “Old 2022 Notes”) and issued and outstanding 5.00% Senior Notes due 2024 (the “Old 2024 Notes” and together with the Old 2022 Notes, the “Old Notes”), for a like principal amount of its 4.75% Senior Notes due 2022 (the “New 2022 Notes”) and 5.00% Senior Notes due 2024 (the “New 2024 Notes” and together with the New 2022 Notes, the “New Notes”), respectively, which have been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to a registration statement of which the Prospectus is a part, upon the terms and subject to the conditions set forth in the exchange offer. Certain terms used but not defined herein have the meanings ascribed to them in the Prospectus.
 
This will instruct you, the registered holder and/or participant of The Depository Trust Company, as to the action to be taken by you relating to the exchange offer with respect to the Old Notes held by you for the account of the undersigned.
 
The aggregate face amount of the Old Notes held by you for the account of the undersigned is (fill in amount):
 
$                      of the 4.75% Senior Notes due 2022.
 
$                      of the 5.00% Senior Notes due 2024.
 
With respect to the exchange offer, the undersigned hereby instructs you (check all applicable boxes):
 
 
o
To tender the following Old Notes held by you for the account of the undersigned (insert principal amount of Old Notes to be tendered) (if any): $______________________________
.
 
 
o
not to tender any Old Notes held by you for the account of the undersigned.
 
If the undersigned instructs you to tender the Old Notes held by you for the account of the undersigned, it is understood that you are authorized to make, on behalf of the undersigned (and the undersigned by its signature below, hereby makes to you), the representations and warranties contained in the Letter of Transmittal that are to be made with respect to the undersigned as a beneficial owner, including but not limited to the representations, that:
 
 
·
it is not an affiliate of CVS Health within the meaning of Rule 405 of the Securities Act or, if it is such an affiliate, it will comply with the registration and prospectus delivery requirements of the Securities Act, to the extent applicable;
 
 
·
it is not participating, and it has no arrangement or understanding with any person to participate in a distribution (within the meaning of the Securities Act) of the New Notes in violation of the provisions of the Securities Act;
 
 
·
it is not a broker-dealer who tendered 4.75% notes due December 1, 2022 issued by Omnicare, Inc. or 5.00% notes due December 1, 2024 issued by Omnicare, Inc. acquired directly from Omnicare, Inc. for its own account in exchange for the Old Notes;
 
 
·
if it is a broker dealer, it has not entered into any arrangement or understanding with CVS Health or any of CVS Health’s affiliates to distribute the New Notes;
 
 
·
it is acquiring the New Notes in the ordinary course of its business; and
    
 
·
it is not acting on behalf of any person or entity that could not truthfully make these representations.
    
If the exchange offeree is a broker-dealer holding Old Notes acquired for its own account as a result of market-making activities or other trading activities, it will deliver a prospectus meeting the requirements of the Securities Act in connection with any resale of New Notes received in respect of such Old Notes pursuant to the exchange offer.
     
If the undersigned is a broker-dealer that will receive New Notes for its own account in exchange for Old Notes, it acknowledges that it will deliver a prospectus in connection with any resale of such New Notes.
 
 
 
2

 
 
SIGN HERE
 
Name(s) of beneficial owner(s):
 
Signature(s):
 
Name(s):
(Please Print)
 
Address(es):
 
Telephone Number(s):
 
Taxpayer Identification or Social Security Number(s):
 
Date:

 
 
 
 
 
 
 
3

GRAPHIC 10 image01.jpg GRAPHIC begin 644 image01.jpg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

60X>F5A3E%+*VY&<4QX47A6;S@P>5%%I8U97=DI';DAM=UAK47$X:4)6:C!!GI6-76-75$@X5F1IG)Q.6DK M,#$S<"]/1G8K34UQ.&PK:U!8-DU51C=J*V-V-5974&XO04UT;49!4]H;WEK67-K3T-186IR:7(V5R])2'E4*U10;DQY.'HS5VER M3#5J$Y'9V16-%!3;E-O3S-H5E%74V9N6BM3 M,VM/3#AU.50Q4%)D2F

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image03.jpg GRAPHIC begin 644 image03.jpg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end GRAPHIC 12 image02.jpg GRAPHIC begin 644 image02.jpg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